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NOMENCLATURE		CHRONIC	ENTEROPATHIES	NOMENCLATURE		
CE Chronic enteropathy, include FRE, ARE, IBD 
FRE Food responsive enteropathy 
ARE Antibiotic responsive enteropathy 
IRE Immunosuppressant-responsive enteropathy 
SRE Steroid responsive enteropathy, term used instead of IRE 
NRE Non responsive enteropathy 
IBD (Idiopathic) Inflammatory bowel disease, include IRE, SRE and NRE 
PLE Protein loosing enteropathy 	OTHER	ABBREVIATIONS:	
 
(q)PCR (quantitative) Polymerase chain reaction 
ACTH Adrenocorticotropic hormone 
AHD Acute hemorrhagic diarrhea 
ALT Alanine aminotransferase  
ARF Adverse reaction to food 
AST Aspartate aminotransferase 
AT III Antithrombin III 
BA Bile acids 
BARF Bone and Raw Food diets 
BCS Body condition score 
BID Bis in die, twice daily, q12h 
BW Body weight 
CCECAI Canine CE clinical activity index 
CIBDAI Canine IBD activity index 
CIPO Chronic intestinal pseudo-obstruction 
cPLI Canine pancreatic lipase 
immunoreactivity 
CRP C reactive protein 
EE Eosinophilic enteritis 
EPI Exocrine pancreas insufficiency 
FC Fecal score 
FISH Fluorescent in situ hybridization 
FOS Fructooligosaccharides 
GI Gastrointestinal 
GSD German shepherd dog 
GSE Gluten sensitivity enteropathy 
HC Healthy control;  
IBS Irritable bowel syndrome  
ICRP Inflammatory colorectal polyps 
IV Intravenously 
LPE Lymphocytic plasmatic enteritis 
LS Lundehund syndrome 
MCS Muscle condition score 
MOS Mannanoligosaccharides  
MSC Mesenchymal stem cells 
NGS Next generation sequencing 
NHD Non-hemorrhagic diarrhea 
NLR Nod like receptor 
PCV Packet cell volume  
PLN Protein loosing nephropathy 
PO Per os, oral route 
PSS Porto-systemic shunt.  
PU/PD Polyuria polydipsia 
RBC Red blood cell  
SAP Serum alkaline phosphatase 
SBS Short bowel syndrome 
SC Subcutaneous  
SCWT Soft Coated Wheaten Terriers 
SIBO Small intestinal bacteria overgrowth 
SID Solum in die, once a day, q24h 
T-RFLP Terminal restriction fragment 
polymorphism 
TEG Thromboelastography 
TIBC Total iron binding capacity 
TID Ter in die, three times daily, q8h 
TLI Trypsin-like immunoreactivity 
TLR Tool like receptor 
UPC Urinary protein to creatinine ratio 
US Ultrasound or ultrasonography  
USG Urine specific gravity 
WBC White blood cell 
WHWT West Highland White Terrier 
α1-PI α1-Protease inhibitor 			 	
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INTRODUCTION			Chronic	enteropathy	(CE)	 is	a	term	used	for	diseases	of	 the	 intestines	regardless	of	etiology	and	pathogenesis,	and	 it	 is	 otherwise	 called	 inflammatory	 bowel	 disease	 (IBD).	 In	 humans	 IBD,	 includes	 two	 different	 chronic	disorders	characterized	by	inflammation	of	the	intestinal	wall:	Crohn’s	disease	(CD)	and	ulcerative	colitis	(UC).	Like	humans,	dogs	frequently	develop	CE	and	it	is	considered	the	main	cause	of	chronic,	persistence	or	episodic	gastrointestinal	 signs	 (GI).1	 Similar	 to	 human	 IBD,	 the	 combination	 of	 underlying	 host	 genetic	 susceptibility,	inappropriate	immune	responses	and	uncontrolled	inflammation,	altered	intestinal	microbiota	(dysbiosis),	and	dietary	and/or	environmental	 factors	are	suspected	as	main	contributing	factors	 in	the	pathogenesis	of	canine	IBD.1,2		CE	in	dogs	can	further	be	subdivided	retrospectively	by	response	to	treatment	into:	food-responsive	enteropathy	(FRE),	 antibiotic-responsive	 enteropathy	 (ARE),	 immunosuppressant-responsive	 enteropathy	 (IRE)	 otherwise	called	 steroid-responsive	 enteropathy	 (SRE)	 or	 idiopathic	 IBD,	 and	 non-responsive	 enteropathy	 (NRE).1,3	 In	addition	 to	 this	 classification,	 according	 to	 treatment	 response,	 dogs	 with	 loss	 of	 protein	 across	 the	 gut	 are	typically	grouped	as	protein-losing	enteropathy	(PLE),	highlighting	the	more	guarded	prognosis	of	this	particular	form	 of	 CE	 compared	 to	 dogs	 with	 normal	 serum	 albumin	 concentration.1,3,4	 PLE	 can	 be	 a	 consequence	 of	inflammation	or	neoplastic	disease.	PLE	dogs	can	potentially	be	FRE	or	ARE,	but	usually	are	IRE.			The	 purpose	 of	 this	 thesis	 is	 to	 review	 the	 literature	 in	 matter	 of	 chronic	 enteropathies.	 Moreover,	 studies	conducted	during	 the	author’s	PhD	were	 reported.	 Investigations	were	 focused	on	 the	different	aspects	of	 the	disease,	 from	 etiopathogenesis	 (chapter	 1.1),	 breed	 or	 sex	 predisposition	 in	 Italian	 population	 (chapter	 2.1),	clinical	signs	associated	with	the	disease	(chapter	3.1),	treatment	options	(chapter	5.1,	5.2,	5.3,	5.4),	and,	finally,	identification	of	prognostic	factors	(chapter	6.1,	6.2).			REFERENCES		
1.		 Dandrieux	 JRS.	 Inflammatory	 bowel	 disease	 versus	 chronic	
enteropathy	in	dogs:	are	they	one	and	the	same?	J	Small	Anim	Pract.	2016:1-
11.		
2.		 Simpson	 KW,	 Jergens	 AE.	 Pitfalls	 and	 Progress	 in	 the	 Diagnosis	
and	Management	of	Canine	Inflammatory	Bowel	Disease.	Vet	Clin	North	Am	-	
Small	Anim	Pract.	2011;41(2):381-398.		
3.		 Allenspach	 K,	 Wieland	 B,	 Gröne	 A,	 Gaschen	 F.	 Chronic	
enteropathies	 in	dogs:	evaluation	of	 risk	 factors	 for	negative	outcome.	 J	Vet	
Intern	Med.	2007;21(4):700-708.		
4.		 Craven	 M,	 Simpson	 JW,	 Ridyard	 E,	 Chandler	 ML.	 Canine	
inflammatory	bowel	disease :	retrospective	analysis	of	diagnosis	and	outcome	
in	80	cases	(	1995-2002	).	J	Small	Anim	Pract.	2004;45:336-342.				 	
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1. PATHOGENESIS					Pathogenesis	of	CE	is	generally	believed	to	be	multifactorial.	A	currently	accepted	hypothesis	 in	humans,	dogs,	and	cats	is	that	a	dysregulation	of	the	gastrointestinal	immune	system	in	genetically	susceptible	individuals,	may	lead	to	aberrant	responses	towards	luminal	microbial	or	dietary	antigens.1–3			
		
Figure 1.a: Factors involved in the pathogenesis of CE. 	INFLAMMATION	AND	GENETIC	PREDISPOSITION	Inflammation	 plays	 a	 crucial	 role	 in	 the	 pathogenesis	 of	 CE.2,4	 Tolerance	 of	 dietary	 and	GI	microbial	 antigens	(oral	tolerance)	 is	achieved	 following	 interactions	between	 the	 intestinal	barrier	and	epithelial	 tight	 junctions,	phagocytes,	 and	 inflammatory	 cells.3,5	 Loss	 of	 oral	 tolerance	 leads	 to	 uncontrolled	 inflammation,	which	 is	 the	result	of	activation	of	 the	many	effector	pathways.	The	 inflammation	can	then	 lead	to	architectural	disruption,	resulting	in	adverse	effects	on	function.3,5	Toll-like	 receptors	 (TLRs)	 and	NOD-like	 receptors	 (NLRs)	 are	 ideally	 situated	 on	 intestinal	 epithelia	 cells	 and	recognize	microbe	associated	molecular	patterns	(MAMPs).6	TLRs	may	play	a	significant	role	in	defense	against	pathogens,	but	 inappropriate	activation	of	 their	 signaling	pathways	may	 lead	 to	deleterious	 inflammation	and	tissue	injury.7	In	genetically	predisposed	individuals,	TLRs	and	NLRs	have	been	shown	to	be	up-regulated	in	the	intestines	 of	 human	 beings	with	 Crohn	 disease,	 ulcerative	 colitis,	 celiac	 disease,	 and	 colon	 cancer.7	 Similarly,	TRLs	2,	4,	and	9	were	found	to	be	up-regulated	in	dogs	with	chronic	enteropathies.6,8,9	A	genetic	predisposition	for	 genes	 encoding	TRL	4	 and	 5	was	 demonstrated	 in	German	 Shepherd	 dog	 (GSD)	 and	 also	 in	 other	 breeds,	underlying	the	importance	of	genetics	and	immune-mediated	mechanisms	in	the	pathogens	of	CE.2,8,10		Although	 little	 information	 is	currently	available	 in	companion	animals,	several	studies	have	characterized	the	cells	and	cytokines	expressed	within	the	canine	and	feline	GI	tract	in	both	healthy	animals	and	those	with	CE.3	Studies	 reveal	 different	 expression	 of	 cytokines,	 different	 lamina	 propria	 T	 and	 B	 cell	 distribution,	 increased	densities	of	different	IgA,	IgG	plasma	cells,	T	cells,	MHC	class	II+	cells,	and	macrophages	[e.g	in	GSD	with	IBD	and	Boxer	with	histiocytic	ulcerative	colitis	(HUC)].	2,3,11–13		Overall,	there	is	a	lack	of	an	obvious	pattern	of	cytokines	expression,	cell	distribution,	genetic	predisposition,	or	expression	 of	 single	 TLR	 (or	 combination	 of	 TLRs)	 in	 dogs	 with	 CE.	 Therefore,	 in	 summary,	 recent	 studies	provide	evidence	that	both	genetics	and	inflammation	have	a	role	in	the	development	of	CE	in	dogs	and	cats,	but	exact	mechanisms	remain	elusive	and	further	studies	are	needed.	
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DYSBIOSIS	DEFINITIONS	OF	-OMES	The	term	microbiome	initially	was	used	to	describe	the	“the	ecological	community	of	commensal,	symbiotic	and	pathogenic	microorganisms	 that	 literally	share	our	body	space”;	nowadays	 it	 refers	 to	 the	entire	genetic	mass	(genome)	of	microorganisms,	including	bacteriome,	virome	and	mycobiome	(Figure	1.b).14–17		The	 term	microbiota	(in	 the	 past	 also	 referred	 to	 as	microflora)	 is	 used	 to	 describe	 bacterial	 communities	 on	mucosal	 surfaces	 (with	 or	without	 luminal	microorganisms)	 or	 on	 other	 body	 sites	 (e.g.	 skin).	 The	 intestinal	microbiota	is,	therefore,	the	collection	of	microorganisms	(bacteria,	fungi,	protozoa,	and	viruses)	inhabiting	the	gastrointestinal	tract	(Figure	1.b).18,19		
Metagenomics	is	the	study	of	the	metagenome	(the	collective	genome	of	microorganisms	from	an	environmental	sample)	and	provide	information	on	the	microbial	diversity	and	ecology	of	a	specific	environment	(Figure	1.a).20	
Metabolomics	 refers	 to	 the	 systematic	 identification	 and	 quantification	 of	 the	 metabolic	 products	 (the	
metabolome)	of	a	biological	system	(cell,	tissue,	organ,	biological	fluid,	or	organism)	at	a	specific	point	in	time.21	Metabolomics	does	not	necessarily	refer	to	microbiota	metabolites,	but	also	to	other	metabolites	(es.	bile	acids,	short	 chain	 fatty	 acids).	 Study	 of	 microbiota	 and	 metabolomics	 can	 therefore	 aid	 in	 comprehension	 of	 the	pathophysiology	of	GI	system	in	health	and	disease	and	are	subject	of	many	studies..21				
		
Figure 1.b: Definition of the microbiota, metagenome and microbiome. Each image represents the same population; 
however, different approaches to define the population provide different information. a Microbiota: 16S rRNA surveys 
are used to taxonomically identify the microorganisms in the environment. b Metagenome: the genes and genomes of the 
microbiota, including plasmids, highlighting the genetic potential of the population. c Microbiome: the genes and 
genomes of the microbiota, as well as the products of the microbiota and the host environment. From Whiteside et al, 
2015.22 
rRNA, ribosomal RNA. 	INTESTINAL	DYSBIOSIS	In	recent	years,	the	GI	microbiota	has	garnered	strong	interest	due	to	the	potential	ethiopathologic	role	in	host	health	and	disease.	Intestinal	dysbiosis	can	be	defined	as	an	alteration	in	the	composition	and/or	richness	of	the	intestinal	 microbiota.	 Studies	 in	 veterinary	 species	 have	 associated	 intestinal	 dysbiosis	 with	 various	 GI	disorders,	such	as	acute	diarrhea,	CE,	granulomatous	colitis,	and	colorectal	polyps.18,23–26	Whether	these	changes	are	a	cause	or	a	consequence	of	the	aberrant	immune	reactions	seen	in	the	GI	tract	remains	a	matter	of	debate,	both	 in	 people	 and	 in	 dogs.15	 There	 is	 likely	 an	 overlap,	 since	 inflammation	 will	 cause	 dysbiosis,	 and	 recent	
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functional	 studies	 have	 demonstrated	 that	 dysbiosis,	 when	 present,	 is	 a	 risk	 factor	 that	 may	 exacerbate	inflammation	in	genetically	susceptible	individuals.19	There	is	no	single	gold	standard	for	assessing	the	GI	microbiota	and	dysbiosis.	Most	current	research	is	focused	on	 evaluating	 the	 bacterial	 microbiota	 and	 methods	 have	 been	 optimized	 for	 characterization	 of	 bacteria.19	Bacterial	culture	can	be	a	useful	in	specific	situation	(e.g.	specific	infection,	antibiotic	sensitivity	testing),	but	in	most	 cases	 it	 not	 useful.	 Since	 the	 gut	 microbiota	 is	 a	 complex	 and	 dynamic	 ecosystem,	 the	 best	 diagnostic	approach	would	be	 a	 combination	of	molecular	 tools	 that	 include	PCR	amplification	of	 16S	 rRNA	genes	using	broad	universal	bacterial	primers,	followed	by	analysis	of	amplicons	by	next	generation	sequencing	(NGS),	direct	quantification	 of	 specific	 bacterial	 taxa	 by	 quantitative	 PCR	 (qPCR),	 and	 the	 use	 of	 fluorescent	 in	 situ	hybridization	(FISH)	to	visualize	the	translocation	of	bacteria	into	the	mucosal	epithelium.19	Many	studies	evaluate	the	alternations	of	microbiota	in	different	samples	and	several	techniques	were	evaluated	for	better	understanding	the	composition	of	microbiota	during	acute	and	chronic	GI	disease	in	dogs.	Results	are	reported	in	Table	1.a				
References Sampling 
location  
Sample size Method Microbial changes  
     
Suchodolski et 
al, 201223 
Duodenal 
biopsies  
IBD (n = 14) 
HC (n=6) 
454-pyrosequencing 
(16S rRNA gene) 
Increase in Proteobacteria (Diaphorobacter, 
Acinetobacter)   
Reduction in Fusobacteria, Bacteroidaceae, 
Prevotellaceae, Clostridiale 
Suchodolski et 
al, 201027 
Duodenal 
biopsies  
IBD (n=7) 
HC (n=7) 
Gene clone libraries 
(16S rRNA gene)  
 
Increase in Proteobacteria   
Decrease in Clostridia 
Allenspach et 
al. 201028 
Duodenal 
brushing 
CE (n=13) 
HC (n=8) 
Gene clone libraries 
(16S rRNA gene)  
Increase in Actinobacteria, Lactobacillales, 
Erysipelotrichales 
Xenoulis et al, 
200829 
 
Duodenal 
brushing 
IBD (n = 10)  
HC (n = 9)  
Gene clone libraries 
(16S rRNA gene)  
Increase in Enterobacteriaceae (E. coli); 
Reduction in biodiversity  
 
Suchodolski et 
al, 200830  
Duodenal 
brushing 
CE (n = 71)  
HC (n = 64)  
Gene clone libraries 
(fungal ITS gene)  
No significant differences in fungal 
communities  
Glanemann et 
al, 200831 
Stomach, 
duodenum, 
Colon biopsies  
Chronic GI 
disease (n = 
42)  
HC (n = 14) 
PCR Presence of Mycobacterium avium subspecies 
paratuberculosis Detected in 8/42 (19%) of 
dogs with chronic GI disease  
Manchester et 
al, 201332 
Colon biopsies HUC (n = 6)  FISH Presence of invasive E. coli  
 
Simpson et al, 
200633 
Colon biopsies HUC (n = 6)  
HC (n = 38)  
FISH Intracellular translocation of adherent and 
invasive E. coli  
Rossi et al, 
201434 
Fecal samples  IBD (n = 20 )  
HC (n = 10)  
qPCR (16S rRNA 
gene)  
Decreased in Faecalibacterium spp. And 
Turicibacter spp.  
Foster et al, 
201314 
Fecal samples  Acute 
diarrhea (n = 
7)  
HC (n = 12)  
454-pyrosequencing 
(18S rRNA gene)  
No significant differences in fungal 
communities  
Suchodolski et 
al, 201224 
Fecal samples  IBD (n = 19)  
AHD (n = 13)  
NHD (n = 12)  
HC (n = 32)  
454-pyrosequencing  
(16S rRNA gene)  
qPCR  
(16S rRNA gene)  
AHD: most profound alterations in their 
microbiome Increase in Sutterella, 
Clostridium perfringens Decrease in Blautia, 
Ruminococcaceae, Turicibacter 
IBD: Decrease in Faecalibacterium spp., 
Fusobacteria  
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References Sampling 
location  
Sample size Method Microbial changes  
Jia et al, 201035 Fecal samples  Chronic 
diarrhea (n = 
9) HC (n = 8)  
FISH Increase in Bacteroides  
Glanemann et 
al, 200831 
Fecal samples  
 
Diarrhea (n = 
4)  
HC (n = 9)  
T-RFLP  Increase in C. perfringens, E. faecalis, and E. 
faecium  
     
Table 1.a: Reported microbial shifts in dogs with gastrointestinal disease. Modified from: Honneffer et al, 2014.18 
n, number of dogs; IBD: Inflammatory bowel disease; HC: Healthy control; HUC, histiocytic ulcerative colitis; AHD: Acute 
hemorrhagic diarrhea; NHD: Non-hemorrhagic diarrhea; CE: chronic enteropathies; FISH: Fluorescence in situ hybridization; T-
RFLP: Terminal restriction fragment polymorphism; qPCR: Quantitative polymerase chain reaction. 	FOOD	INTOLERANCE	AND	ENVIRONMENTAL	FACTORS	In	 humans,	 environmental	 risk	 factors	 for	 IBD	 are	 well	 characterized.	 Epidemiological	 and	 clinical	 evidence	supports	 an	 association	 between	 IBD	 and	many	 environmental	 factors	 such	 as:	 diet,	 oral	 contraceptive	 uses,	smoking,	 geographical	 and	 social	 status,	 occupation,	 appendectomy,	 perinatal	 and	 childhood	 factors	 (hygiene,	diet	and	mode	of	 feeding,	 infections),	vaccinations,	and	microbial	 factors.36–38	Moreover	racial	differences	have	been	 documented,	 although	 studies	 of	migrant	 populations	 suggest	 that	 ethnic	 and	 racial	 differences	may	 be	more	 related	 to	 lifestyle	 and	 environmental	 influences	 than	 true	 genetic	differences.38	 In	dogs,	 environmental	factors	are	way	less	identified	and	are	dietary	habits,	infectious	diseases,	stress	and	physical	activity	are	thought	to	have	a	role.	In	CE,	adverse	reactions	to	food	(ARF)	have	a	role	in	pathogenesis	in	all	the	phenotype	of	the	disease.	ARF	is	a	common	 cause	 of	 gastrointestinal	 signs	 and	 can	 be	 divided	 into	 2	 major	 groups:	 immunologic	 (e.g.,	 dietary	hypersensitivity	 where	 an	 aberrant	 immune	 responses	 is	 involved)	 and	 non-immunologic	 (including	 food	intolerance	and	dietary	indiscretion).39,40	Loss	of	oral	tolerance	is	believed	to	be	the	cause	of	food	intolerance	or	allergy.	 The	 initiating	 events	 that	 lead	 to	 loss	 of	 oral	 tolerance,	 or	 prevent	 it	 from	developing,	 have	 not	 been	described	 in	 dogs	 or	 cats,	 and	 remain	 poorly	 understood	 in	 any	 species.40,41	 Causes	 could	 be	 loss	 of	mucosal	integrity	(e.g.	injury	or	inflammation),	parasitism,	or	dysbiosis.	Loss	of	tolerance	to	dietary	antigens	will	produce	an	aberrant	immune	response	against	the	dietary	antigen,	lead	to	inflammation	locally,	or	in	another	anatomical	site	(e.g	cutaneaous	manifestation	or	otitis	externa).		Infections	such	as	parvovirus	infection,	giardiasis,	or	other	parasites	are	thought	to	be	predisposing	factors	for	development	of	CE.	The	hypothesis,	as	mentioned	above,	is	that	all	these	factors	cause	a	damage	to	the	intestinal	wall,	 causing	a	breaches	 in	oral	 tolerance.	Besides	 these	 theories,	data	on	 this	 aspects	 is	 lacking.	 Finally,	 both	physical	 activity	 and	 stress	 influence	 gut	 function.	 For	 example,	 acute	 diarrhea	 and	 gastric	 ulcers	 occurs	frequently	 in	sled-dogs42	and	 in	dogs	 in	shelters,43	but	whether	 those	 factors	predispose	 the	dogs	 to	CE	 is	not	known.			REFERENCES:	
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Small	Anim	Pract.	2011;41(2):381-398.		
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 	ABSTRACT	Despite	numerous	studies	carried	out	over	the	last	15	years	in	veterinary	medicine,	the	pathogenesis	of	canine	Inflammatory	Bowel	Disease	is	still	not	completely	elucidated.	In	particular,	unlike	what	has	been	demonstrated	in	human	medicine,	the	influence	of	serotonin	on	clinical	signs	in	canine	Inflammatory	Bowel	Disease	is	not	yet	clarified.	 The	 objective	 of	 this	 paper	 has	 been	 to	 seek	 a	 possible	 correlation	 between	 duodenal	 epithelial	distribution	 of	 serotonin-producing	 cells	 (enterochromaffin	 cells)	 and	 disease-grading	 parameters	 (clinical,	clinico-pathological,	endoscopic	and	histopathological)	in	dogs	with	Inflammatory	Bowel	Disease,	The	medical	records	of	dogs	with	a	diagnosis	of	Inflammatory	Bowel	Disease	were	retrospectively	reviewed	and	21	client-owned	dogs	with	a	diagnosis	of	Inflammatory	Bowel	Disease	were	registered.	Clinical	score	(by	Canine	Chronic	 Enteropathy	 Clinical	 Activity	 Index),	 laboratory	 exams	 (albumin,	 total	 cholesterol,	 folate,	 cobalamin),	endoscopic	 score	 and	 histopathological	 score,	were	 compared	 by	 regression	with	 duodenal	 enterochromaffin	cell	percentage.	The	 study	 results	 suggest	 a	 relationship	between	a	decrease	 in	 folate	absorption	and	an	 increase	 in	duodenal	enterochromaffin	 cell	 percentage	 (regression	 equation	 y=16.89-6.14x;	 coefficient	 of	 determination	 r2:	 0.7;	significant	 level:	 P=0.007).	 Meanwhile	 no	 significant	 relationship	 was	 evidenced	 between	 duodenal	enterochromaffin	cell	percentage	and	the	other	analyzed	variables.		
Key words: dog, IBD, serotonin, enterochromaffin cells. 
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INTRODUCTION		Canine	 Inflammatory	Bowel	Disease	 (IBD)	 is	 a	 disease	based	on	 evidence	of	 clinical	 signs	 of	 chronic	diarrhea	and/or	vomiting	associated	with	weight	loss,	once	excluded	enteric	infectious,	parasitic,	endocrine	or	neoplastic	diseases,	food	responsive	enteropathy	(FRE)	and	antibiotic	responsive	diarrhea	(ARD)	(1).		For	more	than	twenty	years,	IBD	has	been	the	major	topic	of	discussion	and	research	in	canine	gastroenterology	and	the	interest	in	deepening	its	pathogenesis	in	the	veterinary	field	is	also	related	to	the	increasing	knowledge	that,	currently,	characterizes	similar	human	diseases,	such	as	Crohn’s	disease	and	ulcerative	colitis.		Untill	 now,	 several	 studies	 about	 its	 ethio-pathogenesis	 and	 treatment	 have	 been	 performed	 in	 veterinary	medicine,	but	 little	attention	has	been	paid	 to	 the	dysfunction	of	 the	 regulation	of	 the	enteric	nervous	system	that	characterizes	this	syndrome.		Nervous	control	of	gastrointestinal	motility	and	secretion	is	a	complex	process,	in	which	serotonin	(5-HT)	plays	an	important	role	(2).		The	majority	 of	 5-HT	 is	 stored	 in	 enterochromaffin	 (EC)	 cells	 included	 in	 gut	 epithelium,	 initiates	 peristaltic,	secretory,	vasodilatory,	and	nociceptive	reflexes,	and	it	is	removed	by	serotonin-selective	reuptake	transporter	(SERT),	 located	 on	 enterocytes,	 central	 or	 peripheral	 serotonergic	 neurons,	 and	 platelets	 (3,	 4,	 5).	 Altered	serotonergic	metabolism	has	been	described	in	human	gastrointestinal	diseases	(6,	7).	In	veterinary	medicine,	a	recent	report	evidences	a	higher	concentration	of	5-HT	and	of	the	EC	cell	marker	chromogranin-A	(CgA)	in	the	intestinal	mucosa	of	dogs	with	IBD	when	compared	with	healthy	controls	(8).		Accordingly,	we	have	evaluated,	in	dogs	with	IBD,	the	relationship	between	duodenal	EC	cell	distribution	and	the	degree	of	the	clinical	condition,	the	result	of	laboratory	tests,	endoscopic	appearance	and	duodenal	histology.	MATERIAL	AND	METHODS		The	 medical	 records	 of	 dogs	 with	 a	 diagnosis	 of	 IBD	 between	 January	 2011	 and	 November	 2013	 were	retrospectively	reviewed.		Twenty-one	 client-owned	 dogs	 were	 included	 (seven	 crossbred	 and	 14	 purebred	 –	 Rottweiler	 [n=2],	 Basset	Hound	[1],	Bolognese	[1],	Boxer	[1],	Cocker	Spaniel	[1],	Dachshund	[1],	Epagneul	Breton	[1],	German	Shepherd	[1],	Great	Dane	[1],	Labrador	Retriever	[1],	Maltese	[1],	Pointer	[1],	West	Highlander	White	terrier	[1]),	4	females	(2	spayed)	and	17	males	(4	castrated),	mean	age	of	5.8±3.2	years,.		The	inclusion	criteria	embraced	history,	a	physical	examination,	a	complete	blood	count,	a	serum	biochemistry	profile,	 serum	 folate	 concentration,	 serum	 cobalamin	 concentration	 and	 a	 negative	 fecal	 flotation	 test	 or	treatment	with	fenbendazole	(Panacur,	Intervet	Italia	Srl,	Milano,	Italy)	50	mg/kg	SID	for	three	days.	Persistence	 of	 clinical	 signs	 that	 followed	 a	 dietary	 modification	 (hypoallergenic	 diet)	 for	 three	 weeks	 was	applied	to	exclude	FRE,	and	treatment	to	exclude	ARD	was	applied	for	3	weeks	with	tylosin	at	15	mg/kg,	PO,	q	12	h	(Tylan,	Eli	Lilly	Italia,	Firenze,	Italy)	or	metronidazole	(Flagyl,	Zambon	Italia,	Vicenza,	Italy)	at	10	mg/kg	PO,	q	12	h.	An	 abdominal	 ultrasound	 examination,	 a	 complete	 endoscopic	 examination	 of	 the	 alimentary	 tract,	 and	 a	histological	examination	of	enteric	bioptic	samples	concluded	the	diagnostic	process,	arising	from	the	diagnosis	of	IBD.	CLINICAL	SCORE	In	order	to	be	later	used	for	comparison,	clinical	data,	obtained	before	treatment,	were	scored	by	the	validated	clinical	 score	 index	 (Canine	Chronic	Enteropathy	Clinical	Activity	 Index,	CCECAI)	 (9).The	analyzed	parameters	were	attitude/activity,	 appetite,	vomiting,	 stool	 consistency,	 stool	 frequency,	body	weight	 loss,	 serum	albumin	concentration,	presence	of	peripheral	edema/ascites	and	severity	of	pruritus.	The	parameters	were	analyzed	with	a	score	moving	from	0	(normal	condition)	to	3	(worst	condition).	The	total	score	from	0	to	3	points	indicates	an	insignificant	disease,	from	4	to	5	points	indicates	a	mild	disease,	from	6	to	8	points	indicates	a	moderate	disease,	from	9	to	11	point	indicates	a	severe	disease,	and	a	score	≥	12	points	indicates	a	very	severe	disease.	
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LABORATORY	ANALYSIS	On	serum	samples	collected	before	treatment,	albumin	(reference	range	[RR]	2.8-3.7	g/dL),	total	cholesterol	(RR	140-350	mg/dL),	serum	folate	(RR	6.5-11.5	μg/L)	and	serum	cobalamin	(RR	250-730	ng/L)	were	employed	for	further	statistical	analysis.	ENDOSCOPIC	SCORE	Endoscopic	 video	 recordings	 of	 the	 duodenum,	 performed	 in	 digital	manner	 during	 the	 diagnostic	 procedure,	were	 revaluated	 and	 scored	 following	 the	 endoscopic	 activity	 score	 index	 (EASI)	 as	 reported	 by	 Slovak	 et	 al.	(2015)	(10).	In	particular	the	endoscopic	parameters,	evaluated	with	a	score	from	0	to	2,	were:	friability	(bleeding	on	contact	with	 endoscope	or	biopsy	 forceps),	 granularity	 (alteration	 in	 the	 texture	of	 the	mucosa),	 erosions	 (superficial	linear	mucosal	defect[s]	with	hemorrhage)	and	lymphatic	dilatation	(multifocal	to	diffuse	white	foci	within	the	mucosa).	HISTOPATHOLOGICAL	SCORE	Three	to	five	duodenal	biopsies,	collected	from	each	dog	during	the	endoscopic	examination,	were	fixed	in	10%	neutral	 buffered	 formalin,	 embedded	 in	 paraffin,	 sectioned	 at	 4µm,	 and	 stained	 with	 hematoxylin	 and	 eosin.	Sections	 were	 re-examined	 in	 all	 dogs	 following	 the	 histopathological	 standard	 of	 the	 World	 Small	 Animal	Veterinary	Association	(WSAVA)	Gastrointestinal	Standardization	Group	(11).		In	 particular	 the	 morphological	 criteria	 (villous	 stunting,	 villous	 epithelial	 injury,	 crypt	 distension,	 lacteal	dilation,	mucosal	fibrosis,	goblet	cells)	and	the	parameters	of	inflammation	(intraepithelial	lymphocytes,	lamina	propria	lymphocytes	and	plasma	cells,	lamina	propria	neutrophils)	were	scored	with	a	0-3	scale	(0,	normal	state;	1,	mild;	2,	moderate;	3,	severe).		The	final	score	was	the	sum	of	all	the	considered	parameters.	IMMUNOHISTOCHEMICAL	ANALYSIS	Immunohistochemistry	was	performed	with	a	streptavidin-biotin-peroxidase	technique	(Biospa,	Milano,	Italy)	in	order	to	evidence	the	percentage	of	EC	cells	with	respect	to	all	the	cells	of	duodenal	epithelial	layer.	Replicate	4µm-thick	sections	were	cut	 from	the	paraffin	block	of	each	case,	 incubated	with	hydrogen	peroxide	0.3%	in	methanol	for	20	min	to	block	endogenous	peroxidase	activity	and	microwaved	in	citrate	buffer	(pH	6.0),	for	two	cycles	of	5	min.,	for	antigen	retrieval.	Sections	were	then	incubated	overnight	at	4°C	in	a	humid	chamber	with	 the	 primary	 antibody	 (polyclonal	 rabbit	 anti-human	 chromogranin-A,	 Dako,	 Glostrup,	 Denmark)	 diluted	1:500	 in	 PBS	 (pH	 7.4,	 0.01	 M).	 Following	 washing	 in	 PBS,	 sections	 were	 then	 incubated	 with	 secondary	biotinylated	 anti-rabbit	 IgG	 for	 30	min	 at	 room	 temperature,	 and	 subsequently	 with	 streptavidin-peroxidase	complex	 for	 25	 min	 at	 room	 temperature.	 After	 incubation	 in	 DAB	 chromogenic	 substrate	 solution	(diaminobenzidine	0.02%,	and	H2O2	0.001%	in	PBS)	for	12	min,	sections	were	immediately	rinsed	in	PBS	and	in	running	tap	water,	counterstained	with	hematoxylin,	dehydrated	and	mounted	with	DPX	(Fluka,	Riedel-de	Haën,	Germany).		Histological	 sections	of	 normal	 canine	pancreas	were	used	 as	positive	 controls	 to	 assess	 the	 specificity	 of	 the	reactions.	As	a	negative	control,	an	isotype-matched	antibody	of	irrelevant	specificity	(NeoMarkers,	Fremont,	CA,	USA)	was	used	in	place	of	the	primary	antibody.		The	slides	were	first	evaluated	at	low	magnification,	assessing	the	sites	with	a	higher	concentration	of	positive	cells.	 These	 sites	 were	 then	 digitally	 captured	 at	 higher	 magnification	 (200X)	 with	 a	 digital	 capture	 system	(Nikon	DS-L3,	Nikon	Instruments	S.p.A,	Firenze,	Italy)	connected	to	a	light	microscope	(Nikon	Eclipse	55i,	Nikon	Instruments	S.p.A,	Firenze,	Italy)	and	five	fields	per	slide	were	stored.		Fields	 were	 considered	 adequate	 for	 evaluation	 if	 villi	 were	 sectioned	 longitudinally,	 and	 the	 images	 were	captured	in	order	to	include	as	many	epithelial	cells	as	possible.		Through	the	Nikon	DS-L3	digital	software	(Nikon	Instruments	S.p.A,	Firenze,	Italy)	the	cells	positively	labeled	for	CgA	(i.e.	dark	brown	color)	were	marked	in	red	and	counted;	thereafter,	the	other	enterocytes	were	marked	in	green,	blue	and	white	and	counted	(Figure	1).		The	positively-labeled	cells	were	then	expressed	as	a	percentage	with	respect	to	the	total	number	of	cells	in	the	epithelial	layer,	which	allowed	a	reliable	comparison	among	fields	with	different	cellularity.		
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Figure 1: Exemplification of the system used to quantify the density of enterochromaffin cells in biopsy sections. In 
chromogranin-A immunostained sections, the positive labeled cells (enterochromaffin cells ) are marked in red, and the 
enterocytes are marked in green, blue or white. The density of enterochromaffin cells is then expressed with respect to 
the enterocytes number, regardless of the area occupied by the inflammatory infiltrate. Streptavidin-biotin-peroxidase 
technique, hematoxylin counterstain, 200x. 	STATISTICAL	ANALYSIS	Statistical	analysis	was	performed	with	a	commercially	available	program	(MedCalc	sofware,	Ostend,	Belgium).		Assessment	of	data	for	normality	was	calculated	by	applying	the	D’Agostino-Pearson	test.		Data	were	expressed	as	median	(95%	confidence	interval).	A	linear	regression	was	applied	between	the	percentage	of	duodenal	EC	cells	and	CCECAI,	serum	albumin,	total	cholesterol,	serum	folate,	serum	cobalamin,	EASI,	and	histopathological	index,	respectively.		Values	of	P	<	0.05	were	considered	significant.	RESULTS	CCECAI	was	performed	in	19/21	dogs;	albumin	was	analyzed	in	20/21;	total	cholesterol	in	18/21;	serum	folate	in	16/21;	serum	cobalamin	in	15/21	dogs;	endoscopic	score	was	calculated	in	20/21;	histopathological	score	in	18/21,	and	EC	cell	percentage	with	respect	to	duodenal	epithelial	layer	cells	in	14/21	dogs.	Median	 (95%	 confidence	 index)	 for	 CCECAI	 was	 8	 (6-10),	 for	 albumin	was	 1.59	 g/dL	 (1.22-3.20),	 for	 serum		cholesterol	was	160	mg/dL	(107-192),	 for	serum	folate	was	8.09	μg/L	(4.55-12.68),	 for	serum	cobalamin	was	232	ng/L	(159-271),	for	duodenal	endoscopic	score		(EASI)	was	1.5	(1-3.8),	for	duodenal	histopathological	score	was	 10.5	 (8.4-13.2),	 and	 for	 duodenal	 EC	 cell	 percentage,	with	 respect	 to	 duodenal	 epithelial	 layer	 cells,	was	1.16%	(0.94-1.98).	A	significant	negative	 relationship	was	evidenced	only	between	duodenal	EC	cell	percentage	and	serum	 folate	(regression	equation	y=16.89-6.14x;	coefficient	of	determination	r2:	0.7;	significant	level:	P=0.007)	(Table	1).		No	significant	relationship	was	evidenced	between	duodenal	EC	cell	percentage	and	the	other	analyzed	variables	(Table	1).		
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Dependent Y CCECAI 
Albumin 
(g/dL) 
 
Serum 
Cholesterol 
(mg/dL) 
Serum folate 
(μg/L) 
 
Serum 
cobalamin 
(ng/L) 
EASI 
Histopathol
ogical score 
Independent X EC cells (%) EC cells (%) EC cells (%) EC cells (%) EC cells (%) EC cells (%) EC cells (%) 
R2 0.06 0.16 0.10 0.67 0.01 < 0.01 <0.01 
Regression 
equation 
Y=8.9999-
0.8328x 
Y=1.1174+0.
7604x 
Y=118.3226+
22.5887x 
Y=16.8928-
6.1360x 
Y=326.5332-
36.5200x 
Y=2.0598-
0.09406x 
Y=11.6543-
0.3543x 
F-ratio 0.6503 2.1287 1.0523 13.9130 0.098187 0.02837 0.05889 
Significance 
Level 
P=0.439 P=0.173 P=0.332 P=0.007 P=0.763 P=0.869 P=0.812 
        
Table 1: Regression between the percentage of entherochromaffin cells (EC cells %) and  clinical score (CCECAI), serum 
albumin, serum cholesterol, serum folate, serum cobalamin, endoscopic activity score index (EASI) and histopathological 
score, respectively. 		DISCUSSION	One	 of	 the	main	 results	 of	 the	 research	 is	 represented	 by	 the	 lack	 of	 relationship	 between	 duodenal	 EC	 cell	concentration	and	the	clinical	condition,	serum	albumin,	 total	cholesterol,	 serum	cobalamin,	endoscopic	 index,	and	histopathological	score	respectively.	Actually,	 this	 is	 not	 a	 surprising	 result.	 Even	 if	 each	 of	 the	 employed	 grading	 systems	 (CCECAI,	 clinico-pathological,	EASI,	histological)	seems	able	to	define	the	severity	of	canine	IBD	(9,	11,	12,	13),	it	is	questionable	if	a	 significant	 association	 between,	 clinical	 signs,	 serum	 biomarkers	 and	 intestinal	 histopathological	 findings	exists	in	canine	IBD	(14,	15).	With	 the	exception	of	 the	 recent	paper	by	Bailey	et	al.	 (8),	no	previous	studies	have	been	performed	on	5-HT	metabolism	in	dogs	with	IBD.	Moreover	these	researchers	(8)	evidenced	a	significant	increase	in	5-HT	and	CgA	expression	in	duodenal	biopsies	of	dogs	with	IBD	with	respect	to	healthy	dogs,	but	no	analysis	was	performed	within	the	IBD	group	in	relation	to	IBD	severity.	On	the	other	hand,	 it	 is	not	possible	 to	compare	our	results	about	CgA	duodenal	expression	with	Bailey	et	al’s	study	due	to	different	cellular	count	criteria.		In	fact,	they	(8)	manually	counted	the	number	of	cells	stained	positively	for	CgA	in	20	random	high	power	fields	per	 slide	 and	 calculated	 average	data,	while	we	 counted	 the	CgA	positive	 cells	 in	 five	 fields	per	 slide	digitally	stored,	then	expressed	it	as	a	percentage	with	respect	to	the	cellular	total	number	of	epithelial	layers.	The	only	 relationship	 that	we	have	been	 able	 to	 identify,	was	 the	negative	 relationship	between	 serum	 folate	concentration	 and	 duodenal	 EC	 percentage,	 indicating	 the	 probable	 involvement	 of	 EC	 cells	 in	 the	 damage	 of	proximal	small	bowel.	In	fact,	even	if	its	sensitivity/specificity	is	not	high,	the	decrease	of	serum	folate	could	be	read	as	an	indication	of	proximal	small	intestinal	malabsorption	(16).		One	of	the	limits	of	our	study	is	that	we	counted	the	CgA	positive	cells,	assuming,	incorrectly,	they	all	produce	5-HT,	with	the	consequence	of	a	possible	5-HT	producing	cells	overcount.		Although	CgA	could	mark	all	EC	cells	and	not	only	the	5-HT	producing	EC	cells,	the	duodenal	CgA	cell	density	has	been	elected	 in	human	gastroenterology	as	a	reliable	biomarker	 for	 the	diagnosis	of	 irritable	bowel	syndrome	(7).		
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Furthermore,	Bailey	et	al.	 (8)	evidenced,	 in	duodenal	histologic	samples	examined	from	healthy	dogs	and	dogs	with	IBD,	a	significant	relationship	between	duodenal	CgA	positive	cells	and	duodenal	5-HT	producing	EC	cells.		In	colonic	biopsies	of	human	beings,	50-60%	of	CgA	positive	cells	are	also	positive	for	5-HT	(6).	We	must	also	point	out	 that	 the	count	of	CgA	cells	 instead	5-HT	producing	EC	cells,	 in	our	study,	 involved	the	entire	population,	and	poorly	affects	the	results.	More	 important	 study	 bias	 is	 represented	 by	 the	 evaluation	 of	 the	EC	 cell	 count	 omitting	 the	 5-HT	metabolic	pathway,	 starting	 from	 tryptophan	hydroxylase-1	 (enzyme	 for	5-HT	synthesis)	up	 to	5-HT	reuptake	 transport	protein	 (SERT),	 expressed	 by	 platelets,	 nerve	 terminals,	 mucosal	 enterocytes,	 and	 vascular	 endothelial	 cells.	These	mediate	the	intracellular	reuptake	of	5-HT,	reducing	its	availability	(3,	4,	5).	In	fact,	an	increase	in	mucosal	5-HT	content	could	be	due	to	a	decrease	of	SERT	level,	rather	than	an	hyperplasia	of	EC	cells	producing	5-HT	(17).	The	membrane	 expression	 of	 SERT	 can	 be	 altered	 by	 phosphorylation	 by	 Protein	 Kinase	 C	 (PKC)	 leading	 to	internalization	of	SERT	and	reduction	in	5-HT	uptake	rates	in	SERT-expressing	cell	lines.	Interferon-γ	and	tumour	necrosis	factor	α	significantly	and	synergistically	impaired	SERT	functions,	inducing	a	decrease	in	both	SERT	mRNA	and	protein	levels	(18).	Instead,	IL-10	showed	a	dual	effect	on	SERT,	in	relation	with	its	concentration.		At	a	high	concentration,	IL-10	induced	an	increase	of	SERT	activity	and	expression	in	the	cell	membrane,	while	a	low	concentration	inhibited	SERT	activity	(19).	In	 conclusion,	 further	 research	 is	 useful	 to	 advance	 the	 involvement	 of	 5-HT	 in	 canine	 IBD	 pathogenesis,	evaluating	if	SERT	activity	is	related	with	IBD	severity,	and	therefore	if	the	decrease	in	5-HT	reuptake	is	linked	to	nociception	and	clinical	signs	in	these	patients.		REFERENCES:	
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2.	 	SIGNALEMENT:	BREED,	AGE	AND	SEX	DISTRIBUTION	BREED:	The	cause	of	CE	 in	human	beings	and	animal	models	 is	multifactorial	and	 includes	genetic	and	environmental	components,	as	well	as	the	mucosal	immune	system	and	intestinal	microbiota,	as	described	in	previous	chapters.	In	a	recent	meta-analysis	of	genome-wide	association	studies	of	Crohn’s	disease	and	ulcerative	colitis	several	loci	positively	associated	with	disease	were	found,	but	further	studies	are	needed	to	investigate	heritability	in	human	IBD	and	the	other	factors	seems	to	be	implicated	in	the	complex	genetic	etiology	of	this	disease.1,2			Moreover,	 the	 mode	 of	 inheritance	 of	 IBD	 in	 dogs	 not	 thoroughly	 understood,	 and	 may	 differ	 between	 dog	breeds.	A	 number	 of	 breed	predispositions	 have	been	described	 in	 canine	 chronic	GI	 disorders,	 thus	 strongly	supporting	a	role	for	host	genetics.	Table	2.a	resumes	breed	predisposition	to	chronic	intestinal	disease.			
References Breed Findings   
 
German et al, 2000; 
German et al, 
2000(1); Craven et al, 
2004; Allenspach et 
al,  2010; Kathrani et 
al, 2010; Dijkstra et 
al, 2010; Kathrani et 
al, 2011; Allenspach 
et al, 2016; 
Dandrieux, 2016 3–11 
 
German Shepherd 
Dogs (GSD). 
Weimaraners, 
Rottweilers, Boxers 
and Border Collies. 
Golden Retrievers, 
West Highland white 
terriers (WHWT) and 
Labradors Retrievers 
 
 GSD appear to be predisposed to both idiopathic IBD and ARE (once 
called small intestinal bacterial overgrouth, SIBO). Possible described 
causes were: genetic predisposition, distinct expression pattern of TLR 
(increase in TLR4 and a very low expression of TLR5), dysbiosis and a 
heightened immune response within the intestinal mucosa.  
Other breeds are described to be highly susceptible to developing IBD 
in a retrospective paper in the south-eastern UK. Golden Retrievers, 
WHWT and Labradors Retrievers were other most commonly affected 
breeds in another retrospective study. 
Lecoindre et al, 2010; 
Dijkstra et al, 2010; 
Dossin and Lauvé, 
2011; Simmerson et 
al, 2014; Rudinsky et 
al, 2014; Bota et al, 
20168,12–16 
Yorkshire Terriers 
Rottweiler 
Rottweiler and Yorkshire terriers are susceptible to a potentially severe 
form of PLE. Clinical signs can be very mild to severe. Outcome is 
variable but in both breeds some dogs completely fail to respond to 
therapy, leading to a poor prognosis. On the contrary, one abstract 
reported retrospectively the effect of diet alone in Yorkshire terriers 
with PLE with complete resolution of clinical signs. 
Wiberg et al, 1999; 
Clark et al, 2005; 
Batchelor et al, 2007; 
Mas et al, 2012; 
Westermarck et al, 
2012; Alvarez et al, 
2015; Evans 2015 17–23 
German Shepherd 
Dogs, Rough-coated 
Collies, Chow 
Chows, and Cavalier 
King Charles 
Spaniels. 
 
Exocrine pancreatic insufficiency (EPI) is a common condition in dogs, 
resulting from inadequate functional reserve of pancreatic acinar 
tissue. The most common cause of EPI in these breeds is pancreatic 
acinar atrophy. Clinical signs and maldigestion are usually not seen 
until 90% of the secretory capacity is lost. The endocrine function of the 
pancreas is usually spared in this process, but juvenile diabetes 
mellitus and concurrent EPI have been reported in the literature. 
Hereditability of EPI is demonstrated and is suggested to be a 
polygenic mode of inheritance. 
Simpson et al, 2006; 
Craven et al, 2011; 
Manchester et al, 
2013 24–26 
Boxers, French 
Bulldogs 
Granulomatous colitis is associated with selective intra-mucosal 
colonization by Escherichia coli, diagnosed by fluorescent in situ 
hybridization (FISH). Treatment of choice is fluorchinolone 
antimicrobials, but antimicrobial resistance has been demonstrated. 
Ohmi et al, 2012; 
Igarashi et al, 2013; 
Igarashi et al, 201627–
29 
Dachshunds 
Miniature dachshunds are predisposed to develop inflammatory 
colorectal polyps (ICRPs), in Japan. Treatment option may be 
immunosuppressive therapy (prednisolone and cyclosporine). 
Dysbiosis is associated with ICRPs and it could be a potential 
therapeutic target. Two previously described dachshunds with ICRPs 
developed polypoid adenomas after a long-term course of the disease.  
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References Breed Findings   
Hall and Batt, 1991; 
Polvi et al, 1998; 
Gardern et al, 200030–
32 
Irish setter 
Irish Setter dogs are predisposed to CE related to gluten sensitivity 
enteropathy (GSE).  Underlying permeability abnormality may be 
involved in the pathogenesis of this enteropathy. Genetic transmission 
of gluten-sensitive enteropathy is under the control of a single major 
autosomal recessive locus.  
Fyfe et al, 1991; 
Battersby et al, 2005; 
Grützner et al, 2009; 
Bishop et al, 2011; 
Grützner et al, 
201333–37 
Chinese Shar Peis,  
Giant Schnauzer dog, 
Border collies,  
Australian shepherd 
dog 
Chinese Shar Pei has a high prevalence of cobalamin deficiency 
compared to other breeds and healthy controls, and it can be 
subclinical. It is associated with mutation on chromosome 13 and could 
be an inheritable disorder. Several Shar-Peis with cobalamin deficiency 
have an alteration in serum homocysteine and methylmalonic acid 
compared to other breeds, suggesting that the function of the two 
intracellular cobalamin-dependent enzymes is impaired.  
Inherited selective intestinal malabsorption of cobalamin was observed 
in a family of Giant Schnauzer dogs and a simple autosomal recessive 
inheritance has been demonstrated. Border collies and Australian 
shepherd dogs in the USA have been reported to be affected by this 
disease. 
Breitschwerdt et al, 
1984; MacLachlan, et 
al 198838,39 
Basenji 
A specific gastrointestinal disease (gastric rugal hypertrophy and 
lymphocytic plasmatic enteritis [LPE]) occurs in Basenji dogs and 
intestinal function was abnormal in both affected and asymptomatic 
Basenji dogs. 
Littman et al, 2000; 
Vaden et al, 200040,41 
Soft Coated Wheaten 
Terriers (SCWT) 
SCWT are predisposed to develop PLE and protein-losing nephropathy 
(PLN) and distinctive familial predisposition were demonstrated. Food 
allergies are present in SCWTs affected with PLE and/or PLN in an 
early phase of the disease process.  
Ohno et al, 2006; 
Ohmi et al, 2011; 
Okanishi et al, 
201342–44 
Shiba dogs 
Shiba dog appears to be predisposed to chronic enteropathy with LPE 
and shows severe duodenal lesions and poor prognosis. 
Berghoff et al, 2007; 
Qvigstad et al, 2008; 
Metzger et al, 2016 45–
47 
Norwegian 
Lundehunds 
Lundehund syndrome (LS) is a severe disease affecting gastro-enteric 
system characterized by atrophic gastritis and PLE, which led to 
predisposition to the development of gastric neoplasia. Approximately 
50% of all Norwegian Lundehund living in North America are affected. 
A genetic predisposition has been investigated but further studies are 
needed to understand the underlying complex genetic mechanisms.  
 
Table 2.a: Breed predisposition to common chronic gastrointestinal disease in dogs.  
IBD, inflammatory bowel disease; ARE, antibiotic responsive enteropathies; TLR, toll-like receptors; PLE, protein loosing 
enteropathies; LPE, lymphocytic-plasmacytic enteritis 	AGE		Although	 there	 is	 no	 definitively	 age	 predilection	 documented	 for	 CE,	 ARE	 and	 FRE	phenotypes	 appear	 to	 be	more	common	in	younger	dogs,	with	respect	to	SRE.10,11,48–50	ARF	is	very	common	in	dogs	younger	than	1	year	of	age51,	 although	 in	many	 studies	 the	 average	 age	 of	 the	 FRE	 dogs	 is	 higher	 than	 1	 year.11,48,52	 ARE,	 as	well	 as	tylosin	 responsive	 enteropathy	 typically	 affects	middle-aged,	 large-breed	 dogs.11,53,54	 To	 the	 contrary,	middle-aged	 to	 older	 dogs	 are	more	 prone	 to	 have	 SRE	 or	 PLE,9–11,44,48,55	 even	 if	 in	 some	breeds	 it	 can	 occur	 even	 in	younger	individuals.12,40	Although	the	age	of	presentation	can	help	distinguish	CE	phenotype,	in	clinical	setting,	it	is	important	to	remind	that	FRD,	ARE	or	SRD	can	occur	at	any	age.11	
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SEX	No	 definite	 sex	 predisposition	 is	 reported	 in	 dogs	with	 CE.7,56	 Even	 if	 in	 some	 breeds	 (Yorkshire	 terrier	with	PLE12	 	 and	 SCWT	 dogs40)	 a	 female	 predisposition	was	 described.	 The	 is	 not	 unanimous	 on	 this	 aspect,	 as	 in	another	study	more	males	than	females	were	affected	by	CE.9	Moreover,	a	recent	study	has	demonstrated	that	neutering	is	associated	with	increased	risk	for	certain	autoimmune	disorders,	included	IBD.57	Female	predisposition	 is	well	established	 in	autoimmune	disorders	 in	human	beings58,59	and	 in	other	acquired	autoimmune	diseases	 in	dogs.	 60–63	Although	 in	 contrast	 to	other	 female-specific	autoimmune	diseases,	 female	predominance	 in	 IBD	 is	 not	 a	 general	 feature	 in	 human	 beings,	 and	 when	 present,	 it	 is	 subject	 to	 great	geographical	 variation.	 Geographical	 differences	 in	 the	 female:male	 ratio	 observed	 across	 different	 IBD	populations	might	be	explained	with	differences	 in	 the	exposure	 to	environmental	 factors	associated	with	 the	disease	(infectious	agents,	use	of	oral	contraceptives,	antibiotics	use,	smoking).64		REFERENCES:	
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Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emilia (BO), Italy. 
 	SUMMARY		Many	breeds	are	predisposed	to	develop	CE	and	many	breed-specific	related	enteropathies	have	been	described	in	 literature,	 and	 no	 definitive	 sex	 predisposition	 have	 been	 demonstrated.	 None	 of	 the	 studies	 available	 in	literature	were	performed	in	Italy,	and	therefore	there	is	no	information	regarding	breed	or	sex	predisposition	in	the	Italian	canine	population.		The	 aim	 of	 this	 study	 was	 to	 evaluate	 the	 sex	 or	 breed	 predispositions	 in	 dogs	 with	 CE	 presented	 to	 the	Veterinary	Teaching	Hospital	of	University	of	Bologna	between	January	2010	and	December	2015.		Dogs	of	any	sex,	breed,	and	age	were	included	if	a	minimum	workup	(hematology,	plasma	biochemistry	profile,	and	 fecal	parasitology)	had	been	performed	and	 if	a	 final	diagnosis	of	CE,	with	no	concomitant	disorders,	was	recorded	(n=268	dogs).	A	control	population	was	included	to	evaluate	sex	and	breed	predispositions	in	CE.	The	control	population	included	all	dogs	admitted	to	the	hospital	in	the	same	period	of	time	(n=33130	dogs).	Odds	ratios	and	Chi	Square	tests	were	used	to	analyze	breed	and	sex	predispositions,	respectively,	significance	was	set	at	p=0.05.		In	 dogs	 diagnosed	 with	 CE	 the	 following	 phenotypes	 were	 diagnosed:	 FRE	 27.9%	 (75/268),	 ARE	 20.8%	(56/268),	 IBD	 20.8%	 (56/268),	 PLE	 13.4%	 (36/268),	 and	 HUC	 1.1%	 (3/268).	 	 In	 15.6%	 (42/268)	 the	 exact	phenotype	could	not	be	determined.		Breeds	predisposed	to	CE	and	each	phenotype	are	reported	in	Table	1.	Male	dogs	were	shown	to	be	predisposed	to	develop	CE,	in	particular	IBD	(Table	2).		Results	of	this	study	confirm	a	predisposition	of	certain	breeds	to	develop	CE,	such	as	GSD,1–4	Boxer,4.5	Yorkshire	Terrier,6.7	and	Border	Collie.4	Other	breeds	that	were	not	previously	reported	include:	French	Bulldog,	Miniature	Puddle,	 Pincher,	 Jack	 Russel	 Terrier	 and	 Siberian	 Husky.	 Moreover,	 two	 Italian	 breeds	 were	 shown	 	 to	 be	predisposed	to	CE:	Maltese	and	Bolognese.	The	results	of	this	study	also	demonstrate	a	male	predisposition	to	IBD	in	the	population	of	interest.	Female	predisposition	is	well	established	in	autoimmune	disorders	in	human	beings8.9	and	in	other	acquired	autoimmune	disease	in	dogs.	10–13	Female	predisposition	in	CE	in	humans	is	not	demonstrated	 and	 it	 is	 subject	 to	 great	 geographical	 variation	 due	 to	 differences	 in	 the	 exposure	 to	environmental	factors	associated	with	the	disease.14	In	 conclusion,	 this	 study	 confirms	 that	 CE	 is	 more	 frequent	 in	 pure	 breed	 dogs	 and	 certain	 breeds	 are	predisposed.	Moreover,	this	is	the	first	study	that	reports	a	male	predisposition	to	IBD	in	dogs.										
28	
			
Breed 
Control 
population 
CE dogs OR 95% CI z statistic P-value 
CE 
Mixed breed  10875 54 1    
GSD 2087 25 2.4295 1.5087 to 3.9125 3.652 P = 0.0003 
Boxer  800 15 3.8291 2.1511 to 6.8159 4.564 P < 0.0001 
Miniature Poodle  882 11 2.5307 1.3185 to 4.8576 2.791 P = 0.0053 
Maltese  710 9 2.5728 1.2651 to 5.2319 2.609 P = 0.0091 
Yorkshire Terrier  665 9 2.7492 1.3516 to 5.5923 2.792 P = 0.0052 
Pinscher  713 8 2.2739 1.078 to 4.7967 2.157 P = 0.0310 
French Bulldog  381 8 4.2979 2.0309 to 9.0956 3.812 P = 0.0001 
Jack Russel Terrier  540 7 2.6317 1.1918 to 5.8113 2.394 P = 0.0167 
Border Collie  346 6 3.5363 1.511 to 8.2764 2.911 P = 0.0036 
Bolognese  362 5 2.8066 1.1159 to 7.0585 2.193 P = 0.0283 
Siberian Husky  161 3 3.8049 1.1772 to 12.2982 2.232 P = 0.0256 
FRE 
Mixed breed 10875 20 1    
Border Collie  346 3 4.7471 1.4039 to 16.0514 2.506 P = 0.0122 
ARE 
Mixed breed 10875 11 1    
Dachshund 675 3 4.4091 1.2271 to 15.8421 2.274 P = 0.0230 
Yorkshire Terrier  665 3 4.4757 1.2456 to 16.0819 2.297 P = 0.0216 
IBD 
Mixed breed 10875 11 1    
GSD 2087 6 2.8476 1.0519 to 7.7084 2.06 P = 0.0394 
Boxer  800 5 6.2115 2.1529 to 17.9216 3.378 P = 0.0007 
Maltese  710 3 4.1908 1.1665 to 15.0561 2.196 P = 0.0281 
PLE 
Mixed breed 10875 7 1    
GSD 2087 5 3.7286 1.1822 to 11.7592 2.246 P = 0.0247 
Rottweiler  372 3 12.6225 3.2511 to 49.0081 3.664 P = 0.0002 
Table 1: Breeds predisposed to CE and each phenotype. Data are presented on the OR of developing CE compared with 
the mixed-breed dog. together with the 95% CI z- statistic and p-value .  
CE, chronic enteropathies; FRE, food-responsive enteropathies; ARE, antibiotic responsive enteropathies; IBD, inflammatory bowel 
disease; PLE, protein loosing enteropathies; CI, Confidence interval; GSD, German shepherd dog; OR, Odds ratio. 			
 FRE  ARE  IBD  PLE  All CE  Control population  
Male  41 (54.7%) 26 (46.4%) 44 (78.6%) 21 (58.3%) 160 (59.7%) 16654 (50.3%) 
Female  34 (45.3%) 30 (53.6%) 12 (21.4%) 15 (41.7%) 108 (40.3%) 16476 (49.7%) 
p-value  0.4467  0.5658  < 0.0001  0.3334  0.0021   
Table 2: Sex predisposition to CE and each phenotype.  		
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3.	 	CLINICAL	SIGNS		Clinical	signs	of	dogs	with	CE	can	vary	from	mild	or	subclinical	to	severe	with	life	threating	GI	signs.	The	severity	of	 clinical	 signs	 (such	 as	 diarrhea,	 vomiting,	 or	 weight	 loss)	 has	 not	 been	 reported	 to	 predict	 response	 to	treatment	or	prognosis,	and	neither	is	related	with	the	disease	severity.1	However	clinical	severity	at	the	time	of	diagnosis	was	significantly	different	between	phenotypes	in	some	reports,	with	FRE	having	less	severe	clinical	signs	 with	 respect	 to	 ARE	 or	 IRE.2,3	 Others	 symptoms,	 such	 as	 anorexia,	 severe	 weight	 loss,	 and	 ascites	 are	associated	with	poor	prognosis.1,4		Therefore	in	a	clinical	settings	is	important	to	recognize	common	mild	or	subclinical	symptoms	and	be	aware	of	the	ones	that	can	be	less	common,	but	more	severe.		In	 the	 following	 section	 clinical	 signs	 of	 dogs	with	 CE	 are	 briefly	 reviewed	 and	 divided	 into	 “common”,	 “less	common”,	and	“uncommon”	symptoms.	Finally,	available	and	widely	used	clinical	scoring	systems	for	dogs	with	CE	are	reported.		COMMON	CLINICAL	SIGNS:	DIARRHEA	AND	DEFECATION	ABNORMALITIES		Diarrhea	is	an	increase	in	the	frequency,	fluidity,	or	volume	of	feces	that	is	best	characterized	by	duration	(acute	versus	chronic),	pathophysiologic	mechanism,	and	anatomic	location.5	Diarrhea	 is	 the	most	 common	 symptom	 in	GI	 disorders,	 although	 it	 is	 important	 to	 remember	 that	 it	may	 be	absent.6	 Stool	 consistency,	 stool	 frequency,	 presence	 of	 blood	 or	 mucus,	 or	 alteration	 of	 defecation	 (such	 as	tenesmus,	dyschezia,	urgency)	allows	clinicians	to	localize	the	GI	problem	(Table	3.a).	Watery	diarrhea	is	typical	for	 small	 bowel	 disease	 and	 is	 commonly	 associated	with	weight	 loss	 and	 sometimes	 vomiting.7	 Large	 bowel	diarrhea,	on	the	other	hand,	characterized	by	increased	frequency	of	defecation	of	small	amounts	of	feces,	often	admixed	with	mucous	and/or	fresh	blood	(hematochezia),	urgency,	and	tenesmus.8–10	In	one	study1	large	bowel	diarrhea	 is	 associated	 with	 FRE,	 although,	 in	 many	 occasions	 patients	 show	 signs	 of	 large	 and	 small	 bowel	involvement,	and	therefore	a	diffuse	GI	disease	is	suspected.			
Sign Small Bowel Large Bowel 
   
Tenesmus Rare Common 
Frequency  Normal to 2-3 times x day >3 time x day 
Urgency Uncommon Common 
Volume Increased Decreased 
Mucus Rare Common 
Blood Melena Hematochezia 
Steatorrehea May be present Absent 
Dyschezia Absent  Often present 
Weight loss Common Uncommon 
Vomiting May be present May be present 
   
Table 3.a: Differentiation of small versus large bowel diarrhea based upon clinical signs and the physical appearance of 
feces.5 	VOMITING	Vomiting	is	seen	in	canine	CE	although	invariably	accompanies	and	is	less	severe	than	diarrhea.	However	in	cats,	vomiting	is	often	the	predominant	clinical	sign	of	small	intestinal	IBD.11		Contents	of	vomit,	association	with	food,	signs	of	nausea,	and	appetite	are	necessary	information	to	 localize	 the	 disease	 (e.g.	 gastric,	 colonic,	 or	 esophageal	 disorders	 or	 systemic	 disease)	 and	 understand	 the	cause	of	vomiting	(e.g.	inflammatory	process	rather	than	dysmotility).		Regurgitation	 is	 usually	 associated	 with	 esophageal	 disorders,	 but	 sometimes	 it	 can	 be	 present	 in	 CE	 as	 a	consequence	 of	 dysmotility	 disorders.12	 Hematemesis	 is	 usually	 associated	 with	 more	 severe	 disease,	 which	causes	mucosal	ulceration	or	erosion.		
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Bilious	vomiting	syndrome	in	dogs	is	a	relatively	common	occurrence,	and	it	is	thought	to	result	from	a	reflux	of	duodenal	 fluid	 into	 the	 gastric	 lumen	 causing	 mucosal	 irritation.13	 Inflammation	 of	 GI	 tract	 and	 motility	disorders	 can	 predispose	 dogs	 to	 this	 syndrome.	 Dogs	 with	 bilious	 vomiting	 syndrome	 will	 tend	 to	 vomit	 a	yellow-colored	bile	vomit	when	they	are	fasted.13	WEIGHT	LOSS	Undernutrition,	also	called	malnutrition,	 is	a	cause	of	weight	loss	in	GI	disorders	(Figure	3.a).	Malnutrition	can	lead	to	cachexia	with	severe	consequences	for	the	patient	(Table	3.b).14	In	one	study,	severe	(≥30%)	weight	loss	was	a	negative	prognostic	factor.4	GI,	 pancreatic,	 and	 hepatobiliary	 disorders	 are	 common	 causes	 of	 malnutrition	 in	 dogs.	 Pathophysiologic	mechanisms	include	decreased	food	intake	(e.g.	decreased	appetite),	maldigestion,	malabsorption,	inflammation,	increased	nutritional	requirements,	and	drug–nutrient	interactions.14	Weight	loss	is	a	typical	finding	in	small	bowel	disease,	but	can	be	also	found	in	large	bowel	disease.			
Complications of malnutrition 
 
Compromised wound healing  
Immune suppression  
Impaired muscle strength  
Fatigue  
Poor thermoregulation  
Decreased respiratory function  
 
 
Decreased gastrointestinal function  
Decreased pancreatic function  
Decreased water and sodium excretion  
Increased tendency to develop edema  
Increased morbidity and risk of secondary diseases  
Increased risk of death 
Table 3.b: Complication of malnutrition15 	
	
Figure 3.a: GSD with CE showing evident weight loss 		APPETITE	CHANGES	Appetite	 changes	 can	 be	 variable	 in	 CE,	with	 some	 cases	 demonstrating	 polyphagia,	 others	 showing	 differing	severities	 of	 anorexia,	 but	most	 cases	 displaying	 no	 appetite	 changes.	 One	 study	 revealed	 that	 a	 decrease	 in	appetite	is	a	negative	prognostic	factor	in	dogs	with	lymphocytic	plasmacitic	enteritis	(LPE).4	Pica	 (ingestion	 of	 non-nutritive	 items),	 ingestion	 of	 foreign	 bodies,	 and	 abnormal	 chewing	 behaviors	 can	 be	common	 in	 dogs	with	CE	 in	 author’s	 experience.	 It	 is	widely	 accepted	 that	 those	 actions	 are	 consequences	 of	behavior	and	GI	disorders,	but	there	are	very	few	studies	(or	anecdotal	reports)	focusing	on	the	relationship	of	pica	and	abnormal	chewing	behaviors	in	dogs	or	cats	with	CE.16–18	
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LESS	COMMON	CLINICAL	SIGNS	ASCITES,	PLEURAL	EFFUSION,	AND	PERIPHERAL	EDEMAS	Ascites	is	defined	as	fluid	accumulation	within	the	peritoneal	cavity.	Ascites	is	usually	associated	with	PLE,	and	the	cause	of	its	formation	is	the	decrease	in	oncotic	pressure	when	serum	albumin	concentration	falls	below	1.5	g/l.	In	PLE	usually	fluid	is	pure	or	modified	transudates,	but	also	chylous	ascites	has	been	reported.19	Presence	of	ascites	in	PLE	dogs	varies	from	18%20	to	100%.1	Pleural	effusion	can	be	associated	with	ascites	and	appears	to	be	common	 in	Yorkshire	Terriers	with	PLE	and	 it	can	be	 the	only	clinical	sign	on	presentantion.6,21	Peripheral	edema,	such	as	pitting	edema	of	the	limbs,	scrotum	or	face,	can	be	present.19	In	author’s	experience	it	seems	less	common,	but	no	studies	evaluate	the	incidence	of	this	clinical	sign	(Figure	3.b).		
	
	
	
Figure 3.b: Two dogs with PLE. The picture on the left shows a GSD with severe ascites. Picture on the right shows a 
mixed breed dog with pleural and abdominal effusion and subcutaneous edema of ventral abdomen. 	DERMATOLOGICAL	ABNORMALITIES	Dermatological	signs	are	characteristic	 in	ARF.	The	most	common	symptom	of	ARF	 is	non-seasonal	pruritus.22	Pruritus	can	be	either	generalized	or	limited	to	face,	ears,	paws,	axillae,	inguinal,	or	perineal	region.23	Other	signs	include	 papules,	 erythema	 excoriations,	 epidermal	 collarettes,	 hyperpigmentation,	 pododermatitis,	 and	seborrhea.	Otitis	externa	 is	an	important	indication	for	ARF	and	it	may	be	the	only	sign.	Finally,	some	dogs	can	only	show	recurrent	bacterial	pyoderma	(with	or	without	pruritus).23	In	 one	 study,	 FRE	 dogs	 showed	 pruritus	 more	 commonly	 compared	 with	 other	 disease	 phenotypes	 (ARE	 or	IBD).1	Presence	of	concurrent	dermatological	signs	in	a	dog	presented	for	chronic	GI	symptoms	could	potentially	be	 indicative	of	 FRE.22	The	 connection	between	dermatologic	 and	GI	 symptoms	 is	not	definitely	 indicative	 for	FRE	and	no	studies	evaluated	this	correlation.22,23	UNCOMMON	CLINICAL	SIGNS	THROMBOSIS	In	PLE	a	hypercoagulable	 state	 is	demonstrated	as	a	 consequence	of	 reduced	antithrombin	 III	 (AT	 III)	plasma	concentration,	increased	thrombin-antithrombin	complexes,	or	an	abnormal	thromboelastogram.24–26	Therefore	thromboembolic	events	in	association	with	PLE	have	been	reported	in	several	studies,19	with	incidence	ranging	from	12-18%27	to	7.5%,28	respectively.	Aortic,	femoral	artery,	and	pulmonary	thrombosis	with	sudden	death	has	been	reported.29–32	
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HYPOCALCEMIA-	RELATED	SYMPTOMS	Hypocalcemia	 is	 a	 common	 finding	 in	dogs	with	PLE.33,34	Usually	no	clinical	 signs	 related	 to	hypocalcemia	are	evident,	 even	with	very	 low	 ionized	calcium.	 In	other	 reports,	hypocalcemia	was	associated	with	 radiographic	evidence	of	osteopenia	alone35,	or	it	induced	twitching	episodes	or	seizures	in	dogs	with	PLE.34,36,37		CLINICAL	SCORING	SYSTEMS	Clinical	 indices	 remain	 the	most	widely	 used	 tools	 for	 assessing	 disease	 activity	 in	 human	 and	 veterinary	 CE	patients.38	Scoring	indexes	can	be	used	to	assess	disease	severity,1,39	correlate	with	prognosis,4	and	can	be	also	used	in	research	setting.	Commonly	used	clinical	score	indexes	are	briefly	described	in	the	following	section.		CIBDAI	AND	CCECAI	Clinical	 IBD	 activity	 index	 and	 Canine	 CE	 clinical	 activity	 index	 were	 developed	 and	 validated	 several	 years	ago.1,39	 Today	 CIBDAI	 and	 CCECAI	 are	 widely	 accepted	 and	 used	 in	 research	 and	 clinical	 settings.	 CIBDAI	evaluates	only	clinical	signs,	whereas	CCECAI	integrates	biochemical	parameters	(serum	albumin	concentration)	(Table	3.c).			BODY	CONDITION	SCORE	(BCS)	AND	MUSCLE	CONDITION	SCORE	(MCS)	Assessment	general	wellness	and	physical	condition	are	important	as	CE	has	a	huge	impact	on	weight	(body	fat	and	muscle	mass).	Using	a	consistent	method	and	scale,	 like	body	condition	score	(BCS)	and	muscle	condition	score	(MCS),	can	assist	clinicians	in	making	a	correct	diagnosis,	recommending	dietary	support,	and	identifying	changes	over	time.40	Moreover,	in	research	it	allows	a	prompt	understanding	of	dog’s	general	state	of	nutrition	better	than	body	weight	(BW)	alone	because	different	dog	sizes	exist.		The	BCS	9	point	scale	 is	widely	used	in	veterinary	practices,	although	a	 limited	number	of	studies	 in	dogs	and	cats	evaluate	its	usefulness	(Table	3.d).41			Evaluation	 of	 MCS	 includes	 visual	 examination	 and	 palpation	 over	 the	 temporal	 bones,	 scapulae,	 lumbar	vertebrae	and	pelvic	bones	in	order	to	appreciate	the	muscle	mass	that	cover	those	bony	prominences.	A	simple	MCS	scale	is	currently	under	development	and	validation.40		FECAL	SCORE	Examination	 of	 characteristics	 of	 defecation	 (attitude	 and	 frequency),	 along	 with	 fecal	 consistency	 provides	insight	 into	the	function	of	the	intestinal	tract.	Fecal	consistency	evaluates	the	amount	of	moisture	in	the	stool	and	can	be	used	for	diagnosis	of	GI	disorders	and	assessing	improvement.	Many	fecal	scoring	(FS)	systems	have	been	used	in	veterinary	literature,	but	none	have	been	correctly	validated.	The	Purina	7	point	fecal	score	is	an	easy	and	widely	used	scoring	system	in	current	literature.42	Ideally,	in	a	healthy	animal,	stools	should	be	firm	but	not	hard,	pliable	and	segmented,	and	easy	to	pick	up	(Score	2-3)	(Table	3.e).						
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CIBDAI 
Canine inflammatory bowel disease activity index 
CCECAI 
Canine chronic enteropathy clinical activity index 
 
Attitude/activity  
0 normal  
1 slightly decreased  
2 moderately decreased  
3 severely decreased 
 
Attitude/activity  
0 normal  
1 slightly decreased  
2 moderately decreased  
3 severely decreased 
Appetite  
0 normal  
1 slightly decreased  
2 moderately decreased  
3 severely decreased  
Appetite  
0 normal  
1 slightly decreased  
2 moderately decreased  
3 severely decreased  
Vomiting  
0 normal  
1 mild (1 x per week)  
2 moderate (2–3 x week)  
3 severe (>3 x week) 
Vomiting  
0 normal  
1 mild (1 x per week)  
2 moderate (2–3 x week)  
3 severe (>3 x week) 
Stool consistency  
0 normal  
1 slightly soft feces  
2 very soft feces  
3 watery diarrhea 
Stool consistency  
0 normal  
1 slightly soft feces  
2 very soft feces  
3 watery diarrhea 
Stool frequency  
0 normal  
1 slightly increased (2–3 x day) or fecal blood, mucus 
or both  
2 moderately increased (4–5 x day)  
3 severely increased (>5 x day) 
Stool frequency  
0 normal  
1 slightly increased (2–3 x day) or fecal blood, mucus 
or both  
2 moderately increased (4–5 x day)  
3 severely increased (>5 x day) 
Weight loss  
0 none  
1 mild (5%)  
2 moderate (5–10%)  
3 severe (>10%) 
Weight loss  
0 none  
1 mild (5%)  
2 moderate (5–10%)  
3 severe (>10%) 
Total: 
0 - 3: clinically insignificant 
4 – 5: mild 
6 – 8: moderate 
≥ 9: severe  
Albumin levels  
0 albumin >20g/L  
1 albumin 15–19.9 g/L  
2 albumin 12–14.9 g/L  
3 albumin <12 g/L 
 Ascites and peripheral edema  
0 none  
1 mild ascites or peripheral edema  
2 moderate amount of ascites/ peripheral edema  
3 severe ascites/pleural effusion and peripheral 
edema 
 Pruritus  
0 no pruritus  
1 occasional episodes of itching  
2 regular episodes of itching, but stops when dog is 
asleep  
3 dog regularly wakes up because of itching 
 Total: 
0 - 4 Clinically insignificant 
5 - 6 Mild 
7 - 9 Moderate  
10 - 12 Severe 
>12 Very severe 
 
Table 3.c: CIBDAI39 and CCECAI1 score for dogs 	
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BCS 
Body condition score, 9 point scale 
BCS1	Ribs,	lumbar	vertebrae,	pelvic	bones	and	all	bony	prominences	evident	from	a	distance.	No	discernible	body	fat.	Obvious	loss	of	muscle	mass. 
	
	
BCS	6	Ribs	palpable	with	slight	excess	fat	covering.	Waist	is	discernible	viewed	from	above	but	is	not	prominent.	Abdominal	tuck	apparent.	
BCS	2	Ribs,	lumbar	vertebrae	and	pelvic	bones	easily	visible.	No	palpable	fat.	Some	evidence	of	other	bony	prominence.	Minimal	loss	of	muscle	mass.	
	
BCS	7	Ribs	palpable	with	difficulty;	heavy	fat	cover.	Noticeable	fat	deposits	over	lumbar	area	and	base	of	tail.	Waist	absent	or	barely	visible.	Abdominal	tuck	may	be	present.	
	
	
BCS	3	Ribs	easily	palpated	and	may	be	visible	with	no	palpable	fat.	Tops	of	lumbar	vertebrae	visible.	Pelvic	bones	becoming	prominent.	Obvious	waist	and	abdominal	tuck. 
	
	
BCS	8	Ribs	not	palpable	under	very	heavy	fat	cover,	or	palpable	only	with	significant	pressure.	Heavy	fat	deposits	over	lumbar	area	and	base	of	tail.	Waist	absent.	No	abdominal	tuck.	Obvious	abdominal	distention	may	be	present.	
BCS	4	Ribs	easily	palpable,	with	minimal	fat	covering.	Waist	easily	noted,	viewed	from	above.	Abdominal	tuck	evident.	
	
BCS	9	Massive	fat	deposits	over	thorax,	spine	and	base	of	tail.	Waist	and	abdominal	tuck	absent.	Fat	deposits	on	neck	and	limbs.	Obvious	abdominal	distention.	
	
	
BCS	5	Ribs	palpable	without	excess	fat	covering.	Waist	observed	behind	ribs	when	viewed	from	above.	Abdomen	tucked	up	when	viewed	from	side. 
	
	 	 	 	
Table 3.d: BCS score for dogs. BCS of 4 and 5 are considered normal.  
Body Condition Score (BCS) chart, Ralston Purina Company, St Louis, Mo 		
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Fecal Score 
7 point scale 
FS1	Very	hard	and	dry;	often	expelled	as	individual	pellets;	requires	much	effort	to	expel	from	body;	no	residue	left	on	ground	when	picked	up. 
	
	 	
FS	5		Very	moist,	but	has	a	distinct	shape;	piles	rather	than	distinct	logs;	leaves	residue	and	loses	form	when	picked	up.	 	
FS	2	Firm,	but	not	hard;	pliable;	segmented	in	appearance;	little	or	no	residue	on	ground	when	picked	up. 
	
	
FS	6	Has	texture,	but	no	defined	shape;	present	as	piles	or	spots;	leaves	residue	when	picked	up.	
	
FS	3	Log-shaped;	little	or	no	visible	segmentation;	moist	surface;	leaves	residue	on	ground,	but	holds	form	when	picked	up. 
	
	
FS	7	Watery;	no	texture;	flat	puddles.	
	
FS	4	Very	moist,	soggy;	log-	shaped;	leaves	residue	and	loses	form	when	picked	up. 
	
	 	 	
Table 3.e: Fecal score for dogs. Fecal score of 2 and 3 are considered normal.  
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 SUMMARY	Chronic	 diarrhea	 and	 chronic	 vomiting	 are	 frequent	 complaints	 in	 clinical	 setting	 and	 are	 the	 clinical	presentations	of	many	diseases	(e.g.	gastrointestinal,	neoplastic,	metabolic	disorders,	and	others	causes).1–3		The	aim	of	this	study	was	to	evaluate	the	final	diagnoses	and	determine	the	prevalence	of	different	diseases	in	dogs	presented	for	chronic	diarrhea	and/or	vomiting.		Medical	 records	of	 608	dogs	presented	 to	 the	Veterinary	Teaching	Hospital	 of	University	 of	Bologna	between	January	2010	and	December	2015	with	chronic	diarrhea,	vomiting,	or	both	were	retrospectively	reviewed.	Dogs	of	any	sex,	breed,	and	age	were	 included	if	a	minimum	workup	(hematology,	plasma	biochemistry	profile,	and	fecal	parasitology)	had	been	performed	and	if	a	final	diagnosis	was	recorded	(463/608).		A	diagnosis	of	CE	was	determined	in	69.7%	(323/463)	and	included:	FRE	25.7%	(83/323),	ARE	19.8%	(64/323),	IBD	21.3%	 (69/323),	 PLE	11.8%	 (38/323),	HUC	0.9%	 (3/323).	 In	 20.4%	 (66/323)	 of	 dogs	with	CE	 the	 exact	phenotype	could	not	be	determined.	In	CE	group,	83%	(268/323)	of	dogs	had	only	CE	and	17%	(55/323)	had	a	concomitant	disorders	that	were	potentially	a	cause	of	chronic	vomiting	and/or	diarrhea.		Another	GI	disorder	cause	of	vomiting	and/or	diarreah	was	diagnosed	in	18.3%	(85/463)	of	dogs.	Of	those,	41%	(35/85)	 had	 hepatic	 or	 pancreatic	 disorders	 (including	 EPI,	 chronic	 hepatitis	 and	 chronic	 pancreatitis),	 21%	(18/85)	 had	 intestinal	 neoplasia,	 26%	 (22/85)	 infectious	 GI	 disease	 (bacterial	 and	 parasitic),	 12%	 (10/85)	mechanical/obstructive	 causes	 (included	 2	 dogs	 with	 short	 bowel	 syndrome	 [SBS]	 and	 1	 dog	 with	 chronic	intestinal	pseudo	obstruction	[CIPO]).		A	metabolic	cause	of	chronic	vomiting	and/or	diarrhea	was	diagnosed	in	11.8%	(55/463)	of	dogs	and	included	43.6%	(24/55)	chronic	nephropathy,	34.5%	(19/55)	endocrine	diseases,	18.1%	(10/55)	extra	GI	neoplasia,	and	1.8%	(1/55)	porto-systemic	shunt	(PSS).		Chronic	diarrhea	was	found	to	be	the	predominant	symptom	in	CE	dogs,	while	vomiting	alone	and	vomiting	and	diarrhea	was	more	frequent	in	dogs	with	metabolic	disorders	(p<0.0001).		In	 conclusion,	 similar	 to	 a	 previous	 study1	 CE	 was	 the	 most	 frequent	 cause	 of	 chronic	 GI	 of	 dogs	 in	 our	population,	followed	by	other	causes	of	GI	disease	and	metabolic	disorders.	Finally,	chronic	diarrhea	was	more	frequent	in	dogs	with	CE,	while	chronic	vomiting	was	more	common	in	metabolic	disorders.			REFERENCES		
1.		 Baumgart	K,	Volkmann	M,	Steiner	JM,	Kohn	B.	Final	Diagnoses	in	
155	Dogs	with	Chronic	Vomiting	and	/	or	Diarrhea.	ECVIM-CA	Congr.	2014	
2.		 Washabau	 RJ.	 Vomiting.	 In:	 Washabau	 RJ,	 Day	MJ,	 eds.	 Canine	
and	Feline	Gastroenterology.	St.	Louis,	Missouri:	Elsevier	Saunders;	2013:167-
173.		
3.		 Marks	 SL.	 Diarrhea.	 In:	 Wahabau	 RG,	 Day	 MJ,	 eds.	 Canine	 and	
Feline	Gastroenterology.	St.	Louis,	Missouri:	Elsevier	Saunders;	2013:99-108.	
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4.	 	DIAGNOSIS			Diagnosis	of	CE	is	based	on	the	recognition	of	clinical	signs,	exclusion	of	other	causes	of	chronic	GI	signs,	assessment	 of	 severity	 (e.g.	 loss	 of	 proteins,	 signs	 of	 malabsorption,	 coagulation	 abnormalities,	 or	electrolyte	imbalance),	and	identification	of	intestinal	inflammation.	The	different	phenotypes	FRE,	ARE,	IRE,	or	NRE	are	subsequently	diagnosed	based	on	the	response	to	treatment.	In	terms	of	frequency,	FRE	is	generally	more	common	in	respect	to	other	phenotypes	and	PLE	is	the	least	frequent	(Figure	4.a).1,2	In	this	section	common	and	newly	discovered	diagnostic	tools	for	CE	in	are	quickly	reviewed.				
	
Figure 4.a: Among CE, FRE phenotype is the most frequent followed by ARE, IRE, and NRE. PLE is usually IRE 
and is still less frequent.  
CE, chronic enteropathies; FRE, food responsive enteropathy; ARE, antibiotic responsive enteropathy; IRE, 
immunosuppressant responsive enteropathy; NRE, non responsive enteropathy; PLE, protein-losing enteropathy.  	BASIC	WORK-UP	FECAL	PARASITOLOGY	GI	parasites	are	a	common	cause	of	chronic	GI	disorders	in	dogs.	A	routine	fecal	examination	for	parasites	should	always	be	included	in	the	early	diagnostic	workup	of	an	animal	with	GI	disease.3,4	Independent	of	the	results	of	fecal	parasitology,	a	treatment	with	broad	spectrum	anthelmintics	drugs	(e.g.	fenbendazole)	is	always	recommended.		Fecal	examination	techniques	include:3	
• Direct	fecal	smears;	to	visualize	motile	trophozoites	(e.g.	Giardia)	
• Fecal	flotation,	with	or	without	centrifugation;	allows	eggs,	oocysts	and	cysts,	to	be	identified	
• Antigen	 testing	 and	 PCR	 assays;	mainly	 used	 for	Giardia,	Tritricomonas	(cat),	Cryptosporidium	spp.,	and	canine	Schistosomiasis.		Fecal	shedding	of	GI	parasites	can	be	intermittent	and	some	clinically	normal	animals	can	shed	parasites	without	 showing	 clinical	 signs.	 On	 the	 other	 hand,	 a	 positive	 diagnostic	 test	 does	 not	 prove	 that	 the	parasite	is	causing	disease.4	Therefore,	a	repeated	fecal	panel	and	collection	of	2-3	day	of	feces,	increases	the	sensitivity	of	the	exam.		
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Giardia	 spp.	 is	 a	 common	 zoonotic5	 GI	 parasite	 that	 can	 cause	 gastroenteritis	 and	 can	 be	 transmitted	directly	via	contaminated	water,	food,	or	physical	contact.6,7	Recognition	of	this	infection	is	important	for	a	 correct	 diagnosis	 of	 CE	 and	 its	 zoonotic	 potential.	 Prevalence	 in	 dogs	 appears	 to	 be	 high,	 but	 it	important	 to	 remember	 that	 commonly	 used	 methods	 for	 Giardia	 identification	 can	 have	 many	 false	positive	results.3,8	Recurrence	of	Giardia	infection	seems	also	a	common	feature	in	CE,	although	no	studies	are	available	to	asses	this	connection.	BLOOD	WORK	AND	URINALYSIS		Most	of	the	time,	hematology	presents	no	typical	alterations.	Signs	of	hemoconcetration	or	leukocytosis	can	be	seen	in	dogs	with	CE	and	are	non-specific.	Biochemistry	panel	had	a	crucial	role	in	understanding	the	presence	of	other	disease	(e.g.	electrolyte	inversion	in	Addison,	increase	in	liver	enzymes	in	chronic	hepatitis,	or	creatinine	in	chronic	kidney	disease)	and	detect	the	severity	of	of	malabsorption.		Table	 4.a	 reports	 principal	 clinicopathological	 abnormalities,	 proposed	 pathophysiological	mechanism,	and	the	importance	for	the	patient.		
Variable Alteration Comment   
   
Neutrophils Increased Neutrophilia with or without left shift can occur.9,10 
Eosinophil Increased 
Eosinophilia is sometimes present11 and it is associated with allergy, 
parasitism, and eosinophilic enteritis (EE).9 In SCWT, eosinophilia is 
present approximately in 21% of dogs and could be an early marker for 
SCWT protein-losing diseases.12  
Lymphocytes Decreased 
Lymphopenia is present in PLE dogs as a consequence of GI loss due to 
lymphangectasia.10,13 In SCWT, it is present in approximately 37% of 
dogs.12 
Platelets 
Increased 
or 
decreased 
Thrombocytosis and thrombocytopenia can be both present in CE. The 
first one is well defined in human patients with IBD, is proportional to 
the activity of the disease,14–16 and is associated with iron deficiency.17,18 
In dogs it is reported in Yorkshire,10 and other dogs,9,11 although 
thrombocytopenia appears to be more common in dogs with CE.11 
PCV and RBC 
Increased 
or 
decreased 
Dehydration, due to water loss and decreased intake, can led to an 
increase in PCV and RBC counts.  
Anemia can be also present, ranging from 12 to 18% in some reports, 
and it has many causes.11,19–21 Microcytic, hypochromic anemia can be 
consequence of a decrease iron absorption. Mild non-regenerative 
anemia can be present as consequence of chronic inflammation.21 
Normocytic, normochromic anemia may be associated with GI 
bleeding, and it can be regenerative or non-regenerative, depending 
upon chronicity of the condition.22 Finally, less frequently 
erythroblastic anemia can be present due to cobalamin deficiency.23  
Total protein 
Albumin 
Decreased 
Panhypoproteinemia is characteristic of PLE, and it is defined as 
albumin concentration is less than 2g/l with normal albumin:protein 
ratio.1,2,13,24 The pathophysiology of hypoprotidemia may involve 
reduced appetite, malabsorption due to a reduction in intestinal surface 
area, such as with villus atrophy or fibrosis, haemorrhage or exudation 
of protein into the gastrointestinal tract, and increased intestinal 
permeability.11 Mild hypoalbuminemia in IBD dogs also occur,13 and in 
both IBD and PLE it increases during treatment.  
Urinalysis with urinary protein:creatinine (UPC) ratio should always be 
performed in presence of decreased albumin in order to exclude PLN. 
Cholesterol Decreased 
Hypocholesterolemia can be frequently observed in dogs with CE and 
PLE. A decrease in cholesterol is caused by lymphangiectasia and 
malabsorption.20,25  
Liver enzymes (ALT, 
AST, SAP) 
Increased 
Liver enzymes may be elevated secondarily in GI disease because of 
portal venous transport of toxins and/or bacteria from a compromised 
intestine, but overall liver function (as assessed by serum bile acids) 
will usually be normal.25 
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Variable Alteration Comment   
Iron profile  Modified 
Iron deficiency mainly results from chronic blood loss in the intestine, 
but iron malabsorption due to inflammatory activity may also 
contribute. In human medicine, it is well described that iron deficiency 
can cause anemia and thrombocytosis.17,18  
Modifications in serum iron profile of CE dogs, along with anemia, 
have been reported in one study.21 Iron profile shows iron values at the 
lower end of the reference range, normal ferritin, normal or slightly low 
total iron binding capacity (TIBC), and high CRP concentration support 
the hypothesis that anemia was due to chronic disease.  
C Reactive Protein 
(CRP) 
Increased 
CRP is commonly increased in dogs with CE. In some reports it seems 
to correlate with clinical activity score,1 but not in others.26–28 In one 
study, CRP appears to be higher in dogs with PLE compared to FRE 
although it was not indicative of outcome or survival time.24 Although, 
for other authors, it is useful to asses severity of the disease and 
monitor the treatment response.29,30 
Canine specific 
pancreatic lipase 
immunoreactivity 
(cPLI) 
Increased 
Serum cPLI concentration is highly specific for exocrine pancreatic 
function, and is the gold-standard for diagnosis of pancreatitis in 
dogs.31 In one study a proportion of dogs with IBD had high cPLI 
concentrations and it was correlated with a poor outcome.32  
Based on this study, measurement of serum PLI concentrations may be 
warranted in dogs and cats with IBD, as animals with IBD and high 
serum PLI concentrations may require more extensive work-up and 
aggressive management.33 
Total Calcium and 
ionized calcium 
Decreased 
Calcium is found in three forms within plasma; the physiologically 
active ionized form accounts for about 50%, the complexes formed with 
lactate, citrate, and bicarbonate accounts for about 10%, and the protein 
bound form about 40%.34 Measurement of total calcium is mostly 
influenced by albumin concentration, phosphate, and acid-base status, 
therefore assessment of ionized calcium is a much better indicator of 
calcium homeostasis.  
Ionized hypocalcemia is commonly reported in CE especially in 
PLE.4,10,35,36 Supplementation of calcium is suggested because clinical 
signs associated with hypocalcemia, such tremors, seizures and 
osteopenia as been reported.10,35–38  
Magnesium Decreased 
Low magnesium concentration is frequently present in dogs with CE 
especially the ones with PLE, and it is frequently associated with 
hypocalcemia.10,35,37 Supplementation of magnesium is warranted to 
reestablish other electrolyte abnormalities (hypocalcemia, 
hypokalemia)37,39 
Sodium, potassium 
and chloride 
Altered 
Electrolyte imbalance such hyponatremia, hypochloremia, 
hypokalemia can be detected in dogs with chronic vomiting. 
Hypokalemia can be more common as a result of decreased intake and 
intestinal losses. Electrolyte inversion (hyperkalemia and 
hyponatremia) instead suggests the presence of concomitant disorders 
(hypoadrenocorticism, salmonellosis, whipworm infection, or if ascites 
and third-space effects associated with PLE).25 
Urea and creatinine Increased 
Pre-renal azotemia (i.e., increased urea and creatinine) will develop if 
the patient is dehydrated, but an increased urea:creatinine ratio in a 
fasted animal is suggestive of GI bleeding, with conversion of blood 
proteins to ammonia by intestinal bacteria, and hence urea formation 
by the liver. Urinalysis should always be performed in the presence of 
increased creatinine in order to exclude primary kidney disease.25 
Folate 
Increase  
or 
decreased 
Folate (vitamin B9) is a water-soluble vitamin present in large amounts 
in canine and feline diets and is absorbed in the jejunum. In CE serum 
folate concentrations can increase due to intestinal bacteria production 
(e.g. consequently to SIBO or EPI or coprophagia)40 or decrease because 
of intestinal malabsorption.4,11,20 
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Variable Alteration Comment   
Cobalamin Decreased 
Cobalamin (vitamin B12) as folate is a water soluble vitamin fully 
available in diet. Dietary cobalamin is absorbed in the ileum by a 
specific carrier, the intrinsic factor, produced by the pancreas and 
stomach. Therefore, cobalamin intestinal metabolism is very dependent 
on normal exocrine pancreatic and intestinal functions. Decreased 
serum cobalaminemia is reported in 6% to 73% of dogs with chronic 
enteropathies1,11,32 and frequently in dogs with EPI.4 Another study 
demonstrated that certain breeds more likely have a decrease 
cobalamin concentration.41 
Hypocobalaminemia is a negative prognostic factor in CE1 and patient 
need oral42 or parenteral supplementation.9 
Coagulation profile  Altered 
In dogs with PLE an hypercoagulabile state is frequent, leading to 
formation of thoromboembolic disease. Dogs with PLE have increased 
fibrinogen, decreased antithrombin III (AT III) and plasminogen 
activity; and an alteration detectable on thromboelastography 
(TEG).43,44 
Urinalysis 
Normal  
or  
altered 
Urine specific gravity (USG) is usually normal in CE, although in some 
patients it can be decreased. Urinalysis is important in CE diagnostic 
protocol to exclude some metabolic disorders causing 
polyuria/polydipsia (PU/PD). Moreover as mentioned above UPC 
ratio should always be performed in presence of hypoalbuminemia in 
order to exclude a PLN. 
   
Table 4.a:. Major alterations of parameters available on routine hematology, biochemistry, coagulation profile 
and urinalysis. 
EE, eosinophilic enteritis; SCWT, Soft Coated Wheaten Terriers; PLE, protein-losing enteropathy; GI, gastrointestinal; CE, 
chronic enteropathies; IBD, inflammatory bowel disease; PCV, packed cell volume; RBC, red blood cell count; UPC, urinary 
protein:creatinine; PLN, protein-losing nephropathy; TIBC, total iron binding capacity; CRP, C reactive protein; FRE, food 
responsive enteropathy; cPLI, canine pancreatic lipase immunoreactivity; SIBO, small intestinal bacterial overgrowth; EPI, 
exocrine pancreas insufficiency; ATIII, antithrombin III; TEG, thromboelastography; USG, Urine specific gravity; PU/PD, 
causing polyuria/polydipsia. 	Chronic	 GI	 signs	 are	 common	 in	 many	 disorders.	 Therefore	 it	 is	 important	 to	 perform	 other	 tests	 to	exclude	 other	 differential	 diagnosis.	 TLI	 and	 PLI	 are	 useful	 to	 exclude	 EPI	 and	 pancreatitis.4,20	 Finally	basal	 cortisol	 and	ACTH	stimulation	 test	 are	 indicated	 to	diagnose	Addison	disease.45	Chronic	hepatitis	and	 or	 hepatic	 insufficiency	 can	 be	 rule	 out	 performing	 blood	 ammonia,	 ammonia	 tolerance	 test,	 and	fasting	and	post	prandial	bile	acid.4	ABDOMINAL	ULTRASOUND	Ultrasonography	 (US)	 is	 an	 important	 tool	 to	 examine	 the	 gastrointestinal	 tract	 of	 small	 animals	with	chronic	 vomiting	 and	 diarrhea.	 Common	 alterations	 in	 dogs	 with	 CE	 are	 described	 in	 Box	 4.a.	 In	 one	study,	 authors	 developed	 an	 ultrasound	 score	 that	 results	 to	 be	 associated	 with	 CIBDAI	 at	 time	 fo	diagnosis,	 but	 not	 post	 treatment.46	 Other	 authors	 have	 evaluated	 the	 diagnostic	 utility	 of	 abdominal	ultrasound	in	the	diagnosis	of	GI	disorders.	That	study	concluded	that	abdominal	US	did	not	substantially	contribute	to	determination	of	the	diagnosis	in	the	majority	of	dogs	(68%)	with	chronic	diarrhea.	In	the	majority	of	dogs	the	diagnosis	required	endoscopy,	or	less	commonly,	celiotomy.47	Contrary	to	the	results	of	 this	study	abdominal	ultrasound	 is	always	useful	 in	 the	diagnostic	workup	of	dogs	presented	 for	GI	signs.	 It	allows	the	evaluation	of	concomitant	disorders,	GI	 tract	appearance	(e.g.	focal	or	diffuse	lesions,	foreign	bodies),	motility,	and	appearance	of	lymphnodes	and	vessels.			
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Box 4.a: Common alterations of abdominal ultrasound in dogs with chronic enteropathy. 
  
Diffuse or focal alterations.48 
 
Image of  small intestinal lymphangectasia from Ultrasonography 
archive of Diagnostic Imaging - Department of Veterinary 
Medical Sciences 
Hyperechogenicity of mucosa and hyperechoic 
spots in mucosa or submucosa and signs of small 
intestinal lymphangectasia are the principal 
alterations48 (see figure). 
Wall layering can be maintained or lost. Mucosa, 
submucosa or muscolaris are mainly affected.46 
Wall thickening can be present or absent, from 
mild to severe.46,48 
Altered intestinal motility, sometime ileus is 
present, but also increased motility can occur.49 
Enlarged hypoechic and dishomogenic 
lymphnodes. 
Free peritoneal fluid and peritonel 
hyperechogenicity. 
  	ENDOSCOPY	Endoscopy	 is	 a	medical	 procedure	 that	 permits	 the	 clinician	 to	 examine	 the	 internal	 structure	 and	 to	perform	diagnostic	and	therapeutic	procedures	in	a	minimally	 invasive	manner	(Figure	4.b,	4.c,	4.d	and	4.e).	Enteroscopy	(gastroduodenal	or	gastroduodenoileumcolonoscopy)	is	indicated	in	dogs	with	chronic	or	recurrent	small	or	large	bowel	diarrhea,	vomiting,	recurrent	abdominal	pain,	weight	loss	of	unknown	origin,	and	signs	of	gastrointestinal	bleeding	such	as	hematemesis,	melena,	hematochezia,	and	microcytic,	hypochromic	anemia.	The	decision	to	perform	endoscopy	should	be	based	on	the	risk	of	anesthesia	and	the	 likelihood	 of	 establishing	 a	 definitive	 diagnosis,	 prognosis,	 definitive	 treatment	 plan,	 and	 positive	outcome.50	In	 dogs	 with	 suspected	 CE,	 endoscopy	 allows	 clinicians	 to	 visualize	 the	 GI	 tract	 (esophagus,	 stomach,	duodenum,	 ileum,	 colon),	 the	aspect	of	mucosa,	 the	presence	of	macroscopic	 lesions	 (lymphangectasia,	masses,	 polypus,	 erosion/ulcers),	 the	 presence	 of	 foreign	 bodies,	 and	 the	 collection	 of	 biopsies.	Endoscopy	and	histology	has	not	been	shown	to	help	in	differentiating	FRE	from	ARE	or	IRE.1,51		The	majority	of	dogs	do	not	require	immunosuppressant	treatment,	therefore	in	most	cases,	endoscopy	may	be	preceded	by	dietary	 and	 antibiotic	 trial.	 Exceptions	have	 to	 be	made	 in	PLE	 cases	 and	dogs	 of	specific	 breeds	 (boxer	 or	 French	 bull	 dog	 with	 signs	 of	 colitis)	 or	 specific	 symptoms	 (emathemesis,	melena,	 regurgitation,	 and	 others).	 Endoscopy	 or	 surgery	 is	 used	 to	 obtain	 biopsies	 in	 poor	 or	 non-responders	to	confirm	the	presence	and	type	of	intestinal	inflammation	and	to	rule	out	diffused	intestinal	tumors	such	as	lymphoma.9			
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Figure 4.b: Structure of flexible endoscope. From Chamness 2011.52 	
  
Figure 4. c: Appearance of normal gastric and duodenal mucosa in dogs. From Endoscopic archive of Internal 
Medicine - Department of Veterinary Medical Sciences 
 
   
Figure 4.d: Altered gastric mucosa (left image) and altered duodenal mucosa with edema, discoloration, and 
signs of lymphangectasia (central image), and visualization of ileo-ciecocolic valve with mucosa edema (right 
image) in dogs. From Endoscopic archive of Internal Medicine - Department of Veterinary Medical Sciences 
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Figure 4.e: Execution of gastric biopsy at level of incisura angularis in retroversion (J-maneuver) in a dog. From 
Endoscopic archive of Internal Medicine - Department of Veterinary Medical Sciences (left image), from 
Chamness (2013)50 (right image).  	For	scientific	study	purposes	and	to	allow	clinicians	 to	have	an	 indication	of	 the	severity	of	endoscopic	classification,	 many	 endoscopic	 scores	 were	 validated.53,54	 Here	 the	 Endoscopic	 Activity	 Score	 (EAS)54	used	in	our	studies	is	described.		
	
	
	
	
Figure 4.f: Representative still images used in the development phase of the endoscopic study. (A) normal 
stomach; (B) gastric erosions; (C) gastric friability; (D) gastric granularity; (E) normal duodenum; (F) duodenal 
erosions; (G) duodenal friability; (H) duodenal granularity; (I) duodenal lymphatic dilatation; (J) normal colon; 
(K) colonic erosions; (L) colonic friability; (M) colonic granularity; (N) colonic mass. For each characteristic a 
score in given ranging from 0 to 2. From Slovak et al, 2015.54 		
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HISTOLOGY		Histopathologic	 evaluation	 of	 biopsy	 specimens	 is	 required	 for	 definitive	 diagnosis	 of	 many	 intestinal	diseases,	 but	 has	 marked	 limitations,	 most	 notably	 variable	 quality	 of	 tissue	 specimens	 obtained	endoscopically	and	poor	agreement	between	histopathologists.25,53	The	aims	of	the	pathologist	are	to	distinguish	normal	from	diseased	tissue,	to	characterize	the	nature	and	severity	 of	 tissue	 changes,	 and	 to	 provide	 an	 accurate	 morphological	 or	 etiological	 diagnosis,	 thus	facilitating	 formation	 of	 a	 prognosis	 and	 appropriate	 therapy.53,55	 By	 now,	 a	 review	 of	 the	 evidence	currently	available	has	not	 identified	a	strong	association	between	clinical	 findings	and	histopathologic	lesions	in	dogs	with	IBD,	especially	when	post-treatment	changes	in	disease	activity	are	compared	to	pre-treatment	histopathologic	finding.53	Forms	of	small	intestinal	IBD	include	lymphocytic-plasmacytic	enteritis	(LPE),	eosinophilic	enteritis	(EE),	granulomatous	 enteritis,	 and	 neutrophilic	 enteritis.	 It	 can	 be	 difficult	 to	 distinguish	 severe	 LPE	 from	lymphoma,	especially	in	cats	and	when	endoscopic	biopsy	samples	are	examined.25	There	 is	 no	 official	 convention	 for	 the	 classification	 of	 colitis	 in	 dogs	 and	 cats.	 Based	 on	 histologic	patterns,	 it	 can	 be	 divided	 into	 lymphoplasmacytic,	 eosinophilic,	 granulomatous	 (most	 limited	 to	histiocytic	ulcerative	colitis	(HUC)	of	Boxer	dogs),	and	ulcerative	colitis	(may	be	seen	as	part	of	several	specific	etiologic	diseases	like	HUC	of	Boxers,	or	other	infectious	colitis).56	Neoplastic	disease	of	the	colon	is	common	in	dogs,	and	for	this	reasons,	endoscopic	and	histopathologic	evaluation	of	dogs	presented	for	large	intestine	signs	is	important.		As	 for	 clinical	 and	 endoscopy	 scores,	 also	 histologic	 scoring	 system	 are	 available.53,57	 Both	 the	WSAVA	histopathologic	scoring	system53	and	the	simplified	one57	integrate	cellular	infiltration	and	architectural	changes.	The	simple	numerical	addition	of	grades	of	histopathological	change	(where	normal	=	0,	mild	=	1,	moderate	 =	 2,	 and	marked	 =	 3)	may	 provide	 an	 overall	 histological	 score	 for	 the	 tissue	 of	 interest,	useful	to	well-designed	studies,	well-represented	patient	populations,	and	adequate	follow-	up.53			NEW	DIAGNOSTIC	TOOLS		FECAL	CULTURE	Bacterial	culture	can	be	a	useful	technique	for	detection	of	specific	enteropathogens	(e.g.	Salmonella	spp.,	
Campylobacter	 jejuni,	 Yersinia	 spp.),	 although	 primary	 bacterial	 gastroenteritis	 occasionally	 occurs	 in	dogs.	Moreover,	positive	cultures	for	enteric	pathogens	are	commonly	reported	in	healthy	individuals.58	Therefore	 fecal	 culture,	 most	 of	 the	 time,	 is	 not	 useful	 in	 diagnosis	 of	 chronic	 GI	 disorders,	 although	sometimes	it	can	be	useful,	especially	in	case	of	acute	diarrhea.	For	acute	diarrhea		If	possible,	collect	2	to	5	g	of	fresh	feces	from	the	rectum.58	If	the	dietary	history	indicates	that	a	raw	food	diet	is	being	fed,	a	Salmonella	culture	may	be	indicated.	In	some	cases,	overgrowth	of	pathogens	such	as	drug-resistant	 E.	 coli	 and	 Campylobacter	 may	 induce	 chronic	 relapsing	 diarrhea.	 In	 such	 cases,	 fecal	culture	may	be	helpful.		FECAL	CYTOLOGY	Fecal	cytology	is	a	simple,	non-invasive,	and	cheap	test	that	can	be	useful	in	the	diagnosis	of	GI	disorders.	It	 can	 be	 performed	 by	 smear	 of	 feces	 collected	 for	 rectal	 scraping	 and	 stained	 with	 Diff-Quik	(Romanowski	stain).	Fecal	cytology	can	identify	cells	such	as	neutrophils	and	eosinophils,	or	pathogens,	such	as	spores	of	Clostridium	spp.	or	Campylobacter	spp..	Rarely,	coccidial	merozoites	or	other	protozoal	trophozoites	are	seen.58	
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ALPHA-1PI	α1-Proteinase	inhibitor	(α1-PI)	is	a	naturally	occurring	endogenous	serum	antiproteinase.	If	lost	into	the	intestinal	 lumen	 because	 of	 PLE	 or	 GI	 blood	 loss,	 it	 can	 be	 found	 in	 feces,	 as	 it	 resists	 bacterial	degradation.	 To	 improve	 the	 diagnostic	 accuracy	 of	 the	 test,	 three	 fresh	 spontaneously	 defecated	 fecal	samples	 should	 be	 sampled.	 Fecal	 α-1PI	 is	 a	 useful	 test	 for	 the	 presence	 of	 intestinal	 crypt	 abscesses	and/or	moderate	 to	severe	 intestinal	 lacteal	dilation	 in	dogs.	Measure	of	α1-PI,	or	 fecal	 to	serum	α1-PI	ratio,	allows	a	prompt	diagnosis	of	PLE	in	dogs.25,28,59	CITRULLINE	Citrulline	is	an	amino	acid	that	is	synthesized	mostly	by	intestinal	enterocytes	and	also	to	some	degree	by	hepatocytes.3	Citrulline	blood	concentration	level	is	highly	dependent	on	small	bowel	enterocytes	mass	in	humans.60	 In	 dogs,	 plasma	 citrulline	 concentration	 has	 been	 measured61	 and	 was	 shown	 to	 be	significantly	 decreased	 in	 dogs	 intestinal	 disease	 and	 increased	 after	 treatment.62,63	 Based	 on	 recent	studies,	 plasma	 citrulline	 could	 be	 a	 putative	 marker	 of	 intestinal	 function	 in	 canine	 IBD.3,63	 Blood	concentration	of	citrulline	 increase	after	meal,	 therefore	food	should	be	withheld	from	dogs	for	8	to	12	hours	before	blood	sample	collection	for	measurement	of	citrulline	concentration.61	DYSBIOSIS		Dysbiosis	is	implicated	in	the	pathogenesis	of	CE	in	dogs.	Assessment	of	dysbiosis	could	be	important	for	the	diagnosis	of	CE	and	several	molecular	methods	are	now	established	for	assessing	intestinal	dysbiosis	in	 dogs	 and	 cats,	 but	 these	 approaches	 are	 not	 yet	 widely	 available.64	 Methods	 commonly	 used	 for	characterization	of	 the	 intestinal	microbiota	 are:	 fluorescence	 in	 situ	hybridization	 (FISH),	quantitative	real-time	 PCR	 (qPCR),	 next-generation	 sequencing	 (e.g.	 454-pyrosequencing,	 Illumina),	 metagenomics	(shotgun	 sequencing	 of	 genomic	 DNA).	 Finally,	 dysbiosis	 index	 is	 an	 index	 that	 summarizes	 the	abundances	of	major	bacterial	taxa	in	each	fecal	sample	as	one	single	numerical	value	(a	positive	number	indicates	 dysbiosis).64	 In	 the	 future	 this	 index	 could	 be	 useful	 to	 recognize	 dysbiosis	 and	 to	 monitor	changes	in	gut	microbiota	over	time.	FLUORESCENCE	IN	SITU	HYBRIDIZATION	(FISH)	The	principle	of	fluorescence	in	situ	hybridization	(FISH)	is	the	detection	of	a	target	DNA	or	RNA	site	by	a	fluorescently	 labelled	probe	molecule.	The	use	of	FISH	 is	 currently	 considered	 to	be	 the	most	 accurate	method	 for	 quantification	 of	 bacterial	 groups	 because	 it	 allows	 direct	 microscopic	 counting	 of	fluorescence-labeled	 bacteria.	 Furthermore,	 the	 location	 of	 bacteria	 with	 regard	 to	 the	 epithelium	 (ie,	intracellular,	adherent,	or	invasive)	can	be	visualized.64,65	VITAMIN	D		The	 traditional	 functions	of	vitamin	D	relate	 to	 its	 role	 in	 the	maintenance	of	 calcium	homeostasis	and	bone	metabolism.	In	humans	that	vitamin	D	status	is	negatively	associated	with	markers	of	inflammation,	and	 in	 a	 number	 of	 many	 chronic	 diseases.	 In	 one	 study,	 Vitamin	 D	 (serum	 25	 hydroxyvitamin	 D	concentration)	has	shown	to	be	inversely	associated	with	markers	of	systemic	inflammation	in	dogs	with	CE	 and	with	 severity	 of	 inflammatory	 changes	 seen	 in	histopathology	 samples.66	 Therefore,	 besides	 its	role	in	calcium	homeostasis,	vitamin	D	could	be	a	new	marker	of	intestinal	inflammation.34,66		CALPROTECTIN	AND	S100A12		Calprotectin	 (S100A8/A9)	 and	 S100A12	 are	 validated	 fecal	 biochemical	 markers	 of	 intestinal	inflammation.67–69	Canine	fecal	S100A12	concentrations	are	increased	in	dogs	with	CE	and	are	correlated	with	 the	severity	of	clinical	signs,	 the	response	 to	different	 forms	of	 treatment,	endoscopic	 lesions,	and	inflammatory	changes	in	dogs	with	CE.24,69–71	Finally,	the	results	of	another	investigation	suggested	that	
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fecal	 S100A12	 concentrations	 have	 prognostic	 value	 in	 dogs	 with	 IBD.69	 Similarly,	 significantly	 higher	serum	 calprotectin	 concentrations	 have	 been	 reported	 in	 dogs	 with	 idiopathic	 IBD,29	 and	 fecal	calprotectin	correlated	with	negative	outcome	and	more	severe	histologic	intestinal	lesions.	72	PERINUCLEAR	ANTINEUTROPHILIC	CYTOPLASMIC	ANTIBODIES	PERINUCLEAR	Perinuclear	antineutrophilic	cytoplasmic	antibodies	(pANCA)	have	been	useful	in	the	diagnosis	of	human	IBD	for	decades.	In	dogs,	the	pANCA	assay	might	be	helpful	in	differentiating	dogs	with	chronic	diarrhea	caused	by	FRE	or	IBD:	if	the	result	is	positive,	a	FRE	is	highly	likely,	however,	if	the	result	is	negative,	IBD	cannot	be	excluded.	28,73		pANCA	also	may	be	associated	with	 the	syndrome	of	 familial	PLE	 in	SCWT.	However	a	positive	pANCA	test	result	occurs	when	other	inflammatory	or	immune-mediated	diseases	are	present.28,74,75		REFERENCES		
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5.	 	TREATMENT		In	CE	loss	of	tolerance	against	food	antigens	and	dysbiosis,	in	genetically	predisposed	individuals,	results	to	 chronic	 inflammation	 and	 consequently	 malabsorption.	 Therefore	 the	 core	 therapies	 (dietary	modification,	 antimicrobials,	 and	 immunosuppressive	 treatment)	 are	 reviewed	 here,	 highlighting	 the	advantages	and	disadvantages	 for	 the	most	commonly	used	 treatments.	Moreover,	other	products	such	probiotics	 and	 vitamin	 supplementation	 commonly	 used	 are	 described.	 Finally,	 new	 therapies	 are	reported	because	scientific	research	in	treatment	of	CE	is	continuously	going	forward.	THERAPEUTIC	TRIALS		A	 staged	 approach	 to	 therapy	 is	 recommended	 whenever	 possible,	 but	 may	 not	 be	 appropriate	 in	seriously	ill	patients	(e.g.,	those	with	PLE)	where	immediate	intervention	with	combination	therapy	may	be	 essential.	 Initial	 treatment	 should	 be	 always	 used	 with	 anthelmintics	 agents	 to	 eliminate	 occult	parasite	 infection.	 Initial	 treatment	with	 fenbendazole	 50mg/kg/day	 for	 3	 to	 5	 days	 is	 recommended,	along	with	 fecal	parasitological	exams,	as	not	all	parasites	are	sensitive	 to	 this	drug	(e.g.	 cestodes)	and	some	are	resistance	(e.g.	Giardia).		
CORE	THERAPIES	DIET	Food	allergy	and	 food	 intolerance	 fall	under	 the	category	of	an	ARF,	clinical	signs	may	be	 identical	and	their	nutritional	management	is	similar.1–3	FRE	can	be	considered	a	GI	manifestation	of	ARF.		Once	ARF	is	suspected,	the	first	step	is	to	collect	an	accurate	feeding	history	from	the	owners	because	the	elimination	 diet	 must	 not	 contain	 any	 of	 the	 ingredients	 previously	 given.4	 In	 most	 cases,	 at	 least	 2	commercial	 diets	 (one	 for	 growth	 and	 one	 for	 adult	 maintenance),	 (dental)	 treats,	 table	 scraps,	 and	human	foods	used	to	hide	medications	have	been	provided	through	years	and	it	is	not	easy	to	identify	all	the	 protein	 sources	 to	 which	 the	 dog	 or	 cat	 has	 come	 in	 contact	 with.4	 Moreover,	 although	 animal	proteins	are	mostly	suspected	as	allergens,	a	complete	diet	also	contains	vegetable	proteins	from	grains,	fiber	sources,	or	other	plants,	as	well	as	flavoring	factors	whose	potential	in	sensitizing	the	animal	should	not	be	underestimated.9	Moreover,	 the	presence	of	 ingredients	not	declared	in	the	label	are	detected	in	commercial	 limited-antigens	 diets.5,6	 Elimination	 dietary	 trial	 can	 be	 done	 with	 novel	 protein	 diet	(commercial	or	home-made)	or	hydrolyzed	diet	(Boxes	5.a,	5.b,	5.c).3,7–9	Vegetable	proteins	can	be	found	in	 traces	 in	 pet	 food,	 but	 are	 less	 likely	 to	 cause	 allergic	 reactions.4	 Therefore	 a	 balanced	 diet	 with	exclusively	proteins	of	vegetable	origin	could	be	an	alternative	elimination	diet	for	dogs	with	ARF,	and	is	the	subject	matter	of	studies	of	the	chapters	5.2	and	5.3.		Apart	 from	novel	or	hydrolyzed	protein,	a	diet	 for	dogs	with	CE	should	be	high	digestible,	 fat	restricted	(<15%	dry	matter),	 easy	 to	 digest	 fats	 (e.g.	 short	medium	 chain	 triglycerides	 oil),	 variable	 amounts	 of	fiber,	and	finally	ω-3	and	ω-6		and	prebiotics	(FOS,	MOS,	inulin)	can	be	added.9		Fiber	content	should	be	carefully	evaluated.	Soluble	fiber	(e.g.	psyllium)	has	a	role	in	treatment	do	dogs	with	large	bowel	diarrhea.10,11	On	the	contrary	in	dogs	with	severe	malabsorption	fiber	content	should	be	low.										
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Box 5.a: Commercial monoprotein or vegetable diet (extruded and/or wet food) 
 
Advantages 
 
Disadvantages 
- Many types of novel proteins, some common (e.g. 
horse, duck, fish, lamb) some rare (venison, 
kangaroo, insects) 
- Easy to use since are balanced and complete, and 
can be given long term. 
- Accessible price.  
- Many options on market, also for growing 
puppies. 
- Usually good palatability 
- Some are added with prebiotics and ω-3 fatty 
acids. 
- Some of the novel protein are so widespread in 
regular pet food that they can no longer be 
considered as novel proteins (e.g. duck or lamb).4 
- Others protein besides the ones declared can be 
found.5,6 
- Paucity of studies regarding its use in dogs with 
CE 
 
Comment: This kind of diet can be considered the first line to use in young dogs with early onset of symptoms in 
which FRE is suspected. Could be considered less suitable for those dogs that have tried many different kind of 
diets without remission of GI signs. Fat content, in most cases, is not the desirable in diet for dogs with PLE.12 
The diets formulated for gastrointestinal problems usually are not suitable options for dogs with CE as contains 
mainly protein from chicken or turkey sources. Those diets can be an options for acute GI problems or other 
diseases such acute pancreatitis, although low fat content may be adequate for PLE dogs.12 
 			
Box5.b: Commercial hydrolyzed diet (extruded and/or wet food) 
 
Advantages 
 
Disadvantages 
- Mainly hydrolysate protein from soy, chicken, 
feather, or fish. 
- Easy to use, balanced and complete, and can be 
given long term. 
- Easy digestible. 
- Some contain high levels of ω-3 fatty acids. 
- Other ingredients can be present5 
- Usually more expensive than other commercial 
diet. 
- Palatability is sometimes a problem. 
- Dogs sensitized to the native protein (e.g. 
chicken) may still react to the hydrolyzed 
protein4 
 
Comment: Hydrolyzed diet should be considered the second line, in those dogs with persistent GI sings that have 
already tried limited-antigens diets and have failed. Hydrolyzed diets can be the first choice in those dogs with 
severe GI signs or with PLE, as most of time fat content is adequate.  
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Box 5.c: Home-made diet 
 
Advantages 
 
Disadvantages 
- Quality of ingredients. 
- Consciousness of the exact ingredients of the diet 
(from protein to oil and minerals). 
- The highest palatability and digestibility. 
- Accessible costs. 
- Managing disease combinations that do not have a 
commercially available option (e.g. ARF and renal 
disease). 
- Require time to be prepared. 
- Costs can be high, depending on body weight of 
patient and chosen protein source. 
- Need support by a Nutritionist. 
- It is mandatory for long period to balance the diet 
with vitamins and minerals. 
- Even balanced recipes have not undergone 
nutrient analysis or food trials. 
 
Comment: As many limited-antigen diets contain other proteins than the ones declared, home-cooked diets 
should be considered whenever the dog fails to respond to dietary restriction, especially in young dogs in which 
FRE is suspected. Home-made diet is also the best option when dogs have a decreased appetite or co-morbidity. 
Balancing a diet with minerals and vitamins is mandatory if the dogs have signs of severe malabsorption (e.g. 
decrease calcium and vitamin).  
 
 
BARF (bone and raw foods) diet is adopted by many clients today, but no scientific data support the use of this 
diet. BARF diet contains a lot of ingredients, and for the most are not complete, so are not suitable for elimination 
diet in patient with GI problems.4,13 Moreover it is important to be aware of complication due to bones ingestion, 
and possible bacterial infection, also with zoonotic potential.14–16 
 	ANTIMICROBIALS	The	 gut	 microbiota	 plays	 an	 important	 role	 in	 the	 pathogenesis	 of	 IBD,	 and	 treatment	 with	 specific	antibiotics	has	always	been	considered	a	key	part	in	treatment	of	CE	in	both	humans	and	dogs	(Boxes	5.d,	5.e,	and	5.f).9,17–19	The	exact	role	of	the	antibiotic	remains	unclear,	although	the	rational	for	their	use	was:	decreasing	concentrations	of	bacteria	in	the	gut	lumen,	altering	the	composition	of	intestinal	microbiota,	and	 immunomodulatory	 effect.17,18,20	Response	 to	 antibiotic	 treatment	defines	ARE.19	After	 cessation	of	antibiotics,	 relapses	are	 frequent,	but	 control	 is	 typically	achieved	by	 reintroducing	 the	antibiotic.9,20–22	Response	 both	 to	 tylosin	 and	metronidazole	 seems	 short-lived.	 The	 optimal	 duration	 of	 antimicrobial	therapy	is	still	unclear.	Usually	4	to	6	weeks	is	the	recommended,	although	some	dogs	have	relapses	and	can	therefore	be	treated	with	low	doses	for	an	extended	period.20	Recent	 studies	 demonstrate	 that	 antibiotics	 lead	 to	 profound	 and	 long	 lasting	 changes	 in	 intestinal	microbiota.23,24	Therefore	in	some	animals	the	use	of	antimicrobial	agents	is	useful	(e.g.	animals	with	HUC	or	EPI),	but	in	others	their	use	may	exacerbate	dysbiosis.25	This	raises	many	questions	about	antibiotics.	How	useful	antibiotics	truly	are?	Are	concurrent	treatments	needed	to	achieve	 long-term	control?	Does	long-term,	 low	 dose	 use	 of	 antibiotics	 cause	 antibiotic	 resistance?20	 Further	 studies	 are	 needed	 to	understand	the	role	of	antibiotic	treatment	in	dogs	with	CE.			
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Box 5.d: Tylosin (Macrolide) 
 
Advantages 
 
Disadvantages 
- Primary gastrointestinal effect, minimum systemic 
absorbance. 
- Response is prompt, some dogs respond within 24 
hours, others respond within 3 days.  
- Antibiotic resistance not demonstrated. 
- Antimicrobial and immunomodulatory effect. 
- Not commercially available.  
- Not palatable, better capsule formulation rather 
than tablets. 
 
Dose: There are no official recommendations available for an oral dosage regimen in dogs. Reported treatment 
doses are: 6-16mg/kg/day, 25mg/kg/day, 15mg/kg BID, 10mg/kg TID, 20mg/kg every 8 to 12h, or 25 to 80 
mg/kg from every 8 to 24h.20,22 In dogs with ARE experiencing relapse a low dose of 5mg/kg/day can be used.22  
 	
Box 5.e: Metronidazole (Nitroimidazoles) 
 
Advantages 
 
Disadvantages 
- Effective against anaerobic bacteria and some 
protozoal infections.  
- Systemic effect, good penetration of bones, blood-
brain barrier, respiratory tract, and skin. 
- Metronidazole is rapidly and highly absorbed 
systemically following oral administration. 
- Antimicrobial and immunomodulatory effect. 
- Resistance to metronidazole is demonstrated but 
is under-reported. 
- Neurotoxicity at high doses. (ataxia, lethargy, 
proprioceptive deficits, nystagmus, and seizure-
like signs). Completely reversible in some days. 
- Not palatable. 
 
 
Dose: 10-15mg/kg every 12 h (maximum dose 60mg/kg/day).20,26 
 	
Box 5.f: Others antibiotics 
 
Oxytetracycline: idiopathic ARE responds well to it for its antimicrobial and immunomodulatory effect.  
Dose: 10 to 20 mg/kg TID PO and for long-term therapy, low doses can often maintain clinical 
remission (10 mg/kg SID PO).21 
 
Enrofloxacin: HUC of Boxer and French bulldogs is the only CE in which bacterial invasion of the intestinal wall 
has been clearly documented. HUC has good response to enrofloxacin treatment, although resistance has been 
described.20,27,28  
Dose: 7 mg/kg, once a day for 9 weeks.26 
 
Rifaximin: is a semisynthetic rifamycin endowed with a wide spectrum of antibacterial activity. It is virtually 
non-absorbable by oral route, thus granting high efficacy and low incidence of side-effects. This antibiotic is 
wieldy used in humans, and in one study in dogs it appears to be equally effective to metronidazole.29 
Dose: 25 mg/kg q12h 
 	IMMUNOSUPPRESSANT	Immunosuppressant	 drugs	 are	 the	 key	 treatment	 in	 idiopathic	 IBD	 and	 PLE.9,20	 Immunosuppressant	drugs	 include	 corticosteroids	 (prednisolone	 or	 budesonide),	 azathioprine,	 cyclosporine,	 and	chlorambucile	 (Boxes	 5.g,	 5.h,	 5.i,	 and	 5.j).20	 Other	 immunosuppressive	 drugs	 such	 as	 mycophenylate	mofetil,	 methotrexate,	 and	 leflunomide	 have	 been	 used	 to	 treat	 immune-mediated	 or	 autoimmune	
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diseases	in	dogs.30,31	Due	to	lack	of	data	and	possible	side	effects	on	the	intestinal	mucosa,	their	use	for	treatment	of	IBD	in	dogs	cannot	be	recommended	at	this	time.		Tacrolimus	 is	 related	 to	 cyclosporine	 by	 its	 similar	 mechanism	 of	 action	 and	 immunosuppression.31	Tacrolimus	is	the	primary	immunosuppressive	agent	developed	for	organ	transplantation	and	in	humans	is	used	for	refractory	IBD.31,32	The	clinical	use	of	tacrolimus	in	veterinary	medicine	is	as	a	topical	therapy	for	perianal	fistulas,	keratoconjunctivitis	sicca,	or	dermatitis.31	A	recent	reports,	evaluated	its	use	in	a	dog	with	refractory	IBD	with	good	results.32	Short-term	remission	rate	in	IBD	dogs	ranging	from	60	to	80%,33–36	and	long	term	seems	less,34	but	some	remain	NRE.20	 Therefore	 evidence	 now	 suggests	 that	 short-term	 control	 of	 CE	 seems	 adequate	with	 a	variety	of	immunosuppressant	drugs,	but	data	regarding	long	term	follow	up	are	still	missing.20						
Box 5.g: Glucocorticoids (prednisone, prednisolone and budesonide) 
 
Advantages 
 
Disadvantages 
- Prednisolone (prednisone) and budesonide are 
the most widely used glucocorticoids used in 
treatment of IBD.20,30,31,37–39 Dexamethasone can 
be used in special circumstances.9 
- Systemic impact on both innate and acquired 
immunity and rapid onset of action.  
- Side effects are reversible with drugs 
suspension. Less clinical signs with budesonide. 
- Low costs for prednisolone (prednisone). 
Budesonide is more expensive, but still has an 
accessible price. 
- May be used in combination with other 
immunosuppressive agents in refractory 
IBD.9,30,31 
- Treating severe canine inflammatory and immune-
mediated disease with glucocorticoids often fails in 
the attempt to achieve disease remission without 
unacceptable side effects (Figure 5.a). 
- Adverse effects include iatrogenic 
hyperadrenocorticism, adrenal gland suppression, 
gastrointestinal ulceration, insulin resistance and 
secondary diabetes mellitus, muscle catabolism, 
delayed wound healing, opportunistic infections, 
and behavior changes. 31 
- P-gp led to resistance of glucocorticoids.40,41 
- Increases the risk of thromboembolic disease. In 
dogs with PLE an accurate thromboprophylaxis is 
recommended.30 
 
Comment: Glucocorticoids are frequently the first choice of immunosuppressive drugs in treatment of IBD. In 
middle-large dogs (greater than 25kg) budesonide should be preferred. Optimal duration of treatment with 
glucocorticoids is not yet defined.20 The goal of therapy is to achieve clinical remission and slowly taper the dose 
of glucocorticoids to the lowest dose that controls the inflammatory disease targeted.31 Often relapses occur and 
glucocorticoids efficacy can be less. In this case a combination of other immunosuppressive drugs should be 
chosen.9,20 
 
Dose: Prednisone/prednisolone starting dose 1-2 mg/kg every 12h PO.42  
Budesonide 3mg/m2 every 24 h37 (3-7 kg BW 1 mg; 7-15kg BW 2mg; 15-30kg BW 3mg; >30kg BW 5mg)38 
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Figure 5.a: Two dogs with CE showing severe adverse effects to glucocorticoids. One dog (left) shows a severe 
calcinosis cutis, and one dog (right) has a diffuse hair loss. 					
Box 5.h: Cyclosporine 
 
Advantages 
 
Disadvantages 
- Cyclosporine is the only immunosuppressant drug 
licensed for systemic administration to dogs.30 
- Rapid onset of immunosuppression and the 
potential for less systemic adverse effects. 
- Side effects are transient or resolve on 
discontinuation of the drug.30 
- Concurrent use of ketoconazole increases 
cyclosporine blood levels, allowing lower doses to 
be used to reduce costs.30 
- Side effects are mainly gastrointestinal signs 
(inappetence and vomiting in a quarter of dogs 
in the firsts weeks), gingival hyperplasia, and 
emergence of neoplasia.20,30,31,42 
- Expensive, especially for large dogs. 
 
Comment: efficacy of cyclosporine in treatment of IBD is demonstrated and can be used in dogs with steroid-
resistance IBD, with variable effects.35,43 Effects of cyclosporine in long lasting treatment are known in dogs with 
atopic dermatitis.  Therefore it may be an alternative in patients with relapses or the ones that have to live with 
immunosuppressant treatment lifelong; but further studies are warranted.20 
 
Dose: 3 to 5 mg/kg PO q12 to 24h35,42 
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5.i: Azathioprine 
 
Advantages 
 
Disadvantages 
- Low cost. 
- Used in combination with glucocorticoids, 
with which it is thought to have a 
synergistic effect, to allow more rapid dose 
reduction or tapering of glucocorticoids 
(the “glucocorticoid sparing” effect).30 
- Immunosuppressive effects in 7 days to 3 weeks.30 
- The most common adverse effect is myelosuppression 
that occurs 1 to 2 weeks after therapy, and it is reversible 
after drug withdrawal.31  
- Regular monitoring of CBC and biochemistry profile is 
advisable during the first weeks to months of treatment.  
- Others adverse effects include hepatotoxicity, 
pancreatitis, and gastrointestinal upset (vomiting and 
diarrhea).30,42 
 
Comment: efficacy of azathioprine is demonstrated in dogs with IBD, and it can be an option in dogs with 
adverse effects to glucocorticoids to taper the dose. The accessible price is the reason why it is chosen most of the 
time because adverse effects may be severe. 
 
Dose: 1-2 mg/kg PO q24h42 
 			
Box 5.j: Chlorambucil 
 
Advantages 
 
Disadvantages 
- Accessible price. 
- Low incidence of adverse effects. 
- Proven efficacy in PLE dogs. 
- Chlorambucil targets B cells and is considered a slow-
acting immunosuppressive agent that may require 2 
weeks to reach therapeutic efficacy.31 
- Myelosuppression (neutropenia and thrombocytopenia) is 
considered mild and generally occurs 7 to 14 days after 
the start of therapy. 
- A CBC should be performed after 1 and 3 weeks of 
treatment and repeated every 2-3 months. 
- Chlorambucil is a chemotherapy, client education is 
warranted. 
 
Comment: It is used as a second-line immunosuppressive therapy in the treatment of IBD that is either severe or 
poorly responsive to prednisone/prednisolone therapy. One study suggested that a chlorambucil-prednisolone 
protocol is more efficacious for treatment of PLE, compared to azathioprine-prednisolone combination.43 There is 
little evidence for its use in IBD dogs, but it seems to induce a good response.  
 
Dose: 2 to 6 mg/m2 PO q24 to 48h42 
 	ADJUNCTIVE	THERAPIES		VITAMIN,	MINERAL	AND	ELECTROLYTE	SUPPLEMENTATION	CE	results	in	malabsorption	that	leads	to	deficiencies	in	cobalamin,	folate,	magnesium,	and	calcium	(see	chapter	4).	Therefore,	their	integration	is	always	recommended	to	avoid	complications	(Box	5.k).		
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Box 5.k: vitamin, mineral and electrolyte supplementation 
 
 
Route and dose 
Cobalamin - 250-1000mcg once a weeks for 6 week, then 1000mcg once a month SC.9,44 
- 1000mcg/day PO.45 
 
Folate - 1 mg of folic acid per day.21 
- 1 to 5 mg/dog PO daily.46 
 
Magnesium - 0.75–1 mEq/kg/day IV ( 0.37–0.5 mmol/kg/day), decreasing to 0.3–0.5 mEq/kg/day IV on 
subsequent days of magnesium sulphate or magnesium chloride. In emergency situations, a 
rapid loading dose of 0.15– 0.3 mEq/kg can be given over 15–30 minutes.47 Attention on renal 
function and calcium and potassium level.  
- 1 to 2 mEq/kg/day PO of magnesium gluconate, magnesium oxide, magnesium carbonate.48 
 
Calcium  - Parental administration of 10% calcium gluconate (0.5–1.5 mL/kg) is advisable in dogs with 
acute onset of hypocalcemia related signs. 
- Vitamin D (calcitriol or 1,25-dihydroxyvitamin D) is recommended in dogs with low ionized 
calcium to prevent the onset of clinical signs. Dose may be 0.025–0.06 mcg/kg/day, but no 
definitive dosage is available in literature.49 
- Correction of hypomagnesaemia favorites the correction of hypocalcemia.  
 	THROMBOPROPHYLAXIS	Recent	 studies	 have	 revealed	 the	 high	 prevalence	 of	 hypercoagulability	 in	 dogs	 with	 PLE,	 which	significantly	increases	the	risk	of	potentially	fatal	thromboembolic	events.50–59	In	dogs	with	documented	or	 suspected	 hypercoagulability	 (panhypoprotidemia,	 low	 AT	 III,	 thrombocytosis,	 and	 glucocorticoids	trearment),	 administration	 of	 low	 doses	 of	 aspirin	 (0.5-1	 mg/kg/day)	 and/or	 clopidogrel	 (1-5	mg/kg/day)	should	be	considered	in	order	to	prevent	thrombosis.	However,	there	is	currently	no	study	confirming	the	beneficial	effect	of	such	a	therapeutic	regimen.49,60	PRE-	PRO-	AND	SYMBIOTIC		DEFINITIONS:	
Probiotics:	 are	 defined	 as	 live	 microorganisms,	 which	 when	 consumed	 in	 adequate	 amounts	 confer	 a	health	benefit	on	the	host.61,62	
Prebiotics:	 are	 defined	 as	 selectively	 fermented	 ingredients	 that	 result	 in	 specific	 changes	 in	 the	composition	 and/or	 activity	 of	 the	 gastrointestinal	 microbiota,	 thus	 also	 being	 a	 benefit	 to	 the	 host	organism.62	 These	 include	 disaccharides	 (lactulose,	 tagatose),	 oligo-	 or	 polysaccharides	[fructooligosaccharides	 (FOS),	 mannan	 oligosaccharides	 (MOS)	 xylooligosaccharides,	 polydextrose,	galacto	oligosaccharides],	or	long-chain	prebiotics	like	inulin.	
Synbiotics:	are	preparations	combining	both	probiotics	and	prebiotics.62	PROBIOTICS	Dysbiosis	plays	a	role	in	the	etiopathogenesis	of	CE	(see	Chapter	1).	This	is	where	the	application	of	pre-	or	 probiotics	 or	 their	 combination	 (so	 called	 synbiotics)	 has	 been	 the	 focus	 of	 much	 attention	 in	treatment	of	CE	in	both	humans	and	animals.62–64	As	probiotics	are	not	usually	defined	as	drugs,	they	do	not	have	 to	undergo	any	process	proving	 their	efficacy	 in	applications,	diseases,	or	even	target	species.	Currently,	many	labeled	products	containing	strains	of	bacteria	are	commercially	available	for	treatment	of	 acute	 and	 chronic	 enteropathies,	 but	 only	 few	 have	 a	 proven	 efficacy	 (Box	 5.l).62	 Moreover,	 the	concentration	 and	 viability	 of	 the	 microbiological	 agent	 present	 in	 available	 product	 is	 sometimes	questionable.65
61	
Probiotics	 are	 shown	 to	 have	 a	 supportive	 effect	 on	 the	microbiota;	 they	may	 have	 anti-inflammatory	properties	 and	may	 compete	with	 pathogenic	 bacteria,	 reducing	 the	 opportunity	 for	 those	 bacteria	 to	adhere	 to	 the	 intestinal	 mucous	 membrane	 and	 cause	 further	 disease	 (Figure	 5.b).61,62	 However,	 the	mechanisms	by	which	probiotics	exert	their	beneficial	effects	have	not	been	clearly	defined.62				
	
Figure 5.b: Proposed mechanism of action of probiotics. From Schmitz and Suchodolski, 201662 		PREBIOTICS	Utilization	 of	 prebiotics	 has	 several	 beneficial	 effects	 in	 the	 canine	 intestine,	 including	 improved	composition	 of	 intestinal	 microbiota,	 reduced	 concentrations	 of	 protein	 catabolites	 and	 enhanced	production	of	SCFA.66	Furthermore,	evidence	exists	that	some	positive	effects	of	prebiotics	in	dogs	might	be	enhanced	if	these	are	used	in	combination	with	specific	probiotic	strains,	in	the	form	of	a	synbiotic.66	Clinical	 effects	 of	 prebiotics	 have	 been	 investigated	 in	 humans	 and	 animal	 models	 but	 little	 evidence	exists	that	prebiotics	may	be	helpful	in	canine	diseases.66		
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Box 5.l: Probiotics 
 
Probiotic 
 
References  
 
Comments 
 
VSL#3 (Vivomix, Sivoy) 
Probiotic mixture that includes: 
Lactobacilli (L. acidophilus, L. 
plantarum, L. paracasei, L. 
delbrueckii ssp. bulgar- icus), 
Bifidobacteria (B. breve, B. longum, 
B. infantis) and Streptococcus 
thermophilus. 
 
Rossi et al, 2014; Mardini 
et al, 2014; White et al, 
2015.67–69 
Used in humans and dogs with IBD and 
puppies with parvovirus enteritis. Led to 
clinical and immunological improvement and 
apparent resolution of dysbiosis. 
Enterococcus faecium  
Two strains approved by 
European Food Safety Authority 
E. faecium NCIMB 10415 E1705, E. 
faecium NCIMB 10415 E1707) 
Benyacoub et al, 2003; 
Marcinakova et al, 2006; 
Simpson et al, 2009; Bybee 
et al, 2011; Gagné et al, 
2013; Schmitz et al, 2014; 
Schmitz et al, 201570–74 
 
E. faecium has been tested in healthy dogs and 
puppies. This probiotic was also tested in 
dogs with giardiasis, acute diarrhea, and FRE 
with various degrees of efficacy. Finally, a 
symbiotic contains E. faecium, FOS, MOS, and 
vitamin (B6, B9) was administered to dogs 
with improvement of clinical signs. 
 
 
Lactobacilli and bifidobacteria 
Two approved by European 
Food Safety Authority 
Lactobacillus acidophilus DSM 
13241 25 and Bifidobacterium sp. 
animalis,but may others strains 
have been proven. 
 
Swanson et al. 2002; Biagi 
et al, 2007; Chung et al, 
2009; Strompfovà et al, 
2012; Strompfovà et al, 
2014.75–79 
Overall data on improving gut health or 
immunological status in dogs using 
lactobacilli or bifidobacteria are not 
compelling.62 
Saccharomyces boulardii 
McFarland, 2010; Bresciani 
et al, 2014;  
 
S. boulardii is a non-pathogenic yeast used to 
treat acute and chronic enteropathies in 
humans. A recent study concluded by our 
group indicates that S. boulardii can be safely 
administered to dogs and it might be useful 
as an adjunctive treatment in CE and PLE 
(see Chapter 5.1). 
 		NEW	THERAPIES	FECAL	MICROBIOTA	TRANSPLANT	(FMT)	Fecal	microbiota	transplantation	(FMT)	is	the	term	used	to	describe	the	process	in	which	fecal	material,	or	 stool,	 is	 collected	 from	 a	 tested	 healthy	 donor	 and	 delivered	 into	 a	 patient	 either	 by	 enema,	colonoscopy,	 or	 via	 the	 upper	 GI	 tract	 (by	 endoscopy,	 oral	 capsules,	 nasogastric	 or	 nasoenteric	 tube).	Nowadays,	this	definition	replaces	other	names	such	as	stool	transplant,	fecal	bacteriotherapy,	and	fecal	flora	reconstitution.80,81		In	human	medicine,	FMT	is	indicated	to	treat	recurrent	or	resistance	Clostridium	difficile	infection.82	FTP	may	 be	 indicated	 for	 other	 GI	 and	 non-GI	 disorders,	 such	 as	 Parkinson’s	 disease,	 chronic	 fatigue	
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syndrome,	 multiple	 sclerosis,	 myoclonus	 dystonia,	 obesity,	 insulin	 resistance,	 and	 metabolic	syndrome.80,83	Recently,	its	usefulness	was	evaluated	in	IBD	patients	with	good	results.84	In	 dogs	 and	 cats,	 FMT	 may	 have	 the	 potential	 to	 improve	 health	 in	 any	 disease	 associated	 with	 an	alteration	 or	 dysbiosis	 of	 intestinal	 microbial	 ecology	 such	 as	 acute	 and	 chronic	 GI	 inflammatory	disease.80	 However,	 there	 is	 currently	 very	 limited	 scientific	 data	 in	 veterinary	 patients	 concerning	efficacy,	safety,	and	techniques	employed.		In	conclusion,	based	on	its	remarkable	results	 in	humans,	the	FMT	therapy	should	be	further	examined	and	 considered	 as	 a	 valid,	 economic,	 and	 potentially	 highly	 efficient	 way	 of	 treatment	 in	 veterinary	medicine.	 BILE	ACID	SEQUESTRANTS	Bile	acid	(BA)	malabsorption	is	a	common	yet	under-recognized,	cause	of	chronic	diarrhea	in	people;	85	however	it	has	never	been	investigated	in	dogs,	despite	clinical	suspicion	of	its	existence.86	Recent	studies	suggested	that	BA	malabsorption	may	be	a	clinically	relevant	disorder	in	dogs	with	chronic	diarrhea.86,87	Colestyramine	 and	 colestipol	 are	 generally	 effective	 treatments	 of	 gastrointestinal	 symptoms	 from	 BA	malabsorption,	but	their	usage	is	often	limited	in	clinical	practice	because	of	their	palatability	and	ability	to	bind	to	other	medications;	other	therapies	as	well	as	dietary	intervention	may	also	have	a	role.85	Colestyramine	has	been	used	successfully	 in	both	dogs	and	cats;	however,	 it	 is	not	 licensed	 in	either	of	these	 species.	 Glucocorticoids	 have	 been	 shown	 to	 up-regulate	 the	 bile	 acid	 transporter,	 therefore	reducing	BA	diarrhea.	Low-fat	diets,	in	humans	also	reduce	secretion	of	BA.	Therefore	we	can	speculate	that	some	dogs	with	a	diagnosis	of	CE	may	actually	have	BA	diarrhea,	but	respond	to	treatment	because	corticosteroids	and	a	reduced	fat	diet	are	used.86	In	conclusion,	based	on	human	experience	and	recent	data,	BA	diarrhea	should	be	suspected	in	dogs	with	chronic	 diarrhea,	 and	 BA	 sequestrants	 may	 be	 a	 therapeutic	 options.	 Further	 studies	 are	 needed	 to	explore	the	clinical	significance;	clinicians	should	be	aware	of	the	potential	for	BA	malabsorption	in	cases	that	are	poorly	responsive	to	conventional	therapies.86	STEM	CELLS	Mesenchymal	stem	cells	(MSCs)	have	shown	immunomodulatory	and	anti-inflammatory	effects	in	animal	models	of	colitis,	and	promising	clinical	results	have	been	obtained	in	humans	with	Crohn’s	disease	and	ulcerative	 colitis.88	A	 recent	 study	 in	dogs	demonstrated	 that	 a	 single	 IV	 infusion	of	 allogeneic	 adipose	tissue-derived	mesenchymal	 stem	cells	was	well	 tolerated	and	appeared	 to	produce	 clinical	benefits	 in	dogs	 with	 severe	 IBD.	 89	 Similarly,	 a	 recent	 study	 of	 the	 use	 of	 IV	 allogeneic	 adipose-derived	 feline	mesenchymal	stem	cells	therapy	in	spontaneous	feline	enteropathy	showed	safety	and	a	positive	clinical	response.90	Both	studies	had	promising	results,	but	further	studies	are	need	to	assess	the	efficacy	and	viability	of	this	treatment	in	a	clinical	setting.	REFERENCES		
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5.1	 EFFICACY	OF	SACCHAROMYCES	BOULARDII	IN	DOGS	WITH	CHRONIC	ENTEROPATHIES:	DOUBLE-BLIND,	PLACEBO-CONTROLLED	STUDY		 D'ANGELO	S.,	FRACASSI	F.,	BRESCIANI	F.,	GALUPPI	R.,	DIANA	A.,	LINTA	N.,	BETTINI	G.,	MORINI	M.,	PIETRA	M.		
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Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emilia (BO), Italy. 
 	ABSTRACT	
Saccharomyces	 boulardii	 is	 used	 to	 treat	 acute	 and	 chronic	 enteropathies	 in	 humans,	 but	 to	 date,	 no	studies	have	evaluated	 the	use	of	 this	yeast	 in	dogs.	The	current	 study,	 a	prospective	non-randomised,	double-blinded	 placebo-controlled	 study,	 evaluated	 the	 effects	 of	S.	boulardii	 in	 healthy	 dogs	 and	 dogs	with	chronic	enteropathies	(CE).		Four	healthy	dogs	and	20	dogs	with	CE	were	included.	In	healthy	dogs,	S.	boulardii	was	administered	for	10	 days.	 Possible	 short-term	 adverse	 effects	were	 recorded,	 and	 quantitative	 stool	 cultures	 for	 yeasts	were	performed.		In	dogs	with	CE,	S.	boulardii	or	a	placebo	was	administered	in	addition	to	standard	treatment	protocols.	Complete	blood	work,	abdominal	ultrasonography,	gastroenteroscopy	and	histology	were	performed	at	the	time	of	diagnosis	and	after	60	days	of	treatment.	In	healthy	dogs,	S.	boulardii	reached	a	steady	state	in	five	days	and	was	completely	eliminated	on	day	4	after	administration.	No	short	term	side	effects	were	seen.	 Clinical	 activity	 index,	 stool	 frequency,	 stool	 consistency	 and	 body	 condition	 score	 improved	significantly	in	dogs	with	CE	receiving	S.	boulardii	versus	the	placebo.	In	 conclusion,	 S.	 boulardii	 can	 be	 safely	 used	 in	 dogs	 with	 CE	 and	 seems	 to	 achieve	 better	 control	 of	clinical	signs	than	standard	therapy	alone.		
Key	words:	Chronic	enteropathy;	Dog;	Probiotics;	Yeast,	Saccharomyces	boulardii	
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INTRODUCTION	Probiotics	are	live	microorganisms	that,	when	consumed	in	adequate	amounts,	confer	a	health	benefit	to	the	 host	 (Thomas	 and	 Versalovic	 2010,	 Martinez	 and	 others	 2015,	 Shmitz	 and	 Suchodolski	 2016).	Numerous	studies	 in	many	species	have	shown	how	a	 single	probiotic	 strain	or	 combination	of	 strains	may	modulate	 gut	 function	 and	 treat	 several	 gastrointestinal	 disorders	 (Thomas	 and	 Versalovic	 2010,	Rossi	 and	 others	 2014,	 Shmitz	 and	 Suchodolski	 2016).	 In	 small	 animal	 practice,	 probiotics	 are	 of	increasing	 interest	 and	 have	 a	 supportive	 effect	 on	 the	microbiota.	 They	may	 have	 anti-inflammatory	properties	 and	 may	 also	 compete	 with	 pathogenic	 bacteria,	 reducing	 the	 opportunity	 for	 bacteria	 to	adhere	 to	 the	 intestinal	 mucosa	 and	 cause	 further	 disease	 (Thomas	 and	 Versalovic	 2010,	 Shmitz	 and	Suchodolski	2016).	However,	the	mechanisms	by	which	probiotics	exert	their	beneficial	effects	have	not	been	clearly	defined	(Shmitz	and	Suchodolski	2016).	
Saccharomyces	 boulardii	 is	 a	 non-pathogenic	 yeast	 used	 to	 treat	 acute	 and	 chronic	 enteropathies	 in	humans	 (Mc	 Farland	 2010).	 Recent	 studies	 have	 investigated	 its	 use	 in	 treating	 gastrointestinal	 (GI)	disease	 in	 the	 zootechnical	 field	 and	 in	 horses	 (Desrochers	 and	 others	 2005,	 Collier	 and	 others	 2011,	Rajput	 and	 others	 2013,	 Boyle	 and	 others	 2013).	 Although	 probiotics	 are	 used	 to	 treat	 chronic	enteropathies	(CE)	 in	dogs,	 the	authors	could	not	 locate	any	 information	 in	the	 literature	regarding	the	use	of	S.	boulardii	in	dogs	(Thomas	and	Versalovic	2010).		The	current	study	evaluated	the	effects	of	S.	boulardii	 in	healthy	dogs	and	dogs	with	CE.	The	hypothesis	was	that	S.	boulardii	can	be	administered	without	any	adverse	effects	and	facilitates	the	control	of	CE	as	an	addition	to	standard	therapy.		MATERIALS	AND	METHODS	STUDY	DESIGN	First,	 a	 prospective	 clinical	 trial	was	 performed	 in	 healthy	dogs	 to	 evaluate	 the	 viability	 of	S.	boulardii	administration	 and	 possible	 short-term	 side	 effects.	 Then,	 the	 therapeutic	 effects	 of	 S.	 boulardii	 were	evaluated	 in	 a	 prospective,	 non-randomised,	 double-blinded	 placebo-controlled	 study	 on	 client	 owned	dogs	with	newly	diagnosed	CE.	The	dogs	were	administered	the	probiotic	(dose	1	×	109	colony-forming	units	 [CFU]/kg	 PO	 q12h)	 or	 a	 placebo,	 in	 addition	 to	 regular	 therapies	 as	 reported	 in	 the	 literature	(Simpson	 and	 Jergens	 2011).	 Two	 galenic	 formulations	were	 prepared	 by	 a	 private	manufacturer,	 and	called	Product	A	and	Product	B,	one	of	which	contained	the	probiotic	and	the	other	contained	the	placebo	without	 the	 clinician’s	 or	 owner’s	 knowledge.	 Patients	were	 assigned	 to	 each	 group,	with	 the	 first	 dog	assigned	to	Group	A,	and	then	patients	were	alternatively	assigned	to	each	group	(A	or	B)	in	a	consecutive	order.	The	study	design	was	extrapolated	from	a	previous	study	(Desrochers	and	others	2005).	The	 study	 was	 approved	 by	 the	 Scientific	 Ethics	 Committee	 for	 Experimentation	 on	 Animals	 of	 Alma	Mater	Studiorum,	University	of	Bologna	(Prot.	n.2-IX/9,	2012).	PREPARATION	AND	QUALITY	CONTROL	OF	SACCHAROMYCES	BOULARDII	For	 the	 study,	 two	galenic	 formulations	were	prepared	 in	gelatin-coated	capsules.	The	capsules	 for	 the	placebo	 group	 contained	 334	 mg	 maltodextrin.	 The	 probiotic	 therapy	 formulation	 (S.	 boulardii)	 was	prepared	with	capsules	containing	10	x	109	CFU	of	lyophilised	S.	boulardii	(523	mg).	The	capsules	for	each	group	were	collected	from	the	producer	in	shaded	plastic	bins,	identified	as	A	or	B.		For	 each	 lot	 produced,	 capsules	 containing	 S.	 boulardii	were	 sent	 from	 the	 producer	 to	 the	 Mycology	Laboratory	of	 the	Department	 for	quality	control	 to	confirm	the	viability	of	yeast	and	the	 titration	of	S.	
boulardii	 in	 the	 preparation.	 Briefly,	 the	 content	 of	 a	 capsule	was	 dissolved	 in	 100	mL	 peptone	 saline	diluent	(1.0	g	peptone,	8.5	g/L	sodium	chloride;	final	pH	7.0	±	0.2	at	25	°C)	and	incubated	at	37	°C	for	30	minutes	 to	 revitalise	 the	yeast.	Ten-fold	 serial	 dilutions	 to	10-6	were	made	 from	 the	 initial	 suspension,	and	0.1	mL	of	each	dilution	was	transferred	in	duplicate	and	uniformly	spread	onto	the	surface	of	petri	dishes	 containing	 Sabouraud	 dextrose	 agar	 (BBL	 Sabouraud	 dextrose	 agar,	 Becton	 Dickinson	 and	Company,	Sparks,	MD,	USA)	with	0.05%	chloramphenicol	(SAB-CAF).	The	plates	were	incubated	at	30	°C	
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for	 at	 least	 48–72	 h.	 Plates	 containing	 fewer	 than	 200	 colonies	 were	 selected	 for	 counting,	 and	 the	number	of	CFUs	was	calculated	for	each	capsule.	HEALTHY	CONTROLS	Client	consent	was	obtained	for	client-owned	dogs	of	various	breeds	and	ages.	The	dogs	were	included	in	the	 study	 if	 they	 had	 a	 negative	 faecal	 parasite	 examination	 and	 a	 normal	 physical	 exam,	 including	 an	absence	of	GI	signs	for	at	least	three	weeks	before	starting	the	study.		Faecal	samples	were	collected	daily	for	two	days	(T1,	T2)	before	beginning	administration	of	S.	boulardii,	and	were	subjected	to	 faecal	 flotation	tests	(to	assess	 for	 intestinal	parasites)	and	to	 faecal	cultures	(to	exclude	 the	presence	of	Saccharomyces	 species).	Then,	S.	boulardii	was	administered	at	a	dosage	of	1	×	109	 CFU/kg	 PO	 q12h	 for	 10	 days.	Dogs	were	monitored	 daily	 through	 anamnestic	 investigation,	 and	 a	physical	exam	was	performed	daily.	Stool	samples	were	collected	every	day	for	the	first	five	days	(T1,	T2,	T3,	T4	and	T5),	and	the	last	day	of	administration	(T10)	for	faecal	cultures	to	assess	the	presence	of	the	yeast	and	 to	evaluate	when	S.	boulardii	 reached	a	 steady	state,	defined	as	10	×	107	CFU/g	of	 faeces,	 as	described	by	Mc	Farland	(2010).	Faecal	samples	were	also	collected	for	five	days	(T11,	T12,	T13,	T14,	and	T15),	as	well	as	on	 the	10th	day	after	probiotic	administration	 (T20),	 to	confirm	 the	eventual	 complete	elimination	of	 the	yeast.	Faecal	cultures	were	performed	by	using	an	 inoculating	 loop	 to	streak	a	bit	of	sample	 directly	 onto	 a	 plate	 containing	 SAB-CAF	 (direct	 smear)	 to	 evaluate	 the	 presence/absence	 of	yeasts	and	by	dissolving	1	g	faeces	in	9	mL	peptone	saline	diluent,	preparing	10-fold	serial	dilutions	to	10-6.	Cultures	and	counts	from	the	dilutions	were	made	as	described	above	for	the	capsules,	to	assess	CFU/g	of	faeces.	In	addition,	in	all	female	dogs,	a	vaginal	swab	and	consecutive	yeast	culture	was	performed	10	days	after	administration	(T20)	to	exclude	vaginal	colonisation	by	the	yeast.		The	 API	 20C	 AUX	 kit	 (API	 20C	 AUX	 kit	 BioMérieux,	 Marcy-l’Étoile,	 France)	 was	 used	 for	 yeast	identification	 according	 to	 the	 manufacturer’s	 instructions.	 The	 probiotic	 tested,	 on	 the	 basis	 of	 the	assimilation	profiles	 highlighted	by	 the	 kit,	was	 classified	 as	S.	cerevisiae	 because	 this	 biochemical	 test	does	not	provide	sufficient	evidence	to	distinguish	between	strains	of	this	yeast	(Rajkowska	and	Kunicka-Styczyńska	2009).	In	the	Results	and	Discussion	sections,	it	will	be	referred	as	S.	boulardii.	DOGS	WITH	CE	Client	consent	was	obtained	 for	client-owned	dogs	with	CE	 for	 inclusion	 in	 the	study.	 Inclusion	criteria	were	the	presence	of	chronic	GI	signs	for	at	least	one	month	before	clinical	examination,	negative	faecal	parasite	 examination	 and/or	 treatment	 with	 fenbendazole	 (Panacur,	 MSD	 Animal	 Health	 S.r.l)	 at	 50	mg/kg	q24h	for	five	days,	and	exclusion	of	other	causes	of	chronic	diarrhoea	(Jergens	and	others	1992).	Dogs	that	experienced	food-responsive	diarrhoea	were	excluded	if	they	responded	to	at	least	two	weeks	of	 an	 exclusion	 diet	 (mono-protein	 commercial	 diet,	 hydrolysed	 diet	 or	 restricted	 home-cooked	 diet).	Dogs	with	antibiotic-responsive	diarrhoea	were	excluded	 if	clinical	signs	disappeared	after	at	 least	 two	weeks	of	treatment	with	antibiotics	(tylosin	15	mg/kg	PO	q12h,	or	metronidazole	10	mg/kg	PO	q12h).		All	 dogs	 that	met	 the	 inclusion	 criteria	were	 subject	 to	 an	 accurate	 anamnestic	 investigation,	 physical	examination,	complete	blood	work	(complete	blood	count	[CBC],	serum	biochemistry	profile,	coagulation	profile,	and	serum	folate	and	cobalamin	concentrations),	abdominal	ultrasound	(iU22	ultrasound	system,	Philips	Healthcare,	Monza,	 Italy),	 gastroenteroscopy	 (Pentax	EG	1840	or	Pentax	EG	290P,	Pentax	 Italia	S.r.L.,	Milano,	Italy)	and	histology	from	endoscopic	intestinal	biopsies.	A	diagnosis	of	inflammatory	bowel	disease	 (IBD),	 with	 or	 without	 concomitant	 hypoproteinaemia	 (protein-losing	 enteropathy	 [PLE]),	defined	 as	 serum	 albumin	 <2	 g/dL,	 normal	 total	 protein/albumin	 ratio,	 and	 normal	 urinary	protein:creatinine	ratio,	was	made	based	on	the	results	of	the	diagnostic	trial.		Dogs	were	treated	with	diet	(mono-protein	commercial	diet,	hydrolysed	diet	or	restricted	home-cooked	diet),	antibiotics	(tylosin	15	mg/kg	PO	q12h,	or	metronidazole	10	mg/kg	PO	q12h),	steroids	(prednisone	0.5–2	mg/kg	PO	q24h,	in	some	cases	associated	with	azathioprine	1–2	mg/kg	PO	q24h	or	chlorambucil	4–6	mg/m2	PO	q48h)	and	S.	boulardii	or	a	placebo,	as	previously	described.		Dogs	with	CE	were	followed	for	60	days	and	re-evaluated	before	(T0)	and	after	histopathologic	diagnosis	at	 days	 14	 (T14),	 30	 (T30),	 45	 (T45)	 and	 60	 (T60).	 The	 validated	 canine	 chronic	 enteropathy	 clinical	
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activity	index	(CCECAI)	(Allenspach	and	others	2007)	and	body	condition	score	(BCS,	9-point	scale)	were	used	to	quantify	improvements	during	treatment.	The	subgroup	consisting	of	 the	dogs	with	PLE	were	evaluated	at	T0,	T14,	T30,	T45	and	T60	via	 serum	albumin	concentration	(g/dL).		After	 60	 days	 of	 treatment,	 complete	 blood	 work	 (CBC,	 serum	 biochemistry	 and	 coagulation	 profile),	abdominal	 ultrasound	 and	 gastroenteroscopy	with	 histological	 examination	 of	 intestinal	 biopsies	were	performed	on	all	dogs.	The	ultrasonographic	appearance	of	 the	duodenum	and	colon	was	evaluated	for	the	 following	 criteria:	 wall	 thickness,	 wall	 layering,	 motility,	 regional	 lymphadenopathy,	 echogenicity	changes	of	mesentery	and	presence	of	 fluid,	by	using	a	scoring	system	modified	by	Ripollès	and	others	(2013).	The	total	score	of	the	duodenum	and	colon	was	expressed,	based	on	the	number	of	alterations	on	ultrasound,	as	normal	(no	alteration,	0	points),	mild	(1–2	alterations,	1	point),	moderate	(3–4	alterations,	2	 points)	 and	 severe	 (≥5	 alterations,	 3	 points).	 Endoscopic	 images	 of	 the	 duodenum	 and	 colon	 were	codified	 following	 Slovak	 and	 others	 (2015),	 and	 histological	 findings	 of	 the	 duodenal	 and	 colonic	biopsies	 were	 reported	 following	 the	 World	 Small	 Animal	 Veterinary	 Association’s	 standardised	guidelines	(Washabau	and	others	2010).	The	 comparison	 of	 ultrasonographic,	 endoscopic	 and	 histologic	 scores	 of	 the	 duodenum	 and	 colon,	performed	 before	 (T0)	 and	 after	 treatment	 (T60),	 were	 used	 to	 quantify	 any	 improvement	 during	treatment.	STATISTICAL	METHODS	All	 statistical	 analyses	 were	 performed	 using	 commercially	 available	 software	 (Med	 Calc	 12.2.1.0,	MedCalc	 Software,	 Ostend,	 Belgium;	 Graph	 prism	5.01,	 GraphPad	 Software	 Inc.,	 La	 Jolla,	 CA,	 USA)	with	significance	designated	as	P	<	0.05.	The	assessment	of	data	for	normality	was	calculated	by	applying	the	D’Agostino-Pearson	 test.	 Data	were	 expressed	 as	 frequency	 and	 percentages	 or	median	 and	minimum	and	maximum.		For	dogs	with	CE,	descriptive	analysis	and	comparisons	between	the	group	receiving	S.	boulardii	and	the	group	receiving	a	placebo	were	performed	by	an	independent	sample	Student’s	t-test,	Mann-Whitney	U	test	 or	 Fisher’s	 exact	 test,	 at	 T0,	 on	 signalment	 (sex,	 age,	 body	weight,	 BCS),	 CCECAI	 score,	 laboratory	results	 (CBC,	 serum	 total	 protein,	 albumin,	 cholesterol,	 triglyceride,	 creatinine,	 urea,	 alanine	aminotransferase,	 aspartate	 aminotransferase,	 alkaline	 phosphatase,	 folate	 and	 cobalamin	concentrations),	ultrasonographic	score,	histopathologic	score	and	endoscopic	score.		Moreover,	 CCECAI	 and	BCS	were	 compared	between	 the	 two	groups	 (S.	boulardii	 and	placebo)	 at	 each	time	(T14,	T30,	T45,	T60)	by	an	independent	sample	t-test	or	Mann-Whitney	U	test.		Ultrasonographic,	 histopathologic	 and	 endoscopic	 scores	were	 compared	 between	 the	 S.	 boulardii	 and	placebo	groups	at	T60	by	an	independent	sample	t-test	or	Mann-Whitney	U	test.		A	comparison	was	performed	by	the	Friedman	Test	or	Wilcoxon	test,	between	T0	and	T60,	in	each	of	the	two	groups	(S.	boulardii	and	placebo)	for	the	following	parameters:	CCECAI,	body	weight,	BCS,	endoscopic	score,	ultrasound	score	and	histopathologic	score.		In	patients	with	PLE,	albumin	concentration	(g/dL)	was	compared	between	the	two	groups	(S.	boulardii	and	placebo)	at	each	time	(T0,	T14,	T30,	T45,	T60)	by	the	Mann-Whitney	U	test,	and	in	each	of	the	two	groups	(S.	boulardii	and	placebo)	between	T0	and	T60	by	the	Friedman	Test.		RESULTS	QUALITY	CONTROL	OF	S.	BOULARDII	CAPSULES	The	analysed	S.	boulardii	capsules	contained	the	yeast	in	the	concentration	declared	by	the	manufacturer.		HEALTHY	DOGS	Four	dogs	 (healthy	 control:	HC1,	HC2,	HC3,	HC4)	were	 included	 in	 the	healthy	group,	 and	 consisted	of	three	mixed-breed	dogs	and	one	pug.	Three	of	 them	were	 spayed	 females	and	one	was	an	 intact	male.	Median	body	weight	was	13.5	kg	 (6.5–21.0	kg)	and	median	age	was	66	months	 (60–84	months).	 In	all	
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dogs,	 a	 faecal	 parasite	 examination	 was	 negative	 for	 the	 two	 days	 before	 the	 administration	 of	 the	probiotic,	and	faecal	cultures	were	negative	for	Saccharomyces	species,	even	if	in	three	samples	colonies	of	 other	 yeasts	 were	 isolated	 (Table	 1).	 Faecal	 cultures	 obtained	 during	 the	 probiotic	 treatment	determined	the	presence	of	Saccharomyces	species	concentrations	in	the	stool	(Table	1).	In	particular	in	all	 dogs,	 Saccharomyces	 was	 present	 in	 the	 faeces	 from	 day	 1	 and	 reached	 the	 steady	 state	 (10	 ×	 107	CFU/g	of	faeces)	on	day	3	and	4.		The	titration	of	Saccharomyces	species	in	faeces	decreased	rapidly	after	the	withdrawal	of	treatment,	and	no	colony	of	Saccharomyces	species	was	isolated	in	any	of	the	dogs	four	days	after	treatment	(T14),	while	other	yeasts	were	occasionally	found,	mainly	from	direct	smears	(Table	1).	Yeast	 cultures	 from	 vaginal	 swabs,	 performed	 the	 10th	 day	 after	 treatment	 (T20),	 were	 negative	 for	
Saccharomyces	 species	 in	 all	 three	 healthy	 female	 dogs.	 In	 HC1,	 a	 large	 number	 of	 Malassezia	
pachydermatis	colonies	were	isolated.	No	short-term	adverse	effects	were	reported	by	the	owners.	One	dog	showed	signs	of	mild	pain	during	abdominal	 palpation	 the	 first	 day	 of	 administration	 of	 the	 probiotic.	 In	 this	 case,	 the	 clinical	 sign	disappeared	after	the	first	day	of	therapy.	DOGS	WITH	CE	Twenty	dogs	with	a	diagnosis	of	IBD	were	initially	included	in	the	trial.		The	predominant	breeds	were	the	German	shepherd	(5/20;	25%)	and	Rottweiler	(2/20;	10%),	and	2/20	(10%)	 were	 sexually	 intact	 females,	 17/20	 (85%)	 were	 sexually	 intact	 males	 and	 1/20	 (5%)	 was	 a	neutered	male.	The	median	age	of	the	dogs	was	38.5	months	(7–108	months),	median	body	weight	was	25.9	kg	(5.3–64.5	kg)	and	median	BCS	was	3/9	points	(1–7).	Ten	dogs	(four	with	PLE)	were	enrolled	in	the	 S.	 boulardii	 group	 and	 10	 (four	 with	 PLE)	 were	 treated	 with	 the	 placebo.	 There	 was	 no	 breed	prevalence,	 nor	 a	 significant	 difference	 in	 sex,	 age,	 body	weight	 and	BCS	 at	 inclusion	between	 the	 two	groups.		Principal	 alterations	 seen	 on	 haematological	 and	 biochemical	 exams	 at	 inclusion	were	 thrombocytosis	(6/20;	median	301500/μL	[93000-947000],	reference	interval	160000-500000/μL),	hypoalbuminaemia	(13/20	 had	 albumin	 <2.8	 g/dL;	 of	 these,	 8/13	 had	 albumin	 <2.0	 g/dL;	median	 2.13	 g/dL	 [0.85-3.74],	reference	interval	2.80-3.70	g/dL),	hypocholesterolaemia	(8/20;	median	150	mg/dL	[82-326],	reference	interval	140-350	mg/dL)	and	alterations	in	serum	folate	(median	14.2	μg/L	[2.53-24],	reference	interval	6.5-11.5	μg/L)	and	cobalamin	concentrations	(median	287	ng/L	[150-1000],	reference	interval	250-730	ng/L);	9/16	had	increased	folate	concentrations	and	decreased	cobalamin	concentrations	and	4/16	had	decreased	folate	concentrations	and	normal	cobalamin.	No	significant	differences	in	haematologic	and	biochemical	variables	at	T0	were	detected	between	the	S.	
boulardii	 and	 placebo	 groups,	with	 the	 exception	 of	 serum	 albumin	 concentration	which	was	 lower	 in	patients	 with	 PLE	 included	 in	 the	 S.	 boulardii	 group	 compared	 to	 patients	 with	 PLE	 included	 in	 the	placebo	group	(median	1.04	g/dL	[0.85-1.16]	vs	1.61	g/dL	[1.22-1.89],	P	=	0.02).	All	dogs	received	dietary	treatment:	9/20	(45%)	home-cooked	diet,	10/20	(50%)	mono-protein	pet	food	diet,	and	one	dog	(5%)	received	both.	All	CE	patients	received	antibiotics:	18/20	(90%)	tylosin,	and	2/20	(10%)	dogs,	 in	the	S.	boulardii	group,	received	metronidazole.	All	dogs	were	treated	with	prednisolone;	2/20	 (10%)	 and	3/20	 (15%)	 received	 azathioprine	 (two	dogs	 in	 the	placebo	 group)	 and	 chlorambucil	(two	 dogs	 in	 the	 S.	 boulardii	 group	 and	 one	 dog	 in	 the	 placebo	 group),	 respectively.	 There	 were	 no	detected	differences	between	the	groups	related	to	diet	and	treatment.	The	median	CCECAI	score	at	inclusion	(T0)	was	6.5	(5–17)	in	the	S.	boulardii	group	and	6.5	(5–16)	in	the	placebo	group,	with	no	significant	differences	between	the	two	groups.	At	diagnosis,	the	median	ultrasound	score	was	1	point	(0–3)	for	the	duodenum	and	0	points	(0-1)	for	the	colon.	The	median	endoscopic	score	of	the	duodenum	was	4	points	(1–5)	and	of	the	colon	was	0	points	(0–4).	The	median	histological	score	for	the	duodenum	was	9.5	points	(3–18)	and	for	the	colon	was	3.5	points	(1–11).				
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Dogs 
Before 
administration 
of S. boulardii 
 
During S. boulardii administration 
(CFU) 
  
After administration of S. boulardii (CFU) 
 
T-2 T-1  T1 T2 T3 T4 T5 T10  T11 T12 T13 T14 T15 T20 
                 
HC1 – – 
 20 × 
106 
12 × 
106 
12.2 
× 107 
56.5 
× 107 
63 × 
106 
15.9 
× 107 
 
– – – 
– 
Rhod) 
– – 
HC2 
– 
(Rhod) 
– 
(Rhod) 
 36 × 
104 
16 × 
106 
10 × 
103 
49.8 
× 107 
34.4 
× 107 
30 × 
107 
 
1 × 104 1 
5 
(Rhod) 
– – – 
HC3 
– 
(Cand) 
– 
 16 × 
106 
20 × 
106 
35.3 
× 107 
17.3 
× 107 
29.3 
× 107 
11 × 
104 
 
2 × 104 
1 × 
104 
– 
– 
(Geo) 
– 
(Cand; 
Rhod) 
HC4 – – 
 
12 × 
105 
90 × 
106 
15.7 
× 107 
38 × 
105 
19.2 
× 106 
1 × 
104 
 
– 
(Rhod) 
– 
– 
(Rhod) 
– 
(Rhod) 
 
– NP 
                 
Table 1 Results of faecal culture in four healthy dogs (HC1, HC2, HC3, HC4) before, during and after Saccharomyces boulardii administration (with 
genera of other yeast colonies isolated via direct smear noted in parentheses). 
HC, healthy control; –, Negative; CFU, Colony-forming unit; NP, Not performed; Rhod = Rhodotorula; Cand = Candida glabrata; Geo = Geotrichum 		No	 significant	 differences	 were	 detected	 between	 the	 S.	 boulardii	 and	 placebo	 groups	 on	 ultrasound,	endoscopic	and	histologic	appearance	at	T0.	Thirteen	dogs	reached	the	end	of	the	study	(six	in	the	S.	boulardii	group	and	seven	in	the	placebo	group).	Three	 dogs	 did	 not	 complete	 the	 study	 because	 of	 low	 owner	 compliance	 (two	 after	 T0	 and	 one	 after	T30),	three	dogs	were	euthanised	for	worsening	of	clinical	conditions	(two	dogs,	one	of	which	had	PLE,	in	the	S.	boulardii	group	[both	after	T30]	and	one	dog	with	PLE	 in	 the	placebo	group	after	T45).	The	 fifth	dog,	 treated	with	 a	 placebo	 and	 standard	 therapy,	 had	 a	 good	 response	 to	 treatment	 but	 died	 due	 to	mesenteric	torsion	(after	T30)	(Fig	1).			
	
Figure 1. Time line flowchart of patients and dropouts during the study. 	All	of	the	data	of	dogs	that	left	the	study	were	used	for	statistical	analysis	when	available.		During	 treatment,	 both	 groups	 showed	 an	 improvement	 in	 the	 CCECAI	 score.	 In	 dogs	 receiving	 S.	
boulardii,	the	CCECAI	score	was	significantly	decreased	(P	<	0.01)	at	T14,	T30,	T45	and	T60	compared	to	T0,	and	at	T45	and	T60	compared	to	T15	and	T30.		In	 dogs	 receiving	 the	 placebo,	 CCECAI	 decreased	 (P	 <	 0.01)	 at	 T30,	 T45	 and	 T60	 compared	 to	 T0.	Comparing	the	CCECAI	 index	of	the	two	groups,	dogs	receiving	S.	boulardii	 improved	significantly	more	than	dogs	receiving	a	placebo	at	T45	(P	<	0.05)	and	T60	(P	<	0.01)	(Fig	2).			
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Figure 2. Canine chronic enteropathy clinical activity index (CCECAI) score in dogs receiving Saccharomyces 
boulardii (gray boxes) or a placebo (white boxes) during treatment. Differences in CCECAI scores were 
significant between groups at T45 (P < 0.05) and T60 (P < 0.01). Values are represented as minimum and 
maximum (edges of the bars) median and interquartile range (boxes). 	Within	CCECAI	 results,	 stool	 frequency	was	significantly	 reduced	 (P	<	0.01)	 in	 the	S.	boulardii	 group	at	T30,	T45	and	T60	compared	to	T0	and	T14;	however,	no	differences	were	detected	in	the	placebo	group.	Dogs	treated	with	S.	boulardii	had	a	significantly	lower	frequency	of	defecation	at	T60	than	the	placebo	(P	<	0.05).		Stool	consistency	improved	significantly	(P	<	0.01)	in	the	S.	boulardii	and	placebo	groups	at	T14,	T30,	T45	and	T60	compared	to	T0	and	returned	to	normal	(point	0)	in	all	dogs	at	T60	in	the	S.	boulardii	group,	but	in	 only	 3/7	 dogs	 in	 the	 placebo	 group,	 although	 no	 significant	 differences	were	 detected	 between	 the	groups.		Differences	 in	 other	 CCECAI	 characteristics	 (attitude,	 appetite,	 vomiting,	 weight	 loss,	 serum	 albumin,	ascites	 or	 peripheral	 oedema,	 and	 pruritus)	 between	 the	 two	 groups	 were	 not	 significant.	 The	 BCS	increased	significantly	(P	<	0.01)	only	in	dogs	treated	with	S.	boulardii	(T45	and	T60	versus	T0	and	T14;	and	 T60	 versus	 T30).	Moreover,	 the	 BCS	 at	 T60	was	 significantly	 higher	 (P	<	 0.05)	 in	 the	 S.	 boulardii	group	compared	to	the	placebo	(Fig	3).		In	the	six	surviving	dogs	with	PLE,	serum	albumin	concentrations	at	the	end	of	treatment	were	>2	g/dL	in	all	dogs	in	the	S.	boulardii	group	and	in	2/3	dogs	in	the	placebo	group.	Dogs	treated	with	both	S.	boulardii	and	the	placebo	showed	a	significant	(P	<	0.01)	increase	in	albumin	concentration	(S.	boulardii	group:	T0	differed	from	T30,	T45	and	T60;	T30	differed	from	T60;	and	T45	differed	from	T60;	placebo	group:	T0	differed	from	T30,	T45	and	T60;	T30	differed	from	T60;	and	T45	differed	from	T60).	Comparing	albumin	concentrations	at	each	experimental	time	between	groups,	a	statistically	significant	difference	was	found	only	 at	 T0,	 where	 dogs	 in	 the	 placebo	 group	 had	 higher	 albumin	 concentrations	 than	 the	 S.	 boulardii	group	(P	<	0.05).	Meanwhile,	during	treatment	(T14,	T30,	T45	and	T60),	no	difference	was	found	based	on	albumin	concentration.	Data	 regarding	 ultrasonography,	 endoscopy	 and	 histology	 of	 the	 duodenum	 and	 the	 colon	 showed	 no	significant	 differences	 before	 and	 after	 treatment,	 nor	 between	 the	 two	 groups	 at	 the	 different	 time	points.		None	of	the	dogs	with	CE	showed	adverse	effects	during	treatment	with	S.	boulardii.		
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Figure 3. Body condition score (BCS) in dogs receiving Saccharomyces boulardii (gray boxes) or placebo (white 
boxes) during treatment. Differences in BCS score were significant between the groups at T60 (P < 0.05). Values 
are represented as minimum and maximum (edge of the bars) median and interquartile ranges (boxes). DISCUSSION	Probiotic	 treatments	 in	 small	 animal	 GI	 diseases	 are	 increasing	 in	 interest	 (Schmitz	 and	 Suchodolski	2016).	 Some	 studies	 have	 evaluated	 the	 use	 of	 a	 number	 of	 strains	 of	 bacteria	 to	 treat	 GI	 disorders	(Ménard	and	others	2004,	Sauter	and	others	2005,	Sturm	and	others	2005,	Rossi	and	others	2014)	but,	to	the	authors’	knowledge,	no	study	has	used	this	strain	of	yeast	in	the	treatment	of	canine	CE.		Currently,	 many	 labeled	 products	 containing	 strains	 of	 bacteria	 are	 commercially	 available	 for	 the	treatment	 of	 acute	 and	 CE.	 One	 of	 the	 main	 concerns	 with	 probiotics	 is	 that	 the	 concentration	 and	viability	of	 the	microbiological	agent	 is	sometimes	questionable	(Weese	2002,	Schmitz	and	Suchodolski	2016).	For	this	reason,	part	of	the	current	study	was	dedicated	to	confirming	the	presence,	viability	and	concentration	of	yeast	in	the	probiotic.	The	authors	consider	these	results	interesting	because	in	the	first	raw	material	initially	provided	by	a	manufacturer	to	conduct	the	study,	S.	boulardii	was	not	present	in	the	concentration	declared	(data	not	shown).	Subsequently,	a	new	product	(the	one	used	in	the	study)	was	provided	and	fulfilled	the	requested	criteria.	Doses	of	S.	boulardii	 used	 in	our	 study	were	extrapolated	 from	other	 studies	 (Weese	2002,	Desrochers	and	others	2005,	Mc	Farland	2010).			The	 results	 from	 healthy	 dogs	 in	 this	 study	 were	 similar	 to	 those	 demonstrated	 in	 human	 medicine.	Administration	of	S.	boulardii	did	not	cause	any	short-term	adverse	effects.	In	one	study	in	humans,	only	13	 cases	 of	 2963	 patients	 analysed	 reported	 adverse	 effects	 (Mc	 Farland	 2010).	 The	most	 commonly	reported	 symptoms	 in	 people	were	 polydipsia	 and	 constipation,	 and	 these	were	 not	 noted	 in	 the	 four	healthy	dogs	included	in	the	present	study.	In	human	medicine,	a	steady	state	is	defined	when	S.	boulardii	in	 faeces	 reaches	107	CFU/g	of	 faeces	 (Mc	Farland	2010).	 In	 the	 current	 study,	 the	 same	 concentration	was	used	to	define	the	steady	state.		Before	and	after	administration	of	S.	boulardii,	the	occasional	presence	of	other	yeast	was	not	surprising.	Despite	limited	information	on	the	presence	of	fungal	organisms	in	the	GI	tract	of	dogs,	the	presence	of	yeast	 pertaining	 to	 the	 genera	 Candida,	 Pichia,	 Cryptococcus,	 Trichosporon,	 Saccharomyces	 and	
Rhodotorula	has	been	previously	described	(Parle	1957,	Suchodolski	and	others	2008).	Nevertheless,	it	is	difficult	 to	determine	whether	 these	yeasts	are	 resident	 fungi	or	 transient	as	a	 result	of	 food	 intake	or	uptake	from	environmental	sources.		In	the	healthy	dogs,	Saccharomyces	species	were	not	found	before	administration.	The	steady	state	of	S.	
boulardii	was	reached	within	five	days,	while	in	humans	it	happens	three	days	after	the	administration	of	
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S.	 boulardii	 (Mc	 Farland	 2010).	 During	 administration,	 the	 concentration	 of	 Saccharomyces	 species	 in	faeces	 of	 healthy	dogs	 changed	between	days.	One	possible	 explanation	 for	 this	 phenomenon	 could	be	related	 to	 the	different	 times	of	 faecal	 production	with	 respect	 to	 the	 administration	of	 the	probiotics.	Results	 in	 humans	 demonstrate	 that	 Saccharomyces	 species	 have	 a	 half-life	 of	 six	 hours	 (Mc	 Farland	2010),	which	could	explain	the	results	seen	here	if	we	assume	a	similar	half-life	in	dogs.		It	is	interesting	to	note	that	in	all	four	healthy	dogs	included	in	the	study,	analogous	to	results	in	humans	(Mc	 Farland	 2010),	 Saccharomyces	 species	 in	 faecal	 samples	 disappeared	 completely	 four	 days	 after	withdrawal	of	the	administration.		The	 results	 from	 healthy	 dogs	 in	 this	 study	 demonstrate	 that:	 1)	 S.	 boulardii	 was	 absent	 in	 faeces	 of	healthy	subjects	before	administration;	2)	when	administered	at	a	dosage	of	1	×	109	CFU/kg	PO	q12h	it	caused	no	short	term	adverse	effects;	3)	S.	boulardii	survived	in	the	GI	tract	and	reached	steady	state	in	five	days;	and	4)	when	the	administration	was	discontinued,	 it	was	completely	eliminated	 in	 four	days.	Although	 evaluations	were	 performed	 in	 only	 four	 dogs	 and	 should	 be	 interpreted	with	 caution,	 these	results	suggest	that	S.	boulardii	can	be	safely	administrated	in	dogs.		The	 population	 of	 dogs	 with	 CE	 in	 this	 study	 was	 similar	 to	 what	 is	 already	 reported	 in	 veterinary	medicine,	 with	 German	 shepherds	 and	 Rottweilers	 being	 the	 most	 commonly	 represented	 breeds	(Jergens	 and	 others	 1992).	Four	 dogs	 died	 during	 treatment	 (three	 dogs	 were	 euthanised	 because	 of	failure	to	respond	to	treatment,	and	one	died	due	to	mesenteric	torsion).	Sudden	death	due	to	thrombosis	or	abdominal	viscera	displacement	has	been	reported	as	a	cause	of	death	in	dogs	with	CE	(Marks	2013).		In	 dogs	with	 CE,	 the	 results	 of	 the	 current	 study	 suggest	 that	S.	boulardii	 is	 effective	 in	 improving	 the	control	 of	 clinical	 signs,	 compared	 to	 standard	 therapy,	 without	 short-term	 adverse	 effects.	 All	 dogs	included	 in	 the	study	showed	 improvements	 in	GI	signs,	but	some	significant	differences	between	dogs	receiving	S.	boulardii	and	controls	were	observed.	Similar	results	have	been	reported	in	human	studies,	in	which	patients	with	Crohn’s	disease	treated	with	S.	boulardii	achieved	better	control	of	clinical	signs	than	controls	(Plein	and	Hotz	1993,	Guslandi	and	others	2000).	Results	in	human	medicine	and	animal	models	demonstrate	the	anti-inflammatory	actions	of	S.	boulardii	in	a	large	number	of	diarrhoea	disease	models.	These	studies	support	the	notion	that	the	beneficial	effects	of	S.	boulardii	 in	GI	inflammatory	conditions	are	mediated	through	modulation	of	host	pro-inflammatory	responses,	not	only	by	whole	yeast,	but	also	by	 secreted	 factors	 able	 to	 interfere	 with	 the	 host’s	 signaling	 molecules	 controlling	 inflammation	 at	different	levels,	such	as	the	NF-κB	and	MAP	kinase	pathways	(Pothoulakis	2009).	At	the	end	of	the	current	study,	dogs	that	received	S.	boulardii	had	significantly	fewer	or	no	clinical	signs	(stool	 frequency,	 stool	 consistency,	 CECCAI	 score)	 and	 significantly	 increased	 their	 BCS	 scores	 with	respect	to	controls.	Moreover,	in	the	absence	of	clinical	and	laboratory	signs	of	dehydration,	in	dogs	with	PLE,	 serum	albumin	 concentration	 seemed	 to	 increased	more	 than	 in	 placebo	dogs.	 At	 diagnosis,	 dogs	with	PLE	that	received	S.	boulardii	had	significantly	lower	serum	albumin	concentrations	than	the	control	dogs.	Otherwise,	at	T60,	all	PLE	dogs	receiving	the	probiotic	had	normal	albumin	concentrations.		In	the	current	study,	and	similar	to	what	was	observed	in	most	previous	studies	of	therapy	for	canine	IBD	(Allenspach	and	others	2007,	Simpson	and	Jergens	2011,	Mandigers	and	others	2010),	ultrasonographic,	endoscopic	and	histologic	findings	did	not	differ	before	and	after	treatment,	and	consequently,	there	were	no	 significant	 differences	 between	 the	 groups.	 Only	 in	 Rossi	 and	 others	 (2014),	 did	 the	 investigators	report	 a	 difference	 in	 histologic	 examination	 of	 canine	 bowel	 samples	 after	 treatment	 with	 strains	 of	probiotics	(VLS#3)	versus	standard	treatment.		The	 current	 research	 has	 some	 limitations.	 The	 first	 limitation	 is	 that	 a	 small	 number	 of	 dogs	 were	included	in	the	study,	mainly	because	the	owners	were	reluctant	to	give	consent	for	repeat	endoscopies	or,	 in	some	cases,	 the	dogs	 left	 the	study	 for	other	reasons.	A	study	with	a	 larger	population	of	healthy	dogs	and	dogs	with	CE	could	better	characterise	the	effects	of	S.	boulardii,	especially	regarding	dogs	with	PLE.	The	second	limitation	is	that	the	standard	therapy	was	not	the	same	for	every	patient,	even	if	there	were	 no	 significant	 differences	 in	 the	 choice	 of	 diet,	 antibiotics	 or	 immunosuppressive	 drugs	 between	groups.		
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All	patients	received	follow-up	by	the	same	clinician	from	the	first	visit	to	the	second	endoscopy,	and,	in	most	cases,	beyond.	Therefore,	the	therapeutic	steps	were	strictly	standardised.	Future	studies	should	be	perfo	rmed	 in	which	 all	 dogs	 receive	 the	 same	 diet,	 antibiotics	 and	 immunosuppressive	 drugs,	 but	 this	 will	require	strict	owner	compliance.		In	conclusion,	the	results	of	the	current	study	suggest	that	S.	boulardii	can	be	safely	used	in	dogs	because	its	administration	did	not	cause	short-term	adverse	effects.	In	dogs	with	CE	treated	with	diet,	antibiotics	and	 immunosuppressive	 drugs,	 S.	 boulardii	 can	 be	 added	 to	 achieve	 better	 control	 of	 clinical	 signs.	Further	 studies	 are	 needed	 to	 evaluate	 the	mechanism	 of	 action	 of	 this	 probiotic	 to	modify	 intestinal	microflora	and	invoke	an	inflammatory	response.		CONFLICT	OF	INTEREST		No	 third-party	 funding	 or	 support	 was	 received	 in	 connection	 with	 this	 study,	 or	 the	 writing	 or	publication	of	the	manuscript.	The	authors	declare	no	conflict	of	interest,	and	the	study	was	entirely	self-funded.		REFERENCES	
ALLENSPACH,	K.,	WIELAND,	B.,	GRÖNE,	A.	&	GASCHEN,	F.	(2007)	Chronic	
enteropathies	 in	dogs:	 evaluation	of	 risk	 factors	 for	negative	outcome.	
Journal	of	Veterinary	Internal	Medicine	21,	700–708	
BOYLE,	 A.	 G.,	 MAGDESIAN,	 K.	 G.,	 DURANDO,	 M.	 M.,	 GALLOP,	 R.	 &	
SIGDEL,	S.	(2013)	Saccharomyces	boulardii	viability	and	efficacy	in	horses	
with	 antimicrobial-induced	 diarrhea.	 Veterinary	 Record	 172,	 128	
doi:10.1136/vr.100833	
COLLIER,	C.	T.,	CARROLL,	J.	A.,	BALLOU,	M.	A.,	STARKEY,	J.	D.	&	SPARKS	J.	
C.	 (2011)	 Oral	 administration	 of	 Saccharomyces	 cerevisiae	 boulardii	
reduces	 mortality	 associated	 with	 immune	 and	 cortisol	 responses	 to	
Escherichia	coli	endotoxin	in	pigs.	Journal	of	Animal	Science	89,	52–58	
DESROCHERS,	A.,	DOLENTE,	B.	A.,	ROY,	M.	F.,	BOSTON,	R.	&	CARLISLE,	S.	
(2005)	Efficacy	of	Saccharomyces	boulardii	for	treatment	of	horses	with	
acute	 enterocolitis.	 Journal	 of	 the	 American	 Veterinary	 Medical	
Association	227,	954–959	
GUSLANDI,	 M.,	 MEZZI,	 G.,	 SORGHI,	 M.	 &	 TESTONI,	 P.	 A.	 (2000)	
Saccharomyces	boulardii	 in	maintenance	 treatment	of	Crohn’s	disease.	
Digestive	Disease	and	Science	45,	1462–1464		
JERGENS,	 A.	 E.,	 MOORE,	 F.	 M.,	 HAYNES,	 J.	 S.	 &	 MILES,	 K.	 G.	 (1992)	
Idiopathic	inflammatory	bowel	disease	in	dogs	and	cats:	84	cases	(1987–
1990).	 Journal	 of	 the	 American	 Veterinary	 Medical	 Association	 201,	
1603–1608	
MANDIGERS,	P.	J.	J.,	BIOURGE,	V.,	VAN	DEN	INGH,	T.	S.,	ANKRINGA,	N.	&	
GERMAN	 A.	 J.	 (2010)	 A	 randomized,	 open-label,	 positively-controlled	
field	trial	of	a	hydrolyzed	protein	diet	 in	dogs	with	chronic	small	bowel	
enteropathy.	Journal	of	Veterinary	Internal	Medicine	24,	1350–1357	
MARKS,	 S.	 T.	 	 (2013)	 Diarrhea.	 In:	 Washabau,	 R.	 G.,	 Day,	 M.	 J.,	 eds.	
Canine	and	Feline	Gastroenterology.	St.	Louis,	MO:	Saunders,	99–108	
MARTINEZ,	R.	C.,	BEDANI,	R.	&	SAAD,	S.	M.	(2015)	Scientific	evidence	for	
health	 effects	 attributed	 to	 the	 consumption	 of	 probiotics	 and	
prebiotics:	 an	 update	 for	 current	 perspectives	 and	 future	 challenges.	
British	Journal	of	Nutrition	114,	1993-2015		
MC	 FARLAND,	 L.	 V.	 (2010)	 Systematic	 review	 and	 meta-analysis	 of	
Saccharomyces	 boulardii	 in	 adult	 patient.	 World	 Journal	 of	
Gastroenterology	16,	2202–2222	
MÉNARD,	 S.,	 CANDALH,	 C.,	 BAMBOU,	 J.	 C.,	 TERPEND,	 K.,	 CERF-
BENSUSSAN,	 N.	 &	 HEYMAN,	 M.	 (2004)	 Lactic	 acid	 bacteria	 secrete	
metabolites	 retaining	 anti-inflammatory	 properties	 after	 intestinal	
transport.	Gut	53,	821–828	
PARLE,	J.	N.	(1957)	Yeasts	isolated	from	the	mammalian	alimentary	tract.	
The	Journal	of	General	and	Applied	Microbiology	17,	363–367	
PLEIN,	 K.	 &	 HOTZ,	 J.	 (1993)	 Therapeutic	 effects	 of	 Saccharomyces	
boulardii	on	mild	residual	symptoms	in	a	stable	phase	of	Crohn’s	disease	
with	 special	 respect	 to	 chronic	 diarrhea	 -	 A	 pilot	 study.	 Zeitschrift	 für	
Gastroenterologie	31,	129–134	
POTHOULAKIS,	C.		(2009)	Review	article:	anti-inflammatory	mechanisms	
of	 action	 of	 Saccharomyces	 boulardii.	 Alimentary	 Pharmacology	 &	
Therapeutics	30,	826–833		
RAJKOWSKA,	 K.	 &	 KUNICKA-STYCZYŃSKA,	 A.	 (2009)	 Phenotypic	 and	
genotypic	 characterization	 of	 probiotic	 yeasts.	 Biotechnology	 &	
Biotechnological	Equipment	23,	662–665	
RAJPUT,	I.	R.,	LI,	L.	Y.,	XIN,	X.,	WU,	B.	B.,	JUAN,	Z.	L.,	CUI,	Z.	W.,	YU,	D.Y.	&	
LI,	 W.F.	 (2013)	 Effect	 of	 Saccharomyces	 boulardii	 and	 Bacillus	 subtilis	
B10	 on	 intestinal	 ultrastructure	 modulation	 and	 mucosal	 immunity	
development	 mechanism	 in	 broiler	 chickens.	 Poultry	 Science	 92,	 956–
965	
RIPOLLÉS,	T.,	RAUSELL,	N.,	PAREDES,	J.	M.,	GRAU,	E.,	MARTÍNEZ,	M.	J.	&	
VIZUETE,	 J.	 (2013)	 Effectiveness	 of	 contrast-enhanced	 ultrasound	 for	
characterization	 of	 intestinal	 inflammation	 in	 Crohn's	 disease:	 a	
comparison	with	surgical	histopathology	analysis.	Journal	of	Crohn’s	and	
Colitis	7,	120–128	
ROSSI,	G.,	PENGO,	G.,	CALDIN,	M.,	PALUMBO	PICCIONELLO,	A.,	STEINER,	
J.	 M.,	 COHEN,	 N.	 D.,	 JERGENS,	 A.	 E.	 &	 SUCHODOLSKI,	 J.	 S.	 (2014)	
Comparison	 of	 microbiological,	 histological,	 and	 immunomodulatory	
parameters	 in	 response	 to	 treatment	with	 either	 combination	 therapy	
with	 prednisone	 and	metronidazole	 or	 probiotic	 VSL#3	 strains	 in	 dogs	
with	idiopathic	inflammatory	bowel	disease.	PLoS	One	9,	E94699.			
SAUTER,	S.N.,	ALLENSPACH,	K.,	GASCHEN,	F.,	GRÖNE,	A.,	ONTSOUKA,	E.	
&	BLUM	J.	W.	(2005)	Cytokine	expression	in	an	ex	vivo	culture	system	of	
duodenal	samples	from	dogs	with	chronic	enteropathies:	modulation	by	
probiotic	bacteria.	Domestic	Animal	Endocrinology	29,	605–622	
SCHMITZ,	 S.	 &	 SUCHODOLSKI,	 J.	 (2016)	 Understanding	 the	 canine	
intestinal	microbiota	and	 its	modification	by	pro-,	pre-	and	 synbiotics	 -	
what	is	the	evidence?	The	Journal	of	Veterinary	Medical	Science	2,	71-94	
SIMPSON,	 K.	 W.	 &	 JERGENS,	 A.	 E.	 (2011)	 Pitfalls	 and	 progress	 in	 the	
diagnosis	 and	 management	 of	 canine	 inflammatory	 bowel	 disease.	
Veterinary	Clinics	of	North	America:	Small	Animal	Practice	41,	381–398	
SLOVAK,	 J.	 E.,	WANG,	 C.,	 SUN,	 Y.,	 OTONI,	 C.,	MORRISON,	 J.,	 DEITZ,	 K.,	
LEVINE,	 D.	 	&	 JERGENS	A.	 E.	 (2015)	 Development	 and	 validation	 of	 an	
endoscopic	 activity	 score	 for	 canine	 inflammatory	 bowel	 disease.	 The	
Veterinary	Journal	203,	290–295	
	77	
STURM,	A.,	RILLING,	K.,	BAUMGART,	D.	C.,	GARGAS,	K.,	ABOU-GHAZALÉ,	
T.,	 RAUPACH,	 B.,	 ECKERT,	 J.,	 SCHUMANN,	 R.	 R.,	 ENDERS,	 C.,	
SONNENBORN,	 U.,	 WIEDENMANN,	 B.	 &	 DIGNASS,	 A.	 U.	 (2005)	
Escherichia	 coli	 Nissle	 1917	 distinctively	 modulates	 T-cell	 cycling	 and	
expansion	 via	 toll-like	 receptor	 2	 signaling.	 Infection	 and	 Immunity	 73,	
1452–1465	
SUCHODOLSKI,	 J.	 S.,	 MORRIS,	 E.	 K.,	 ALLENSPACH,	 K.,	 JERGENS,	 A.	 E,	
HARMOINEN,	J.	A,	WESTERMARCK,	E.	&	STEINER,	J.	M.	(2008)	Prevalence	
and	 identification	 of	 fungal	 DNA	 in	 the	 small	 intestine	 of	 healthy	 dogs	
and	dogs	with	chronic	enteropathies.	Veterinary	Microbiology	132,	379–
388	
THOMAS,	C.	M.	&	VERSALOVIC,	J.	(2010)	Probiotics-host	communication:	
modulation	of	signaling	pathways	in	the	intestine.	Gut	Microbes	1,	148–
163	
WASHABAU,	R.	J.,	DAY,	M.	J.,	WILLARD,	M.	D.,	HALL,	E.	J.,	JERGENS,	A.	E.,	
MANSELL,	J.,	MINAMI,	T.	&	BILZER,	T.	W.	(2010)	Endoscopic,	biopsy,	and	
histopathologic	 guidelines	 for	 the	 evaluation	 of	 gastrointestinal	
inflammation	 in	 companion	 animals.	 Journal	 of	 Veterinary	 Internal	
Medicine	24,	10–26	
WEESE,	 J.	 S.	 (2002)	Microbiologic	 evaluation	 of	 commercial	 probiotics.	
Journal	of	the	American	Veterinary	Medical	Association	220,	794–797	
	
	78	
	
	79	
5.2	 	EFFICACY	OF	AN	EXTRUDED	VEGETABLE	DIET	IN	DOGS	WITH	CHRONIC	ENTEROPATHIES:	CLINICAL	PATHOLOGICAL	ANALYSIS		F.	BRESCIANI,	G.	GALIAZZO,	M.	PIETRA		
Student	thesis,	year	2015	
	
Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emilia (BO), Italy. 
 		SUMMARY			CE	are	common	disorders	 in	dogs,	and	 food	 intolerance	plays	a	crucial	 role	 in	 the	pathogenesis	of	 this	disease.1,2	Therefore,	the	aim	of	this	study	was	to	evaluate	the	efficacy	of	an	extruded	vegetable	diet	in	the	treatment	of	dogs	with	CE.	Dogs	with	a	diagnosis	of	CE	was	prospectively	enrolled	 in	 the	study	(n=20)	and	divided	in	3	phenotypes:	FRE	(n=7),	ARE	(n=6)	or	SRE	dogs	(n=7).3	Dogs	with	SRE	included	dogs	with	normal	 albumin	 concentration	 (IBD,	 n=2)	 and	 dogs	 with	 albumin	 concentration	 less	 than	 2g/dl	 (PLE,	n=5).	Dogs	were	fed	a	specifically	formulated	dry	food	(provided	by	Effeffe	Pet	Food	S.p.A.,	Italy)		based	on	the	following	ingredients:	corn,	corn	gluten	meal,	potato	protein,	animal	fat,	mineral	salts,	linen	seed,	fish	oil,	sunflower	oil,	beet	pulp,	dried	yeasts,	chicory	pulp,	fructo-oligosaccharides,	Yucca	schidigera.	The	chemical	composition	of	the	diet	(as	fed)	was	the	following:	water	44	g/kg,	crude	protein	210	g/kg,	crude	fat	130	g/kg,	crude	ashes	49.7	g/kg,	 starch	345	g/kg.	crude	 fiber	21.5	g/kg.	Besides	 the	vegetable	diet,	dogs	 included	 in	 the	 trial,	 with	 exception	 of	 FRE	 dogs,	 received	 antibiotic	 (in	 ARE)	 or	 antibiotic	 and	immunosuppressive	drugs	(in	SRE).		Dogs	included	were	evaluated	at	time	of	diagnosis	and	after	15,	30	and	60	days	(T15,	T30,	T60).	In	dogs	with	 SRE,	 a	 complete	 enteroscopy	 was	 also	 performed	 at	 time	 of	 diagnosis	 and	 after	 4	 months	 after	therapy.	 To	 evaluate	 changes	 in	 clinical	 signs,	 feces	 and	 endoscopy	 lesions	 were	 evaluated	 with	 the	following	 available	 scoring	 systems:	 body	 condition	 score	 (9	 point,	 BCS),4	 canine	 IBD	 activity	 index	(CIBDAI),5	fecal	score	(7	point,	Purina,	FS),	and	IBD	endoscopic	activity	score	(EAS).6		Results	show	no	differences	in	clinical	scores	at	diagnosis	between	phenotypes.	Otherwise,	dogs	with	SRE	had	different	clinicopathological	abnormalities.	Dogs	with	SRE	showed	a	significant	 increase	 in	platelet	count	 (p=0.041),	 a	 significant	 decrease	 serum	 albumin(p=0.018),	 total	 protein	 (p=0.0025),	 cholesterol	(p=0.0011),	 and	 total	 calcium	 concentration	 (p=0.0057),	 and	 a	 significant	 increase	 in	 AST	 serum	concentration	(p=0.0095).		CIBDAI	 improved	 significantly	 after	 15	days	 in	 FRE	 and	 SRE	dogs,	 and	FS	 improved	 significantly	 in	 all	phenotypes	 (see	 Figure	 5.2a).	 BCS	 did	 not	 improve	 during	 the	 60	 day	 trial.	 No	 differences	 between	phenotype	 based	 on	 clinical	 score	were	 noted	 during	 treatment,	 as	 no	 dogs	 had	 clinical	 signs	 after	 15	days	of	diet.	EAS	did	not	show	any	modification	of	SRE	before	or	after	treatment.		Results	 of	 this	 study	 confirm	 that	 severity	 of	 clinical	 signs	 did	 not	 differ	 between	 phenotype,7,8	 but	clinicopathological	alterations	are	more	severe	in	SRE	dogs.8	Moreover,	this	study	demonstrated	that	the	vegetable	diet	resulted	in	a	rapid	and	uniform	improvement	in	clinical	signs	in	all	dogs,	along	with	other	therapies.	The	main	limitation	in	this	study	was	the	lack	of	a	control	group	treated	with	a	different	diet.		
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In	 conclusion,	 the	 extruded	 vegetable	 diet	 can	 be	 use	 in	 dogs	 with	 CE	 in	 addition	 to	 other	 therapies	(antibiotic	 and/or	 immunosuppressive	 drugs)	 because	 it	 results	 a	 rapid	 and	 uniform	 improvement	 in	clinical	signs.				
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Figura 5.2a. Upper row: Modification of clinical IBD activity index (CIBDAI) in dogs with FRE (A) and SRE (B) 
after 15, 30, and 60 days of vegetable diet. Lower row: Modification in fecal scores in dogs with FRE (C), ARE (D) 
and SRE (E) after 15, 30, and 60 days of vegetable diet. 	REFERENCES		
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5.3	 	EFFECT	OF	AN	EXTRUDED	VEGETABLE	DIET	ON	FECAL	MICROBIOTA	OF	DOGS	WITH	FOOD-RESPONSIVE	ENTEROPATHY		 F.	BRESCIANI1,	Y.	MINAMOTO2,	J.S.	SUCHODOLSKI2,	G.	GALIAZZO1,	C.G.	VECCHIATO1,	C.	PINNA1,	G.	BIAGI1,	M.	PIETRA1		
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 		ABSTRACT	Intestinal	 dysbiosis	 and	 adverse	 food	 reactions	 are	 involved	 in	 the	 pathogenesis	 of	 food	 responsive	enteropathy	(FRE)	in	dogs.	Various	options	for	an	elimination	diet	are	available,	and	a	vegetable	dry	food	is	 one	 alternative.	 Dietary	 interventions	 are	 thought	 to	 alter	 gut	 microbial	 communities	 in	 healthy	individuals	and	the	resolution	of	dysbiosis	is	expected	in	diseased	animals	concurrent	with	remission	of	clinical	signs.	Therefore,	the	aim	of	this	study	was	to	evaluate	changes	in	faecal	microbiota	in	dogs	with	FRE	before	and	after	an	elimination	dietary	trial	with	a	vegetable	diet.	The	same	vegetable	diet	trial	was	performed	in	healthy	control	dogs	(HC)	to	evaluate	changes	in	faecal	microbiota	before	and	after	the	trial,	and	to	compare	them	to	FRE	dogs.	Dogs	 with	 FRE	 (n=10)	 and	 HC	 (n=14)	 were	 fed	 the	 vegetable	 diet	 for	 60	 days.	 Faecal	 samples	 were	collected	 before	 and	 after	 the	 dietary	 trial.	 Faecal	 genomic	 DNA	 was	 extracted	 and	 used	 for	 Illumina	sequencing	 of	 16S	 rRNA	 genes.	 Sequence	 data	were	 analysed	 using	 the	 QIIME	 pipeline.	 The	 dysbiosis	index	 of	 the	 sequence	 data	was	 calculated	 using	 a	 published	mathematical	model,	 and	 a	 score	 >0	was	considered	as	dysbiotic.	Statistical	significance	was	set	at	p<0.05.		Significantly	lower	alpha	diversity	was	observed	in	dogs	with	FRE-baseline	compared	to	HC-baseline	and	FRE-after	 trial.	 Distinct	microbial	 communities	were	 observed	 in	 dogs	with	 FRE-baseline	 compared	 to	HC-baseline	(ANOSIM	p=0.001)	and	dogs	with	FRE-after	trial	(ANOSIM	p=0.032).	Microbial	communities	were	 still	 different	 in	 FRE-after	 trial	 compared	 to	 HC-baseline	 (ANOSIM	 p=0.001).	 The	 calculated	dysbiosis	 index	 was	 higher	 in	 dogs	 with	 FRE-baseline	 compared	 to	 HC-baseline	 (p=0.022),	 but	 no	significance	difference	was	observed	between	FRE-after	 trial	 and	HC-baseline.	The	 faecal	microbiota	 in	HC	did	not	show	any	significant	differences	before	vs.	after	the	vegetable	dietary	trial.	Results	of	this	study	suggest	that	in	FRE	dogs,	treatment	with	the	vegetable	elimination	diet	led	to	partial	recovery	of	the	faecal	microbiota	by	significantly	increasing	microbiota	richness,	which	was	significantly	closer	to	healthy	microbiota	after	treatment.	In	contrast,	no	changes	were	detected	in	faecal	microbiota	of	healthy	control	dogs	fed	with	the	same	vegetable	diet.			
	82	
A) B)  
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D)  
 
Figure 5.3a: Bacterial diversity measures and microbiota index. Principal finding of sequencing analysis PCoA 
plot representing beta diversity of microbial communities, based on unweighted (A) and weighted (B) UniFrac 
distance matrices. Analysis of similarity between groups show significant differences between FRE-baseline and 
HC-baseline, between FRE-baseline compare to FRE-after, and FRE-after and HC-baseline (C) alpha rarefaction 
curves of different groups as determined by observed species. Differences were found in dogs with FRE-baseline 
compared to HC-baseline and FRE-after trial. (D) 16S rRNA sequence dysbiosis index calculated based on 
abundance of specific bacterial taxa. Paired samples are connected with lines. Significant differences were found 
between FRE-baseline and HC-baseline.  
FRE, food responsive enteropathy: HC, healthy control; Baseline, time first visit; After, after 30 or 60 days of vegetable diet. 		
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 	ABSTRACT	Exact	etiology	for	inflammatory	chronic	enteropathies	in	dogs	remains	unknown.	Accumulating	evidence	suggests	a	pivotal	role	for	intestinal	dysbiosis	in	disease	pathogenesis.	Many	studies	have	evaluated	the	alteration	of	fecal	microbiota	in	canine	chronic	gastrointestinal	(GI)	disease,	and	less	research	is	focused	on	mucosal	microbiota,	 especially	 in	 the	 ileum	 and	 colon.	 The	 objectives	 of	 the	 current	 study	were	 to	evaluate	ileal	and	colonic	mucosal	microbiota	in	dogs	with	steroid	responsive	enteropathy	(SRE)	before	and	after	4	months	of	treatment,	and	to	compare	them	to	control	dogs	(CD).		A	total	of	10	dogs	diagnosed	with	SRE	were	enrolled.	Complete	GI	endoscopy	was	performed	and	samples	were	 collected	 by	 a	 cytology	 brush	 at	 diagnosis	 (SRE-Baseline,	 n=10)	 and	 after	 4	month	 of	 treatment	(SRE-After,	n=8).	Oral	laxative	and	2-4	water	enemas	were	performed	before	endoscopy.	A	total	of	6	CD	that	were	euthanized	for	reasons	unrelated	to	this	study,	with	no	GI	disease,	were	included.	Samples	from	CD	were	 obtained	 during	 necropsy	within	 3	 hours	 of	 death.	Mucosal	 genomic	DNA	was	 extracted	 and	used	for	Illumina	sequencing	of	16S	rRNA	genes.	Sequence	data	were	analyzed	using	the	QIIME	pipeline.	Statistical	significance	was	set	at	p	<	0.05.		Clinical	signs	improved	significantly	after	4	month	of	treatment	in	SRE,	but	no	improvement	was	seen	on	endoscopic	 or	 histological	 evaluation.	 Significant	 differences	 in	 microbial	 communities	 between	 SRE-baseline	and	CD	were	observed	in	the	colon	(ANOSIM	p=0.002),	but	not	in	the	ileum	(ANOSIM	p=0.180).	In	 dogs	 with	 SRE,	 both	 ileal	 and	 colonic	 microbial	 communities	 remained	 similar	 after	 4	 month	 of	treatment	 (ANOSIM	p=0.189	and	p=0.637,	 respectively),	and	were	different	 from	CD	(ANOSIM	p=0.001	and	p=0.004,	respectively).		Results	of	this	study	suggest	that	the	mucosal	microbiota	in	the	colon	of	dogs	with	SRE	is	different	from	that	of	CD.	Although	clinical	signs	improved,	colonic	mucosal	dysbiosis	was	still	present	after	4	months	of	treatment.			 	
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6.	 	PROGNOSIS		Prognosis	 in	 dogs	 with	 CE	 can	 be	 variable.	 In	 some	 dogs	 it	 can	 be	 favorable	 after	 a	 short	 period	 of	treatment,	such	as	dogs	with	FRE	or	some	IBD	dogs.	On	the	contrary	other	dogs,	such	the	ones	with	IBD	or	PLE,	often	fail	to	respond	to	treatment	and	consequently	die	due	to	CE	or	can	have	several	relapses.		In	this	chapter	prognosis	and	prognostic	factors	are	reviewed.		PROGNOSIS	AND	SURVIVAL	TIME	Prognosis	and	survival	time	mostly	depends	on	the	phenotype	of	CE.	Usually	FRE	dogs	have	a	favorable	prognosis	 after	 a	 good	 response	 to	diet.	 In	dogs	with	ARE	no	 information	 regarding	 survival	 times	are	available.	Most	of	the	studies,	instead,	evaluate	the	prognosis	and	survival	time	of	dogs	with	IRE-PLE,	as	this	phenotype	is	the	most	severe	and	in	all	cases	prognosis	is	considered	guarded.		In	general,	a	reported	prognosis	can	vary	from	few	days	(2	days	to	some	months)	to	some	years	(1	to	6-7	years),1–8	and	 it	depends	on	many	 factors	 that	will	be	reviewed	 later.	For	example,	some	breed	such	as	Shiba	 dogs,	 Rottweilers	 and	 SCWT	 seem	 to	 have	 a	 worse	 prognosis	 than	 other	 breeds.	 In	 Yorkshire	Terriers,	 instead,	 outcome	 and	 survival	 varied	 widely;	 some	 dogs	 achieved	 prolonged	 survival	 and	remission	of	clinical	signs,	whereas	others	failed	to	respond.3,4		PROGNOSTIC	FACTORS	Many	prognostic	factors	have	been	reported	in	literature.	Prognostic	factors	can	be	specific	clinical	signs	or	clinical	scores,	but	also	clinicopathological,	fecal,	or	histopathological	markers.		In	Table	6.a	available	prognostic	factors	are	reviewed.				
References Factor Findings   
 
MacLachlan et al, 1988;  
Ohno et al, 2006; 
Berghoff et al, 2007; 
Okanishi et al., 2013; 
Dijkstra et al, 2010; Bota 
et al, 2016; 2,3,5,7,9,10 
Breed 
Specific breeds have a worse prognosis than others, and 
somehow this could be interpreted as a prognostic factor. 
Reported breeds with the worse prognosis are: Shiba dog, 
Rottweiler, SCWT, Yorkshire terrier, Basenji and Norwegian 
Lundehunds.  
Kimmel et al, 2000; 
Mellanby et al, 2005; 
Ohno et al, 2006; 
Goodwin et al, 2011; 
Dossin and Lavoué, 2011; 
Simmerson et al, 2014 
4,5,11–14 
Clinical signs 
Specific clinical signs are associated with a worse outcome, 
such as: decreased appetite, severe weight loss (≥ 30%), and 
vomiting. Ascites, pleural effusion, peripheral edema, 
thromboembolic diseases and hypocalcemia related symptoms 
are clinical signs associated with PLE, that usually have a 
worse prognosis with respect to others phenotypes.  
Allenspach et al. 2007; 
Okanishi et al. 2013; 
Simmerson et al, 2014; 
Nakashima et al. 2015; 
Equilino et al, 2015; 
Gianella et al, 2017 1,4,7,15–
17 
CCECAI and 
CIBDAI 
High scores of commonly used clinical scoring systems are 
associated with a negative outcome for some authors but not 
for others.  
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References Factor Findings   
Craven 2004; Ohno et al, 
2006; Allenspach et al. 
2007; Allenspach, 2013; 
Equilino et al, 2015; 
Nakashima et al. 2015 
1,5,15,16,18,19 
Albumin  
To many authors hypoalbuminemia is considered a negative 
prognostic factor in dogs with IBD, but for others it is not. 
Similarly, an increase in albumin concentration with treatment 
is considered a good response and it is associated with a 
favorable outcome.  
Allenspach et al, 2007; 
Batchelor et al, 2007 15,20 
Cobalamin 
Hypocobalaminemia has also been reported to be a negative 
prognostic factor in dogs with CE or EPI, associated with an 
increased risk of euthanasia. 
Ohno et al, 2006; McCann 
et al, 2007; Allenspach et 
al, 2007; Heilmann et al, 
2012; Steiner, 2014; 
Equilino et al, 2015 1,5,15,21–
23  
CRP 
CRP seems to correlate with clinical activity score in some 
studies, but not in others. In one study, CRP failed to correlate 
with outcome, although for other authors it is useful to assess 
severity of the disease and monitor the treatment response.  
Kathrani et al, 2009 24 cPLI 
In one study, a proportion of dogs with IBD had high cPLI 
concentrations and it was correlated with a poor outcome.  
Heilmann et al, 2012; 
Grellet et al, 2013; 
Heilmann et al, 2014; 
Heilmann et al, 2014 (1); 
Equilino et al, 2015; 
Heilmann et al, 2016 
1,22,25–28 
Calprotectin and 
S100A12 
Higher levels of fecal calprotectin and S100A12 are both 
associated with negative outcome. Moreover, fecal S100A12 
concentration predicts a lack of response to treatment in dogs 
with CE. 
Equilino et al, 2015; 
Heilmann et al, 2016 1,29 
α1-PI α1-PI is an early marker of PLE, but in one study it does not 
associate with outcome.  
Steiner, 201423 
N-
methylhistamine 
N-methylhistamine, is the final metabolite of histamine, and it 
is an indicator of mast cell inflammation. It can be quantified in 
serum, urine, or even feces using gas chromatography- mass 
spectrometry. Fecal N-methylhistamine concentrations have 
been shown to be significantly higher in dogs with PLE.  
Allenspach et al, 2006; 
Van der Heyden et al, 
2011; Allenspach, 2013; 
Okanishi et al, 2014 19,30–32 
P-gp 
P-glycoprotein (p-gp) is a transmembrane protein functioning 
as a drug-efflux pump in the intestinal epithelium. High 
expression of P-gp in T cells of human patients suffering from 
many neoplastic and autoimmune disorders is associated with 
poor response to treatment. Similarly in dogs lamina propria 
lymphocyte expression of p-gp is upregulated after 
prednisolone treatment in dogs with IBD, and low P-gp score 
before initiation of steroid treatment was significantly 
associated with a positive response to treatment. 
Ohno et al, 2006; Craven 
et al, 2011; Gianella et al, 
2017 5,17,33 
Response to 
treatment 
Treatment refractory dogs with IBD and granulomatous colitis 
is associated with a poor outcome.  
In a recent study no response to treatment one month after 
diagnosis had a worse prognosis (see chapter 6.2).  
 
Table 6.a: Prognostic factor in chronic enteropathies in dogs.  
CE, chronic enteropathies; IBD, inflammatory bowel disease; PLE, protein loosing enteropathies; CCECAI, canine chronic 
entheropathies anctivity index: CIBDAI canine, IBD activity index; EPI, exocrine pancreas insufficiency; cPLI, canine 
pancreatic lipase immunoreactivity; α1-PI, alfa 1proteasi inhibitor; P-gp, P- glycoprotein;  	
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6.1	 INFLAMMATORY	BOWEL	DISEASE	IN	DOGS:	PROGNOSTIC	FACTORS	FOR	THERAPEUTIC	RESPONSE		BRESCIANI	F.,	LICARINI	S.,	OSTANELLO	F.,	FRACASSI	F.,	PIETRA	M.		
Abstract	presented	to:	ECVIM-CA	Congress,	Göteborg,	September	2016		
Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emilia (BO) Italy. 
 BACKGROUND:	In	dogs	with	idiopathic	inflammatory	bowel	disease	(IBD)	the	response	to	treatment	influences	the	dog’s	quality	of	life,	time	of	survival,	economic	impact	on	owners	and,	sometimes,	the	decision	for	euthanasia.		AIM:	The	aim	of	this	retrospective	single-center	study	was	first	to	evaluate	if	response	to	treatment	is	able	to	influence	 the	 time	 of	 survival,	 and	 consequently	 to	 evaluate	 prognostic	 factors	 able	 to	 influence	 the	response	to	treatment	in	dogs	with	IBD.		MATERIAL	AND	METHODS	ANIMAL:		Dogs	with	a	diagnosis	of	 idiopathic	 IBD,	 treated	with	 immunosuppressive	drugs,	were	enrolled.	History	about	drugs	and	diet	previously	employed,	 clinical	 signs,	 laboratory	 findings,	 treatment,	 and	 follow-up,	were	recorded.	Data	from	September	2004	to	December	2014	were	reviewed.		GROUP:	Group	1:	were	defined	as	dogs	that	had	responded	to	treatment,	in	which	immunosuppressive	drugs	and	antibiotic	treatment	was	discontinued	without	relapses.	The	group	includes	dogs	alive	or	dead	(for	other	reasons)	that	in	the	moment	that	were	included	were	receiving	any	therapies	(except	diet).	Group	 2:	 were	 defined	 as	 dogs	 that	 responded	 to	 treatment	 with	 immunosuppressive	 drugs	 but	 the	disease	 relapsed	 after	 interruption	 of	 treatment.	 This	 group	 includes	 dogs	 alive	 or	 dead	 (for	 other	reasons)	 that	were	 constantly	 on	 treatment	with	 immunosuppressive	 drugs	 or	 dogs	 that	 had	 relapses	treated	with	immunosuppressive	drugs.		Group	3:	were	defined	as	dogs	that	did	not	respond	to	diet,	antibiotic	and	immunosuppressive	drugs,	dog	that	died	 spontaneously	or	were	euthanized	 for	 correlated	 cause	or	dogs	alive	or	dead	 for	other	 cause	with	symptoms	of	IBD	not	controlled.		STATISTICAL	ANALYSIS:	Kaplan–Meier	survival	curves	were	obtained	for	Groups	1,	2	and	3;	the	survival	curves	for	these	groups	were	compared	using	the	log-rank	test.	A	two	stage-analysis	was	also	applied.	In	the	first	univariate	stage,	the	variables	were	screened	using	x2	test.	In	the	second	stage,	factors	that	screened	through	P<0.15	were	evaluated	using	multivariate	logistic	regression.	The	odds	ratio	(OR)	and	95%	confidence	intervals	(95%	CI)	were	calculated	from	the	final	model.	Receiving	operating	characteristic	(ROC)	curve	were	performed	to	evaluate	cut	of	value	of	factor.		
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RESULTS	One	hundred	and	four	dogs	met	the	inclusion	criteria.	Dogs	of	group	1	 (n=36)	and	2	 (n=41)	had	a	median	survival	 longer	 than	dogs	of	group	3	 (n=19),	1215	days	 (range	 210-4380)	 and	 913	 days	 (range	 61-3100)	 versus	 210	 days	 (range	 30-2005),	 respectively	(Figure	6.1a).	At	univariate	regression	analysis,	a	statistical	difference	in	dogs	of	group	3	with	respect	to	dogs	of	 group	1	and	2	 in	 following	variables,	were	observed:	previous	 treatment	with	 steroids;	weight	loss;	prevalence	of	small	bowel	diarrhea;	decreased	hematocrit,	serum	albumin,	total	protein,	creatinine,	cholesterol;	increased	concentration	of	aspartate	amino	transferase	(AST)	and	alanine	aminotransferase	(ALT);	 and	 received	 treatment	 with	 other	 immunosuppressive	 drugs	 than	 steroids	 at	 diagnosis.	 In	multivariable	 model	 analysis	 previous	 treatment	 with	 steroids	 and	 decreased	 total	 proteins	 were	independent	 variables	 associated	 with	 belonging	 to	 group	 3.	 ROC	 curve	 of	 total	 protein	 (AUC	 0,754)	identify	a	cut	off	value	of	≤	5.3	g/dl	associated	with	belonging	to	group	3,	with	a	sensitivity	and	specificity	of	78.9%	and	75%,	respectively	(Figure	6.1b).				
	
 
Figure 6.1a: Kaplan–Meier survival curves results of Group 1, 2 and 3. Dogs that responded to therapies, had no 
relapses and live without drugs (Group 1) had a longer survival time respect to dog that had relapses or are on 
treatment with immunosuppressive drugs (Group 2), and respect to dogs that did not respond to therapies 
(Group 3).  	 	
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Figure 6.1b: ROC curve analysis of total protein in dogs with IBD (Group 1 and 2 vs Group 3). A cut off value ≤ 
5.3 g/dl is indicative of a lack of response to treatment with a sensitivity and specificity of 78.9% and 75%, 
respectively. 	CONCLUSION	AND	CLINICAL	IMPORTANCE	In	 conclusion,	 time	 of	 survival	 and	 response	 to	 treatment	 in	 IBD	 dogs	 was	 related	 with	 previous	treatment	 with	 steroids,	 and	 hypoproteinemia.	 The	 first	 condition	 could	 depend	 on	 an	 increased	expression	of	P-glycoprotein	(P-gp),	a	transmembrane	drug	efflux	pump,	 in	 lymphocytes	infiltrating	the	intestinal	 lamina	propria.1	High	 expression	of	P-gp	has	been	associated	with	 a	 less	 response	 to	 steroid	treatment.1	The	second	negative	prognostic	factor	for	therapeutic	response	(hypoproteinemia)	is	already	known	 to	 be	 related	 with	 a	 negative	 outcome.2	 In	 summary,	 our	 study	 demonstrates	 that,	 over	 35	parameters	 exanimated,	 only	 2	 (previous	 treatment	 with	 steroids,	 along	 with	 decreased	 serum	 total	proteins	at	beginning	of	treatment)	are	negative	prognostic	factors	in	dogs	with	IBD	and	are	associated	with	a	lack	of	response	to	treatment,	and	therefore	a	shorter	survival	time.		REFERENCES	
1		 Allenspach	 K.	 et	 al.	 P-glycoprotein	 expression	 in	 lamina	
propria	 lymphocytes	 of	 duodenal	 biopsy	 samples	 in	 dogs	 with	 chronic	
idiopathic	enteropathies.	J	comp	pathol,	2006,	134.1:	1-7.		
2		 Allenspach	 K.	 et	 al..	 Chronic	 enteropathies	 in	 dogs:	
evaluation	 of	 risk	 factors	 for	 negative	 outcome.	 J	 Vet	 Intern	 Med	
2007;21:700-708.		 	
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6.2	 CLINICOPATHOLOGIC	AND	PROGNOSTIC	FACTORS	IN	SHORT-	AND	LONG-TERM	SURVIVING	DOGS	WITH	PROTEIN-LOSING	ENTEROPATHY			GIANELLA	P.,1	LOTTI	U.,3	C.	BELLINO	C.,1	BRESCIANI	F.,2	CAGNASSO	A.,1	FRACASSI	F.,2	D’ANGELO	A.,1PIETRA	M.2	
 
Published	in	SAT	-	Schweizer	Archiv	für	Tierheilkunde	March	2017		
1 Department of Veterinary Sciences, University of Turin, Turin, Italy 
2 Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emilia (BO), Italy. 
3 Veterinary Clinic Valdinievole, Monsummano Terme (PT), Italy 
 	ABSTRACT	The	aim	of	the	present	study	was	to	investigate	the	differences	in	the	characteristics	of	short-	and	long-term	 surviving	 dogs	 with	 protein-losing	 enteropathy	 (PLE)	 and	 to	 identify	 factors	 that	 predict	 its	outcome.	We	retrospectively	reviewed	the	medical	records	of	59	client-owned	dogs	with	PLE	diagnosed	at	three	different	hospitals	between	January	2009	and	November	2013.	The	dogs	were	classified	as	either	short-term	(≤	6	months;	STs)	or	 long-term	(>	6	months;	LTs)	survivors.	Clinical	and	clinicopathological	variables	 were	 investigated	 between	 the	 groups	 and	 receiver	 operating	 characteristic	 (ROC)	 curve	analysis	was	performed.	Nineteen	dogs	were	classified	as	STs	and	40	as	LTs.	Body	weight	and	blood	urea	nitrogen	 concentrations	were	 significantly	 higher	 in	 the	 STs	 at	 diagnosis	 (P	 <	 0.05).	 At	 1	month	 after	initiation	 of	 immunosuppressive	 therapy	 (data-driven	 cut-off,	 T1),	 chronic	 canine	 enteropathy	 clinical	activity	 index	 (CCECAI)	 scores	 were	 higher	 (P	 <	 0.01)	 and	 albumin,	 serum	 total	 protein	 and	 total	cholesterol	concentrations	were	lower	(P	<	0.01)	in	the	STs.	ROC	curve	analysis	showed	that	CCECAI	>	5	evaluated	at	T1	was	 the	best	predictor	of	poor	outcome.	Although	 the	severity	of	clinical	 signs	and	 the	majority	 of	 clinicopathological	 findings	 at	 diagnosis	 did	 not	 influence	 the	 outcome,	 survival	 time	 was	shorter	in	the	dogs	with	high	CCECAI	scores	at	T1	and	that	did	not	respond	to	therapy.			
Keywords:	canine,	inflammatory	bowel	disease,	chronic	enteropathy,	risk	factors,	outcome		
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INTRODUCTION		Protein-losing	enteropathy	(PLE)	in	dogs	results	from	severe	small	intestinal	disease	that	allows	leakage	of	 protein	 into	 the	 intestinal	 lumen	 (Dossin	 and	 Lavoue,	 2011).	While	 panhypoproteinemia	 associated	with	loss	of	albumin	and	globulin	is	the	most	common	clinicopathological	abnormality,	isolated	albumin	loss	can	also	be	observed	(Willard	et	al.,	2000;	Allenspach	et	al.,	2007).	The	major	causes	of	PLE	in	dogs	are	 intestinal	 lymphangiectasia,	 inflammatory	 bowel	 disease,	 and	 lymphoma	 (Craven	 et	 al.,	 2004;	Dandrieux	et	al.,	2013;	Nakashima	et	al.,	2015).	Because	PLE	is	associated	with	decreased	serum	albumin	and	increased	loss	of	α1-PI	into	the	gastrointestinal	tract,	measurement	of	serum	albumin	and	fecal	α1-proteinase	inhibitor	(α1-PI)	should	be	included	in	the	diagnostic	workup	(Murphy,	2003;	Willard,	2013).	But	since	the	α1-PI	test	is	not	readily	available,	PLE	is	usually	diagnosed	after	excluding	other	conditions	associated	 with	 hypoalbuminemia	 and	 intestinal	 histopathology	 (Dossin	 and	 Lavoue,	 2011;	 Willard,	2013).	As	compared	with	chronic	enteropathy	(CE)	with	normal	albumin	(Craven	et	al.,	2004;	Allenspach	et	al.,	2007;	Simpson	and	Jergens,	2011),	the	prognosis	for	PLE	is	usually	considered	guarded	(Allenspach	et	al.,	2007;	Dossin	and	Lavoue,	2011),	and	the	response	to	therapy	is	variable	(Simmerson	et	al.,	2014).		Moreover,	 information	 on	 factors	 that	 predict	 outcome	 of	 PLE	 at	 diagnosis	 is	 limited	 and	 long-term	follow-up	data	are	lacking.	Negative	prognostic	indicators	include	medium	size	(11	to	20	kg),	high	canine	IBD	activity	index	(CIBDAI)	score,	a	history	of	vomiting,	monocytosis,	mildly	increased	C-reactive	protein,	normal	 serum	 calprotectin	 and	 S100A12	 concentrations,	 clonal	 rearrangement	 of	 lymphocyte	 antigen	receptor	genes,	and	intestinal	villous	blunting	(Simmerson	et	al.,	2014,	Equilino	et	al.,	2015;	Nakashima	et	al.,	 2015).	 Information	 on	 the	 impact	 of	 serum	 albumin	 and	 blood	 urea	 nitrogen	 concentrations	 on	outcome	or	survival	time	is	controversial.	One	study	found	the	survival	time	to	be	significantly	influenced	by	low	blood	urea	nitrogen	concentration	and	severity	of	hypoalbuminemia	(Simmerson	et	al.,	2014),	two	others	 reported	 that	 elevated	 blood	 urea	 nitrogen	 concentration	 and	 hypoalbuminemia,	 but	 not	 its	severity,	 were	 negatively	 correlated	 with	 outcome	 (Owens	 et	 al.,	 2011;	 Nakashima	 et	 al.,	 2015),	 and	another	 found	 that	 outcome	 or	 survival	 time	 were	 	 not	 significantly	 influenced	 by	 the	 initial	 serum	albumin	 concentration	 (Equilino	 et	 al.,	 2015).	 Finally,	 while	many	 dogs	with	 PLE	 secondary	 to	 CE	 die	shortly	after	initiation	of	treatment,	there	are	some	that	achieve	prolonged	survival.		The	 aim	of	 this	 study	was	 to	 retrospectively	 evaluate	 the	differences	 in	 clinical	 and	 clinicopathological	findings	between	short-	and	 long-term	surviving	dogs	with	PLE	secondary	 to	CE	at	diagnosis	and	after	treatment,	and	to	identify	potential	risk	factors	for	poor	outcome.		ANIMALS,	MATERIAL	AND	METHODS		HISTORY	AND	LABORATORY	FINDINGS	We	retrospectively	reviewed	 the	medical	 records	of	dogs	with	PLE	secondary	 to	CE	diagnosed	at	 three	different	hospitals	between	January	2009	and	November	2013.	Inclusion	criteria	were	complete	history	and	 physical	 examination	 findings,	 chronic	 gastrointestinal	 signs	 lasting	 for	 more	 than	 3	 weeks,	hypoalbuminemia	 (<	 2	 g/dL)	 of	 gastrointestinal	 origin	 with	 or	 without	 hypoglobulinemia,	 and	histopathological	 evidence	 of	 gastrointestinal	 inflammation	 on	 biopsies	 collected	 by	 endoscopy	 or	laparotomy.	 Histologic	 examination	 was	 performed	 in	 all	 dogs	 according	 to	 the	 histopathological	standards	of	 the	World	Small	Animal	Veterinary	Association	 (WSAVA)	Gastrointestinal	 Standardization	Group.	 All	 biopsies	 were	 retrospectively	 reviewed	 by	 a	 pathologist	 blinded	 to	 the	 diagnosis.	 Chronic	canine	 enteropathy	 clinical	 activity	 index	 (CCECAI)	 scores	 (Allenspach	 et	 al.,	 2007),	 	 complete	 blood	count,	 serum	 biochemistry	 and	 coagulation	 profiles,	 pancreas	 specific	 lipase	 levels,	 	 serum	 folate	 and	cobalamin	concentrations	were	gleaned	 from	the	medical	 records.	The	reference	ranges	of	 the	hospital	laboratories	were	substantially	similar.	During	review	of	the	medical	records	(February	2015),	follow-up	information	was	obtained	by	telephone	from	the	owners	or	referring	veterinarians.	
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CLASSIFICATION	AND	THERAPY	Dogs	were	classified	as	either	short-term	(STs)	or	 long-term	(LTs)	survivors	 if	 they	had	died	within	or	were	still	alive	at	6	months	after	diagnosis,	respectively.	Additionally,	the	medical	records	were	searched	for	 information	 about	 the	 categorization	 of	 CE	 as	 food-,	 antibiotic-,	 or	 immunosuppressive-responsive.	Dogs	that	showed	complete	remission	of	clinical	signs	while	on	elimination	diet	(hydrolysed	or	restricted	antigen	diets)	were	categorized	as	having	food-responsive	CE.	Dogs	that	showed	complete	remission	of	clinical	 signs	while	 on	 tylosin	 (15	mg/kg,	 PO,	 q	 12	 h)	 or	metronidazole	 (10	mg/kg,	 PO,	 q	 12	 h)	were	categorized	as	having	antibiotic-responsive	CE.	Dogs	that	responded	to	oral	prednisone	(1	mg/kg,	twice	a	day	for	2-3	weeks	before	considering	dose	reduction),	oral	azathioprine	(1	or	2	mg/kg,	once	a	day),	oral	chlorambucil	 (4-6	mg/m2,	 once	 a	 day	 for	 at	 least	 2	weeks	 before	 considering	 dose	 reduction),	 or	 oral	cyclosporine	(5	mg/kg,	once	a	day)	were	categorized	as	having	immunosuppressive-responsive	CE.	Dogs	were	 classified	 as	 immunosuppressive-unresponsive	 if	 they	 showed	 poor	 or	 no	 clinical	 response	 to	immunosuppressives	(partial	disappearance	or	persistence	of	clinical	signs).	Since	the	medical	records	also	reported	the	results	of	repeated	exams	at	 follow-up	visits	 ,	we	set	T1	(1	month	 after	 initiation	 of	 immunosuppressives)	 as	 the	 time	 point	 at	 which	 the	 clinical	 and	clinicopathological	information	was	complete	for	the	majority	of	the	dogs.		STATISTICAL	ANALYSIS		Statistical	 analysis	 was	 performed	 with	 a	 commercially	 available	 statistical	 data	 analysis	 program	(MedCalc®).	 Assessment	 of	 data	 for	 normality	 was	 calculated	 using	 the	 D’Agostino-Pearson	 test.	Continuous	variables	were	expressed	as	mean	(±	sd),	median	(minimum	and	maximum),	percentages	or	both.	 Categorical	 variables	 were	 expressed	 as	 normal/negative	 (0)	 or	 abnormal/positive	 (1).	 Fisher’s	exact	test	was	used	to	compare	between	the	STs	and	the	LTs	the	variables:	sex,	complaints/clinical	signs	(small	 bowel	 diarrhea,	 mixed	 diarrhea,	 decreased	 appetite,	 increased	 appetite,	 vomiting,	 peripheral	edema,	 ascites,	 pleural	 effusion,	 pruritus,	 polyuria	 and	 polydipsia,	 lethargy,	 and	 muscular	twitching/convulsions),	 results	 of	 the	 SNAP	 cPL®	 test,	 coagulation	 profile	 at	 T0,	 and	 treatments	 with	different	types	of	immunosuppressives.	Student’s	 t-test	 was	 used	 to	 compare	 between	 the	 STs	 and	 the	 LTs	 the	 variables:	 age,	 body	 weight,	CCECAI	 scores,	 serum	 albumin,	 folate	 concentrations,	 and	 lipase	 activity	 at	 T0	 and	 the	 CCECAI	 scores,	serum	albumin	and	globulin	concentrations		at	T1.	The	Mann-Whitney	test	was	used	to	compare	between	the	STs	and	the	LTs	the	variables:	number	of	monocytes	and	platelets,	globulin,	serum	total	protein,	total	cholesterol,	 blood	 urea	 nitrogen,	 magnesium,	 cobalamin	 and	 fibrinogen	 concentrations	 at	 T0	 and	 the	serum	 total	 protein,	 magnesium	 and	 total	 cholesterol	 concentration	 at	 T1.	 Values	 of	 P	 <	 0.05	 were	considered	significant.	A	 receiver	operating	characteristic	 (ROC)	curve	was	used	 to	 select	 the	optimum	cut-off	value	of	the	variables	at	T1	to	discriminate	the	STs	from	the	LTs.	RESULTS		HISTORY,	PHYSICAL	EXAMINATION,	AND	CCECAI	SCORES	We	 reviewed	 the	medical	 records	 of	 59	dogs	with	PLE	 secondary	 to	 CE	diagnosed	between	 January	1,	2009	and	November	30,	2013.	Of	these	59	dogs,	19	were	classified	as	STs	and	40	as	LTs.	Among	the	STs	were	dogs	from	9	different	breeds	and	2	mixed-breed	dogs.	Fourteen	were	males	and	5	females.	The	age	range	was	 from	9	months	 to	13.4	years	 (mean,	5.9	±	3.3),	 and	 the	weight	 range	was	 from	14	 to	40	kg	(mean,	 23.6	 ±	 7.3).	 Table	 1	 reports	 the	 presenting	 complaints/clinical	 signs.	 The	 median	 duration	 of	clinical	signs	prior	to	diagnosis	was	2	months	(range	1-36).	The	median	survival	time	was	90	days	(range	31	to	180).	Among	the	LTs	were	dogs	from	20	different	breeds	and	9	mixed-breed	dogs.	Twenty-two	dogs	were	male	and	18	female.	The		age		range	was	from	1	to	11.6	years	(mean,	6.5	±	2.5),	and	the	weight	range	was	from	1.9	to	45	kg	(mean	17.4	±	12.4).	Table	1	reports	the	presenting	complaints/clinical	signs.		
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Variables STs (n/t) LTs (n/t) 
   
Small bowel diarrhea 19/19 39/40 
Mixed diarrhea 5/19 14/40 
Decreased appetite 13/19 22/40 
Increased appetite 1/19 3/40 
Vomiting 9/19 24/40 
Peripheral edema 1/19 5/40 
Ascites 6/19 20/40 
Pleural effusion - 3/40 
Pruritus 1/19 4/40 
Polyuria and polydipsia 4/19 5/40 
Lethargy 2/19 8/40 
Muscular twitching/convulsion 1/19 4/40 
   
Table 1. List of presenting complaints/clinical signs at diagnosis (T0) in short-term (ST) and long-term (LT) 
survivors. 
n= number of dogs showing the complaint/clinical sign; t= total number of dogs 		The	median	duration	of	clinical	signs	prior	to	diagnosis	was	2	months	(range	1-36).	The	median	survival	time	was	880	days	(range	210	to	1,787).	No	statistically	significant	differences	in	sex	and	age	between	the	two	groups	were	found	at	T0;	body	weight	was	significantly	higher	in	the	STs	(P	<	0.05).	There	was	no	difference	in	presenting	complaints/clinical	signs	between	the	STs	and	the	LTs.	CCECAI	scores	were	available	for	all	dogs	at	T0,	and	for	all	dogs	except	1	at	T1.	No	significant	differences	in	 the	 CCECAI	 scores	 between	 the	 groups	were	 found	 at	 T0;	 at	 T1	 the	 CCECAI	 score	was	 significantly	higher	in	the	STs	(Figure	1).			
	
Figure 1: Comparison of canine chronic enteropathy activity scoring index (CCECAI) between short-term (ST) 
and long-term (LT) survivors at T0 and T1. 
 	CLINICOPATHOLOGICAL	FINDINGS	Tables	 2	 and	 3	 present	 the	 clinicopathological	 findings	 and	 the	 number	 of	 dogs	 that	 had	 undergone	testing,	respectively.	At	T0,	no	statistically	significant	differences	between	the	two	groups	were	found	for:	number	of	monocytes	and	platelets,	serum	albumin,	globulin,	total	protein,	total	cholesterol,	magnesium,	cobalamin,	 folate	 and	 fibrinogen	 concentrations,	 lipase	 activity,	 results	 of	 the	 SNAP	 cPL®	 test,	 and	coagulation	profile.	Blood	urea	nitrogen	concentrations	were	significantly	higher	in	the	STs	(P	<	0.05).	At	T1,	albumin,	serum	total	protein	and	total	cholesterol	concentrations	were	significantly	lower	in	the	STs	(P	<	0.01).			
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Variables 
STs LTs 
Reference values Positive or 
abnormal 
Mean (±SD) 
Positive or 
abnormal 
Mean (±SD) 
      
Albumin - 1.49 (±0.42)  - 1.45 (±0.31)  2.80-3.70 g/dL 
Globulin - 2.08 (±0.87)  - 1.88 (±0.61)  2.80-4.20 g/dL 
Total Protein - 3.57 (±0.97)  - 3.32 (±0.75) 5.60-7.90 g/dL 
Total Cholesterol - 118 (±54)   - 122 (±48)   140-350 mg/dL 
Magnesium - 1.67 (±0.86)   - 1.88 (±1.90)   1.60-3.20 mg/dL 
Blood Urea 
Nitrogen 
- 37.62 (±18.65)   - 28.72 (±17.32)   18-55 mg/dL 
Cobalamin - 219 (±128)   - 229 (±107)   250-730 ng/L 
Folate - 9.95 (±5.80)   - 10.42 (±5.90)   7-17 µg/L 
Fibrinogen - 450 (±146)   - 555 (±225)   150-450 mg/dL 
Lipase - 191 (±123)   - 302 (±205)   70-700 U/L 
SNAP cPL® 2 - 3 - - 
Platelets - 463,684 
(±218,761) 
- 426,056 
(±252,977) 
150,000-500,000 
cells/µL 
N of monocytes - 686 (±482) - 634 (±396) 100-1400 
cells/µL 
Coagulation 
profile 
9 - 10 - - 
      
Table 2. Summary of laboratory results at diagnosis (T0) in short-term (ST) and long-term (LT) survivors. 		
Variable 
T0 T1 
STs (n/t) LTs (n/t) STs (n/t) LTs (n/t) 
     
Albumin 19/19 40/40 18/19 40/40 
Globulin 19/19 40/40 18/19 39/40 
Total Protein 19/19 40/40 18/19 39/40 
Total Cholesterol 19/19 38/40 13/19 31/40 
Magnesium 9/19 26/40 6/19 18/40 
Blood Urea Nitrogen 19/19 37/40 - - 
Cobalamin 13/19 30/40 - - 
Folate 13/19 32/40 - - 
Fibrinogen 5/19 16/40 - - 
Lipase 10/19 27/40 - - 
SNAP cPL® 5/19 17/40 - - 
Number of platelets 19/19 38/40 - - 
Number of 
monocytes 
18/19 32/40 - - 
Coagulation profile 6/19 13/40 - - 
     
Table 3. Summary of clinicopathological variables tested at diagnosis (T0) and 1 month after initiation of 
immunosuppressive therapy (T1) in short- term (ST) and long-term (LT) survivors.  
n=number of dogs in which the variable was measured; t=total number of dogs 		
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GASTROINTESTINAL	HISTOPATHOLOGY	RESULTS	Gastroduodenoscopy	was	performed	in	58	dogs.	Additional	 ileoscopy	and	colonoscopy	were	performed	in	 14	 and	 28	 dogs,	 respectively.	 Laparotomy	was	 performed	 in	 1	 dog.	 Tissue	 quality	was	 classified	 as	adequate	 in	 all	 cases.	 Moderate	 to	 marked	 histopathologic	 abnormalities	 in	 the	 small	 intestine	 were	found	 in	 all	 dogs.	 Lymphocytic-plasmacytic	 inflammation	 (50	 dogs)	 and	 	 lymphangiectasia	 (28	 dogs)	were	the	most	common	abnormalities.	Moderate	to	severe	lymphocytic-plasmacytic	colonic	inflammation	was	found	in	24	dogs.	TREATMENT	AND	OUTCOME	No	 significant	differences	 in	 the	 treatments	with	different	 types	of	 immunosuppressive	 therapies	were	found	between	the	two	groups.	Based	on	their	response,	all	STs	were	categorized	as	immunosuppressive-unresponsive.	Among	the	LTs,	32	dogs	were	categorized	as	 immunosuppressive,	1	and	1	each	as	 	 food-	and	 antibiotic-responsive	 CE,	 respectively;	 6	 dogs	 were	 categorized	 as	 immunosuppressive-unresponsive.	Follow-up	information	was	available	for	all	dogs.	Thirty-three	dogs	(55.9%;	31	with	immunosuppressive-responsive	 CE;	 1	 with	 food-responsive	 CE;	 1	 with	 antibiotic-responsive	 CE)	 were	 alive	 at	 the	 time	 of	medical	record	review	(73	months),	and	26	(44.1%;	19/19	STs	and	7/40	LTs	with	immunosuppressive-responsive	CE)	had	died	because	of	PLE-related	complications.	The	main	cause	of	death	was	deterioration	of	clinical	conditions	presumably	due	to	malabsorption.	A	cut-off	CCECAI	score	of	>	5	at	T1	was	found	to	be	the	best	predictor	for	poor	outcome	(Figure	2).		
	
Figure 2: The receiver operating characteristic (ROC) curve used to select the optimum cut-off value of the 
variable CCECAI associated with survival to discriminate between short-term (ST) and long-term (LT) 
survivors. 
 	DISCUSSION		With	this	retrospective	multicenter	study	we	compared	the	clinical	and	clinicopathological	findings	of	59	short-	 and	 long-term	 surviving	 dogs	 with	 PLE	 secondary	 to	 CE,	 and	 investigated	 potential	 prognostic	factors.	 Consistent	 with	 previous	 observations,	 the	 adult	 dogs	 of	 any	 size	 were	 affected	 by	 PLE	(Allenspach	 et	 al.,	 2007;	 Lecoindre	 et	 al.,	 2010;	 Dossin	 and	 Lavoue,	 2011;	 Dandrieux	 et	 al.,	 2013;	Simmerson	 et	 al.,	 2014),	 with	 a	 predominance	 of	males,	 however	 (Kull	 et	 al.,	 2001;	 Simmerson	 et	 al.,	2014).	Medium	size	(11	to	20	kg)	has	recently	been	reported	as	a	negative	prognostic	indicator	(Equilino	et	al.,	2015).	When	we	compared	the	two	groups,	we	observed	that	body	weight	was	significantly	higher	
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among	the	STs.	This	might	simply	reflect	 the	 type	of	study	population	or	suggest	 that	 large	breed	dogs	might	be	affected	by	more	severe	forms	of	PLE.	Small	 bowel	 diarrhea	 and	 decreased	 appetite	 were	 the	 most	 common	 historical	 complaints	 in	 both	groups.	A	recent	retrospective	study	found	that	vomiting	was	a	negative	prognostic	factor	(Simmerson	et	al.,	 2014),	 however,	 we	 noted	 no	 significant	 differences	 in	 the	 presenting	 complaints/clinical	 signs	between	 the	 two	 groups	 at	 T0.	 As	 seen	 also	 in	 our	 sample,	 ascites	 or	 pleural	 effusion	 are	 common	complaints	or	physical	examination	 findings	 in	dogs	with	PLE	(Allenspach	et	al.,	2007,	Lecoindre	et	al.,	2010)	but	they	do	not	seem	to	be	negative	prognostic	indicators	(Simmerson	et	al.,	2014).	Activity	indices	for	assessing	disease	severity	can	also	be	used	as	prognostic	markers	(Jergens	et	al.,	2003;	Allenspach	et	al.,	 2007).	 According	 to	 one	 study,	 CCECAI	 ≥12	 at	 diagnosis	 predicted	 refractoriness	 to	 treatment	 and	euthanasia	within	3	years	(Allenspach	et	al.,	2007).	To	the	contrary,	in	our	and	in	a	recent	study	(Equilino	et	al.,	2015),	outcome	or	survival	time	were	not	significantly	influenced	by	activity	indices	at	diagnosis.		The	only	significant	difference	in	pathologic	variables	between	the	two	groups	at	T0	was	the	blood	urea	nitrogen	concentration,	which		can	be	influenced	by	dehydration,	renal	failure	or	severe	GI	protein	loss.	But	 because	we	 had	 no	 information	 about	 prerenal	 and	 renal	 azotemia	 values	 in	 these	 PLE	 dogs,	 this	result	should	be	interpreted	with	caution.	Furthermore,	the	retrospective	design	of	the	present	study	is	an	 additional	 limitation.	 Several	 variables	 tested	 at	 T0	 were	 not	 available	 at	 T1	 for	 all	 dogs,	 and	treatments	were	not	strictly	standardized.	That	said,	collectively,	our	results	may	support	the	hypothesis	that	the	severity	of	clinical	signs	and	the	majority	of	serum	biochemistry	and	coagulation	profile	findings	at	diagnosis	do	not	appear	to	correlate	with	outcome.			The	prognosis	for	dogs	with	PLE	in	the	current	veterinary	literature	is	guarded	(Allenspach	et	al.,	2007;	Dossin	and	Lavoue,	2011).	Except	for	a	recent	retrospective	study	(Simmerson	et	al.,	2014),	there	are	few	reports	 of	 survival	 data	 for	 dogs	with	PLE	 (Craven	 et	 al.,	 2009;	 Simmerson	 et	 al.,	 2009;	Dijkstra	 et	 al.,	2010;	 	Goodwin	et	al.,	2011;	Owens	et	al.,	2011;	Equilino	et	al.,	2015).	Although	32.2%	of	 the	dogs	had	died	within	6	months	of	diagnosis,	a	greater	proportion	(55.9%)	was	still	alive	at	the	time	of	manuscript	preparation,	suggesting	that	not	only	PLE-affected	Yorkshire	Terriers,	but	also	other	PLE-affected	breeds	may	 experience	 remission	 of	 clinical	 signs	 and	prolonged	 survival	 despite	 severity	 of	 clinicopathologic	findings	at	diagnosis,	as	recently	described	(Equilino	et	al.,	2015).		To	our	knowledge,	no	long-term	data	on	the	follow-up	of	dogs	with	PLE	exist.	At	T1	(6	months	follow-up)	the	 CCECAI	 scores	were	 higher	 and	 the	 albumin,	 total	 protein,	 and	 total	 cholesterol	 concentrations	 all	lower	in	the	STs.	Moreover,	the	dogs	with	a	CCECAI	score	>	5	were	more	likely	to	die	within	6	months	of	initial	diagnosis.	Since	these	variables	at	T0	did	not	significantly	influence	the	outcome,	they	might	simply	reflect	 a	 poor	 response	 to	 therapy.	 Finally,	 since	 all	 STs	 were	 categorized	 as	 immunosuppressive-unresponsive,	it	 is	reasonable	to	assume	that	a	poor	response	to	therapy	is	a	poor	prognostic	indicator.	Indeed,	survival	time	was	shorter	in	the	dogs	with	high	CCECAI	scores	at	T1	and	that	were	unresponsive		to	therapy.		In	conclusion,	the	clinical	outcomes	of	PLE	are	variable,	with	the	majority	of	the	dogs	having	prolonged	survival	despite	the	severity	of	clinicopathological	findings	at	diagnosis	REFERENCES		
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CONCLUSION				Chronic	GI	signs	are	daily	concerns	for	veterinarian	patients	in	clinical	practice.	This	thesis	was	intended	to	 increase	awareness	among	clinicians	 in	 the	recognition	of	CE	and	assess	 the	severity	of	 this	disease.	Moreover,	once	the	diagnosis	 is	made,	 it	 is	 important	 for	the	patient’s	quality	of	 life	to	choose	the	right	treatment;	from	simple	dietary	changes	for	some	dogs	to	important	immunosuppression	for	others.	In	conclusion,	CE	is	a	common	disorder	with	variable	prognosis	from	favorable	to	poor,	in	both	dogs	and	humans.	 Unfortunately,	 even	 though	 GI	 disease	 is	 currently	 an	 intense	 area	 of	 scientific	 research,	pathogenesis,	diagnosis,	and	treatment	are	still	not	completely	understood.	For	this	reason,	the	study	of	CE	is	important	for	canine	health	and	shares	a	common	interest	with	human	medicine.		
